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The Amish communities of Ohio (USA) are a distinct group of endogamous, rural-
living Anabaptist Christians. An ancestral bottleneck, caused by migratory events 
in the 17th century and subsequent rapid population expansion, has led to the 
enrichment of a number of inherited conditions within these communities. This 
provides significantly enhanced power to identify genes responsible for rare 
monogenic disorders, as well traits with more complex inheritance patterns. The 
studies detailed in this thesis aims to provide diagnoses to individuals and their 
families for the underlying genetic causes responsible for the difficulties they 
experience and contributes to a long-running, non-profit community clinical-
genetic research programme called the Windows of Hope (WoH). 
 
Forming part of a wider Amish Hearing Loss Program the studies described in 
chapter three document the discovery of the genetic causes of hearing loss for 
eight Amish families. Through a combination of targeted gene sequencing, 
genome-wide SNP mapping and exome sequencing this study identified a variant 
in the Gap junction beta-2 (GJB2) gene, not previously reported in the Amish, as 
the cause of non-syndromic hearing loss in six families. Additionally, one family 
initially thought to be affected by a neurodevelopment disorder which included 
syndromic hearing loss, was found to possess two distinct genetic disorders; a 
16p11.2 microdeletion, responsible for the developmental delay, and a 
homozygous GJB2 variant, responsible for the hearing loss. Finally, this chapter 
proposes two novel hearing loss genes and details the functional work 
undertaken to assess the pathogenicity of one of these genes (SLC15A5). This 
work provided important diagnoses for many families and acquired significant 
information regarding the spectrum and frequency of hearing loss-associated 
gene variants across distinct Amish communities. 
 
Chapter four details work undertaken to define the clinical phenotype and 
molecular basis of a novel complex autosomal recessive neurological disorder. 
Work undertaken by one of our collaborators, Dr Zineb Ammous, was 
instrumental in precisely defining the clinical phenotype of this disorder. A 
combination of genome-wide SNP mapping and exome sequence identified a 
sequence variant in Smad Nuclear Interacting Protein 1 (SNIP1), which encodes 
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an evolutionary-conserved transcriptional regulator, as the likely underlying 
genetic cause. Due to its role as a transcription regulator whole transcriptome 
sequencing was undertaken to determine the impact of this gene mutation. This 
work provided important information regarding the specific biological role of 
SNIP1 and identified gene expression pathways of direct relevance to the clinical 
phenotype, highlighting therapeutic approaches likely to benefit affected 
individuals. Additionally, this study determined that SNIP1-associated syndrome 
is one of the most common conditions across many Amish communities.  
 
In recent years the WoH Project has accumulated extensive single nucleotide 
polymorphisms (SNP) and exome sequencing datasets from patients and 
individuals from the Amish community. Chapter five outlines a pilot, proof-of-
principle study undertaken to explore this data with the aim characterising the 
architecture of the Amish genome. The interrogation of 26 exomes identified the 
presence of 12 pathogenic variants known to cause autosomal recessive (AR) 
diseases that have not yet been reported in the Amish but are likely to be present. 
Additionally, a PLEXseq sequencing approach was implemented to determine 
the prevalence of 165 pathogenic variants in 171 unaffected Amish individuals. 
The findings indicated diverse carrier frequencies within the different Amish 
communities and contributed to the consolidation of two genes responsible for 
ultra-rare inherited AR diseases (CEP55, MNS1). By developing approaches to 
improve knowledge of the specific causes of inherited diseases in the community, 
this work has laid the foundation for the development of a new genetic-based 
approach to diagnostic testing in the community.   
 
This thesis, and the wider programme of work of Windows of Hope, occupies a 
privileged positioned at the interface between scientific research and clinical care. 
The findings described here have made a significant contribution to our 
understanding of the pathomolecular cause of a number of rare inherited 
disorders by increasing our knowledge of the nature and spectrum of inherited 
disease within the Amish laying the foundations to aid the future discovery of new 
disease genes and improving clinical outcomes by enabling focussed clinical 






ACKNOWLEDGMENTS ..................................................................................... 5 
ABSTRACT ........................................................................................................ 7 
 Introduction .................................................................................................... 27 
1.1 The Amish ............................................................................................... 27 
1.1.1 A brief history of the Amish .............................................................. 27 
1.1.2 Population bottleneck and the founder effect in the Amish ............... 28 
1.1.3 Amish demes ................................................................................... 32 
1.2 Other population isolates ........................................................................ 33 
1.2.1 The Finnish population ..................................................................... 33 
1.2.2 The Samoan population ................................................................... 34 
1.2.3 Orkney Island population .................................................................. 35 
1.3 Genetic studies in the Amish .................................................................. 37 
1.3.1 Windows of Hope Project ................................................................. 39 
1.4 Genomic technologies ............................................................................ 41 
1.4.1 Autozygosity mapping ...................................................................... 41 
1.4.2 Whole exome sequencing ................................................................ 49 
1.4.3 The future of sequencing technologies ............................................. 54 
1.5 Aims ........................................................................................................ 56 
 Materials and Methods .................................................................................. 58 
2.1 Family recruitment and sample acquisition ............................................. 58 
10 
 
2.1.1 Recruitment to the Amish Windows of Hope (WOH) project ............ 58 
2.1.2 Phenotyping of affected individuals .................................................. 59 
2.1.3 Data management ............................................................................ 59 
2.2 Molecular DNA methods ......................................................................... 60 
2.2.1 Buffers, Reagents and Stock Solutions ............................................ 60 
2.2.2 DNA extraction from whole blood ..................................................... 60 
2.2.3 DNA extraction from buccal swabs................................................... 62 
2.2.4 Single nucleotide polymorphism (SNP) genotyping.......................... 64 
2.2.5 Whole-exome sequencing (WES) .................................................... 66 
2.2.6 PLEX-seq sequencing ...................................................................... 69 
2.2.7 Primer design ................................................................................... 69 
2.2.8 Resuspension of lyophilised primers ................................................ 70 
2.2.9 Optimisation of primer conditions ..................................................... 70 
2.2.10 LabTAQ Polymerase Chain Reaction (PCR) .................................. 71 
2.2.11 Agarose gel electrophoresis ........................................................... 73 
2.2.12 PCR product purification ................................................................ 75 
2.2.13 Sequencing reaction ....................................................................... 75 
2.2.14 Sequencing reaction purification .................................................... 77 
2.2.15 Genotyping by restriction digest ..................................................... 78 
2.3 Molecular cloning techniques .................................................................. 80 
2.3.1 Buffers, reagents and stock materials .............................................. 80 
2.3.2 DNA Plasmid preparation ................................................................. 82 
11 
 
2.3.3 Mini preps: Inoculating a liquid bacterial culture and recovering plasmid 
DNA from bacterial culture ........................................................................ 83 
2.3.4 Midi preps: Inoculating a liquid bacterial culture and extracting plasmid 
DNA from bacterial culture ........................................................................ 84 
2.3.5 Pfu PCR of extracted bacterial DNA................................................. 86 
2.3.6 PCR product purification .................................................................. 87 
2.3.7 Gel purification of DNA ..................................................................... 88 
2.3.8 Ligation ............................................................................................. 89 
2.3.9 Bacterial transformation ................................................................... 89 
2.3.10 Human Embryonic Kidney (HEK) 293 cell culture .......................... 90 
2.3.11 Transient transfection ..................................................................... 91 
2.3.12 Immunocytochemistry .................................................................... 92 
2.4 Western blotting ...................................................................................... 94 
2.4.1 Preparation of cell lysates ................................................................ 94 
2.4.2 Protein quantification ........................................................................ 94 
2.4.3 SDS-PAGE separation of proteins ................................................... 95 
2.4.4 Membrane transfer ........................................................................... 97 
2.4.5 Immunodetection and visualisation .................................................. 97 
2.5 Gene expression methods ...................................................................... 99 
2.5.1 RNA extraction ................................................................................. 99 
2.5.2 Whole transcriptome sequencing ..................................................... 99 
 Hearing Loss .................................................... Error! Bookmark not defined. 
12 
 
3.1 Hearing ................................................................................................. 102 
3.1.1 The mammalian ear ....................................................................... 102 
3.1.2 Mechanoelectrical transduction in the mammalian ear ................... 104 
3.1.3 Ion Homeostasis in the mammalian ear ......................................... 106 
3.2 Hearing Loss ......................................................................................... 108 
3.2.1 Types of hearing loss ..................................................................... 108 
3.2.2 Impact of hearing loss .................................................................... 111 
3.2.3 Diagnosing hearing loss ................................................................. 112 
3.2.4 Treatments ..................................................................................... 113 
3.3 The genetics of hearing loss ................................................................. 117 
3.3.1 Syndromic hearing loss .................................................................. 117 
3.3.2 Non-syndromic hearing loss ........................................................... 118 
3.4 Causes of HL known in the Amish community ...................................... 123 
3.5 Results .................................................................................................. 126 
3.5.1 Molecular studies of a large Amish family with multiple individuals 
affected by a neurodevelopmental disorder and hearing loss ................. 127 
3.5.2 GJB2 gene mutation is a common cause of NSHL in the Amish .... 134 
3.5.3 Investigating SLC15A5 as a candidate molecule responsible for AR 
NS-SNHL ................................................................................................ 137 
3.5.4 Genetic studies define variant frequencies of causative gene mutations 
in distinct Amish communities ................................................................. 149 
3.5.5 Identification of novel hearing loss gene ........................................ 152 
13 
 
3.6 Discussion ............................................................................................ 154 
3.6.1 Identification of two distinct genetic disorders within the same Amish 
family ....................................................................................................... 156 
3.6.2 GJB2 variants in the Amish occur on a distinct SNP genomic haplotype
 ................................................................................................................ 160 
3.6.3 Exclusion of the SLC15A5 variant as a cause of NSHL ................. 161 
3.6.4 Allele frequencies of SHL in the Amish population ......................... 166 
3.6.5 Future work and considerations ..................................................... 167 
 Defining the phenotype and pathomolecular basis of a novel form of 
neurodevelopmental disorder associated with the missense mutation of Smad 
nuclear interacting protein 1 (SNIP1) ............................................................. 171 
4.1 Introduction ........................................................................................... 171 
4.1.1 Cell signalling ................................................................................. 172 
4.1.2 TGF-β signalling pathway ............................................................... 173 
4.1.3 Smad proteins ................................................................................ 176 
4.1.4 SNIP1 ............................................................................................. 180 
4.2 RESULTS ............................................................................................. 182 
4.2.1 Identification of a pathogenic variant in SNIP1 ............................... 182 
4.2.2 Defining the clinical phenotype of a neurological disorder displaying 
severe psychomotor delay with seizures, epilepsy and dysmorphic features
 ................................................................................................................ 185 
4.2.3 Effect of SNIP1 mutation on gene expression and cellular pathways
 ................................................................................................................ 188 
14 
 
4.3 Discussion ............................................................................................ 192 
4.3.1 SNIP1 variant (p.Glu366Gly) responsible for novel autosomal 
recessive neurodevelopmental disorder .................................................. 192 
4.3.2 Defining the clinical phenotype of a neurological disorder displaying 
severe psychomotor delay with seizures, epilepsy and dysmorphic features
 ................................................................................................................ 194 
4.3.3 Gene expression and cellular pathway data analysis ..................... 196 
4.3.4 Future work .................................................................................... 212 
 Interrogation of Amish aggregated exome data to identify potentially deleterious 
coincidental heterozygous sequence variants and determine the allele 
frequencies of pathogenic variants seen within the various Amish communities
 ....................................................................................................................... 215 
5.1 Aims ...................................................................................................... 215 
5.2 Introduction ........................................................................................... 216 
5.2.1 Variant annotation .......................................................................... 217 
5.2.2 International effort to share genomic variant data .......................... 226 
5.2.3 Contribution of Amish knowledge to the international genetic 
community ............................................................................................... 229 
5.3 Results .................................................................................................. 231 
5.3.1 Identifying potentially deleterious coincidental heterozygous sequence 
variants .................................................................................................... 231 
5.3.2 Determining the AF of pathogenic variants seen within the various 
Amish communities ................................................................................. 246 
15 
 
5.3.3 Community allele frequency data confirming rare disease ............. 250 
5.4 Discussion ............................................................................................ 252 
5.4.1 Analysis of Amish aggregated exome data .................................... 252 
5.4.2 Determining allele frequencies ....................................................... 255 
5.4.3 Community allele frequency data confirming rare disease genes .. 257 
5.4.4 Future work and considerations ..................................................... 262 






LIST OF FIGURES 
FIGURE 1.1: ANCESTRAL BOTTLENECK LEADING TO THE FOUNDER EFFECT. IMAGE HAND-DRAWN. ................................... 28 
FIGURE 1.2: AMISH HORSE AND BUGGY TRANSPORTATION. PERSONAL PHOTOGRAPH PROVIDED BY PROFESSOR ANDREW 
CROSBY, TAKEN IN OHIO, JUNE 2014. ....................................................................................................... 30 
FIGURE 1.3: SIMPLIFIED SCHEMATIC PRESENTATION OF THE CONCEPT OF AUTOZYGOSITY. AN ANCESTRAL HAPLOTYPE (RED 
BOX) CONTAINING A VARIANT OF INTEREST () IS TRANSFERRED THROUGH THE GENERATIONS. IN EACH GENERATION 
DIFFERENT HAPLOTYPES ENTER THE PEDIGREE REPRESENTED WITH A DIFFERENT COLOURED BAR. RECOMBINATION 
EVENTS (SHOWN BY DOTTED LINES) IN EACH GENERATION SHORTEN THE SIZE OF THE HAPLOTYPE. (MODIFIED FROM 
[36] AND [34]). .................................................................................................................................... 42 
FIGURE 1.4 CNV ANALYSIS OF ILLUMINA BEAD CHIP DATA. B ALLELE FREQUENCY AND LOG2 R (NORMALISED SIGNAL 
INTENSITIES) RATIO ARE PLOTTED OVER THE ENTIRE GENOME FOR ALL SNPS. THE PLOT EXHIBIT DIAGNOSTIC SIGNATURE 
PROFILES OF COPY NUMBER. CN=2, 1; & 3 SHOWN (ADAPTED FROM [48]). ..................................................... 45 
FIGURE 2.1: SUMMARY OF BIOINFORMATICS PIPELINE UNDERTAKEN ON EXOME SEQUENCING. ....................................... 68 
FIGURE 3.1: SCHEMATIC ILLUSTRATION OF THE HUMAN EAR. (A) THE EAR CONSISTS OF THE OUTER, MIDDLE AND INNER EAR. 
(B) A SECTION THROUGH THE COCHLEAR. (C) THE ORGAN OF CORTI. IMAGE ADAPTED FROM [107]. .................... 103 
FIGURE 3.2: (A) SCANNING ELECTRON MICROSCOPY SHOWING THE ORGANISATION OF THE IHCS VIEWED FROM THE TOP OF 
THE ORGAN OF CORTI. SCHEMATIC REPRESENTATION OF AN IHC WITH RELAXED TIP LINKS AND CLOSED MET CHANNELS 
(BI) AND WITH TIP LINKS UNDER TENSION AND MET CHANNELS OPEN AS A RESULT OF MECHANICAL DEFLECTION BY A 
SOUND WAVE (BII). ADAPTED FROM BENJAMIN CUMMINGS, PEARSON 2008. ................................................ 105 
FIGURE 3.3: POTASSIUM ION (K+) RECYCLING IN THE INNER EAR. MET OF THE IHCS CAUSES AN INFLUX OF K+ INTO THE HAIR 
CELLS. THESE IONS ARE THEN SECRETED BACK INTO THE ENDOLYMPH BY THE STRIA VASCULARIS (SV) VIA SUPPORTING 
CELLS AND THE SPIRAL LIGAMENT (SL). IMAGE TAKEN FROM [114]. ............................................................... 107 
FIGURE 3.4: CAUSES OF PRELINGUAL HEARING LOSS IN DEVELOPED COUNTRIES FIGURE ADAPTED FROM [131]. ............... 110 
FIGURE 3.5: A TYPICAL MODERN COCHLEAR IMPLANT SYSTEM THAT CONVERTS SOUND TO ELECTRIC IMPULSES DELIVERED. 
IMAGE SHOWS THE LOCATION OF THE; MICROPHONE (1), SPEECH PROCESSOR (2), TRANSMITTER (3), RECEIVER (4), 
STIMULATOR (5),  ELECTRODES (6&7) AND THE AUDITORY NERVE (8) [147]. .................................................. 114 
FIGURE 3.6: TOPOLOGICAL STRUCTURE OF A TYPICAL CONNEXIN PROTEIN. SHOWING THE FOUR TRANSMEMBRANE (TM) 
DOMAINS, THE TWO EXTRACELLULAR LOOPS (E1 AND E2) AND THE SINGLE CYTOPLASMIC LOOP (CL). ................... 119 
17 
 
FIGURE 3.7: CONNEXINS, CONNEXONS AND GAP JUNCTIONS. SIMPLIFIED DIAGRAM SHOWING THE ASSEMBLY OF A GAP 
JUNCTION FROM THE INTERCELLULAR JOINING OF TWO CONNEXONS, ON ADJACENT MEMBRANES, EACH CONSISTING OF 
SIX SINGLE CONNEXIN MOLECULES [156]. ................................................................................................. 120 
FIGURE 3.8: INITIAL SCREENING STRATEGY IMPLEMENTED FOR INDIVIDUALS RECRUITED TO THE AMISH HEARING LOSS 
PROGRAMME. ..................................................................................................................................... 126 
FIGURE 3.9: SIMPLIFIED PEDIGREE OF THE EXTENDED AMISH FAMILY INVESTIGATED FOR A SYNDROMIC FORM OF HEARING LOSS 
PRESENTING WITH DEVELOPMENTAL DELAY. DEVELOPMENT DELAY REPRESENTED BY BLACK SYMBOLS, HEARING LOSS 
DENOTED BY RED SEGMENTS................................................................................................................... 127 
FIGURE 3.10: AUDIOGRAMS SHOWING THE TWO SIBLINGS UNAFFECTED BY HEARING LOSS (A AND B) AND THE FOUR AFFECTED 
INDIVIDUALS (C-F). DIFFERENT SYMBOLS ARE USED TO PLOT THE RESULTS OF THE DIFFERENT CONDUCTION TESTS FOR 
EACH EAR. AIR CONDUCTION TESTS IN THE RIGHT () AND LEFT () EAR ARE PERFORMED FIRST WITH SOUNDS BEING 
PLAYED THROUGH HEADPHONES. MASKING CAN BE USED TO PREVENT SOUND FROM THE EAR UNDER TEST BEING 
DETECTED BY THE OTHER EAR. THIS INVOLVES A NOISE BEING PLAYED INTO THE LEFT EAR WHEN THE RIGHT EAR IS BEING 
TESTED () OR THE RIGHT EAR WHEN THE LEFT EAR () IS BEING TESTED. BONE CONDUCTION TESTS, USED IF THE AIR 
CONDUCTION TEST IDENTIFIES A HEARING IMPAIRMENT, INVOLVE THE USE OF AN INSTRUMENT THAT VIBRATES THE 
BONES OF THE SKULL AND DETERMINES THE FUNCTION OF THE RIGHT (<) OR LEFT (>) COCHLEAR. AGAIN MASKING CAN 
BE USED TO PREVENT THE PROBLEM OF “CROSSOVER” AND ENSURES ONLY THE RIGHT ([) OR LEFT (]) EAR IS TESTED AT 
ONE TIME. SOUND FIELD TESTING MAY BE ALSO BE USED, THIS IS WHERE A SOUND STIMULI IS PLAYED VIA A LOUD 
SPEAKER, SO IS NOT EAR SPECIFIC, AND CAN BE CONDUCTED WITH (A) OR WITHOUT (S) MASKING. ....................... 129 
FIGURE 3.11: OUTPUT FROM KARYOSTUDIO SOFTWARE (ILLUMINA) SHOWING IDEOGRAM OF CHROMOSOME 16 AND THE 
PRESENCE OF A HEMIZYGOUS MICRODELETION AT 16P11.2. MICRODELETION IS 0.56MB SPANNING RS2549956 TO 
RS35967690. .................................................................................................................................... 131 
FIGURE 3.12: (AII) SIMPLIFIED PEDIGREE OF THE EXTENDED AMISH FAMILY INVESTIGATED WITH PICTORIAL REPRESENTATION 
OF GENOTYPES ACROSS A ~8MB REGION OF CHROMOSOME 13 ENCOMPASSING THE DISEASE LOCUS. BOLD RED BOX 
DENOTES THE 0.96MB REGION UNIQUE TO THE FOUR AFFECTED SIBLINGS (AND FOUR OTHER MORE DISTANTLY RELATED 
INDIVIDUALS; XIII:1, XIIII:2, XIII:3 AND XII:3) AFFECTED BY HEARING LOSS CONTAINING GJB2. DASHED RED BOX 
HIGHLIGHTS A HOMOZYGOUS REGION SHARED BY ALL AFFECTED INDIVIDUALS AND ONE UNAFFECTED SIBLING. PATIENT 
XI:13 APPEARS TO HAVE A RECOMBINATION EVENT OCCUR 33KB AWAY FROM GJB2 PREVENTING HIM FROM 
18 
 
DEVELOPING HEARING LOSS, THIS ALSO PERMITTED THE SHARED REGION CONTAINING GJB2 TO BE REFINED TO 0.35MB 
(AI) SEQUENCING CHROMATOGRAMS SHOWING THE POSITION OF THE GJB2 C.229T>C MUTATION. ................... 133 
FIGURE 3.13: SIMPLIFIED PEDIGREES OF EIGHT AMISH FAMILIES WITH HEARING LOSS CAUSED BY VARIANTS IN GJB2. HEARING 
LOSS OBSERVED IN FAMILIES 1-5 IS CAUSED BY THE C.229T>C VARIANT. FAMILY 1 RESIDE IN GEAUGA, FAMILY 2 ARE 
FROM WISCONSIN AND FAMILIES 3-5 ARE LOCATED IN INDIANA. GENOTYPES OF SEQUENCED INDIVIDUALS ARE SHOWN 
BELOW (IN GREEN). A WILDTYPE ALLELE FOR THIS VARIANT IS SHOWN BY WT. HEARING LOSS IN FAMILY 6, FROM 
GEAUGA, IS CAUSED BY A C.35DEL VARIANT WITH THE GENOTYPES FOR SEQUENCED INDIVIDUALS SHOWN BELOW (IN 
BLACK). A WILDTYPE ALLELE FOR THIS VARIANT IS SHOWN BY WT. AFFECTED INDIVIDUALS IN FAMILIES 7 AND 8, BOTH 
LOCATED IN INDIANA, ARE COMPOUND HETEROZYGOUS FOR BOTH THE C.229T>C (IN GREEN) AND C.35DEL (IN BLACK) 
VARIANTS. .......................................................................................................................................... 136 
FIGURE 3.14: SIMPLIFIED PEDIGREE OF THE EXTENDED AMISH FAMILY INVESTIGATED FOR INHERITED HEARING LOSS. ........ 137 
FIGURE 3.15: AUDIOGRAMS SHOWING THE TWO SIBLINGS AFFECTED BY HEARING LOSS. DIFFERENT SYMBOLS ARE USED TO 
PLOT THE RESULTS OF THE DIFFERENT CONDUCTION TESTS FOR EACH EAR. AIR CONDUCTION TESTS IN THE RIGHT  AND 
LEFT  EAR ARE PERFORMED FIRST WITH SOUNDS BEING PLAYED THROUGH HEADPHONES. MASKING CAN BE USED TO 
PREVENT SOUND FROM THE EAR UNDER TEST BEING DETECTED BY THE OTHER EAR. THIS INVOLVES A NOISE BEING 
PLAYED INTO THE LEFT EAR WHEN THE RIGHT EAR IS BEING TESTED  OR THE RIGHT EAR WHEN THE LEFT EAR  IS 
BEING TESTED. BONE CONDUCTION TESTS, USED IF THE AIR CONDUCTION TEST IDENTIFIES A HEARING IMPAIRMENT, 
INVOLVE THE USE OF AN INSTRUMENT THAT VIBRATES THE BONES OF THE SKULL AND DETERMINES THE FUNCTION OF 
THE RIGHT (<) OR LEFT (>) COCHLEAR. AGAIN MASKING CAN BE USED TO PREVENT THE PROBLEM OF “CROSSOVER” AND 
ENSURES ONLY THE RIGHT ([) OR LEFT (]) EAR IS TESTED AT ONE TIME. SOUND FIELD TESTING MAY BE USED, THIS IS 
WHERE A SOUND STIMULI IS PLAYED VIA A LOUD SPEAKER, SO IS NOT EAR SPECIFIC, AND CAN BE CONDUCTED WITH (A) 
OR WITHOUT (S) MASKING. .................................................................................................................... 138 
FIGURE 3.16: SEQUENCING CHROMATOGRAMS COMPARING THE IDENTIFIED SLC15A5 MUTATION TO THE WILDTYPE 
REFERENCE SEQUENCE. .......................................................................................................................... 140 
FIGURE 3.17: TMHMM SERVER V. 2.0 OUTPUT. SHOWING THE PREDICTION OF TRANSMEMBRANE HELICES IN SLC15A5.
 ........................................................................................................................................................ 142 
FIGURE 3.18:  DISTRIBUTION OF TAGGED SLC15A5 IN HEK293 CELLS. CELLS WERE TRANSFECTED WITH PCMV6-SLC15A5-
MYC-FLAG (ORIGENE) FIXED IN 4% PFA AND IMMUNOLABELLED WITH ANTI-FLAG (GREEN) AND ANTI-SLC15A5 
(MAGENTA) ANTIBODIES. NUCLEI ARE COUNTERSTAINED WITH DAPI (BLUE). SCALE BAR = 7.5µM ....................... 145 
19 
 
FIGURE 3.19: SLC15A5 PARTIALLY ASSOCIATES WITH LATE ENDOCYTIC STRUCTURES IN LIVE CELLS. SLC15A5-MYC-YFP 
(GREEN) ASSOCIATES WITH RAB7-RFP (MAGENTA). HEK 293 CELLS WERE TRANSFECTED WITH SLC15A5-MYC-YFP 
AND VIEWED ON THE WIDE FIELD MICROSCOPE. SCALE BAR = 7.5µM .............................................................. 145 
FIGURE 3.20: SLC25A5 WESTERN BLOT ........................................................................................................... 146 
FIGURE 3.21: RT-PCR ANALYSIS OF SLC15A5 IN THE P7 C57BL/6J MOUSE. A) RT-PCR AMPLIFICATION OF SLC15A5 WAS 
OBTAINED USING PRIMERS IN EXONS 5 AND 6 (NM_177787). A 294 BP PRODUCT IS OBSERVED IN THE COCHLEA, 
HIPPOCAMPUS, CEREBELLUM, WHOLE BRAIN, KIDNEY, EYES, AND LIVER. B) PCR AMPLIFICATION OF UBIQUITOUSLY 
EXPRESSED HPRT IS SHOWN BELOW AS A POSITIVE CONTROL. AMPLIFICATION PRODUCTS WERE CONFIRMED VIA SANGER 
SEQUENCING. IMAGE DEPICTS RESULTS OBTAINED FROM INVESTIGATIONS CARRIED OUT BY BARBARA VONA. ......... 147 
FIGURE 3.22: SIMPLIFIED PEDIGREE LINKING TWO AMISH FAMILIES COMPRISING OF FIVE INDIVIDUALS AFFECTED WITH AR 
SNHL AND NEURODEVELOPMENTAL DELAY. .............................................................................................. 153 
FIGURE 3.23: SUMMARY OF FAMILIES RECRUITED INTO THE AMISH HEARING LOSS PROGRAMME. VARIANTS RESPONSIBLE FOR 
THE HEARING LOSS HAVE BEEN DETAILED WHERE POSSIBLE. GREEN BOXES DENOTE FAMILIES WHERE THE 
INVESTIGATIONS UNDERTAKEN FORM PART OF THIS THESIS. THE YELLOW BOX HIGHLIGHTS A FAMILY WHERE THE 
VARIANT BELIEVED TO BE RESPONSIBLE WAS IDENTIFIED AS PART OF THIS THESIS (CHAPTER 5) DESPITE THE FAMILY 
STUDIES BEING CARRIED OUT BY ANOTHER GROUP MEMBER (NOT INCLUDED IN THIS THESIS). BLUE BOXES DENOTE 
FAMILIES WHERE NOVEL VARIANTS WHERE DISCOVERED BY OTHER GROUP MEMBERS (NOT INCLUDED IN THIS THESIS). 
RED BOXES REPRESENT FAMILIES THAT HAVE NOT YET RECEIVED A DIAGNOSIS WITH INVESTIGATIONS ONGOING. ..... 155 
FIGURE 3.24: UPDATED SCREENING STRATEGY IMPLEMENTED FOR INDIVIDUALS RECRUITED TO THE AMISH HEARING LOSS 
PROGRAMME. ..................................................................................................................................... 159 
FIGURE 3.25: RESULTS FROM QUANTITATIVE REAL-TIME PCR DATA FOR SLC15A5. THE DATA HAS BEEN NORMALIZED 
AGAINST THE DETECTED EXPRESSION LEVELS FOR THAT PARTICULAR GENE IN 25 NG OF MOUSE GENOMIC DNA (TAKEN 
FROM [194]). ..................................................................................................................................... 162 
FIGURE 4.1: MEMBERS OF THE TGF-Β FAMILY. MAJOR FAMILIES OF THE TGF-Β SUPERFAMILY INCLUDE TGF-Β, BMP, MIF 
AND ACTIVIN–INHIBIN. IMAGE TAKEN AND MODIFIED FROM DRABSCH & DIJKE, 2012 [229]. ............................ 174 
FIGURE 4.2: TGF-Β SIGNALLING PATHWAY. SUMMARISING THE DIFFERENT SIGNAL TRANSDUCTION PATHWAYS INITIATED BY 
THE DIFFERENT TGF-Β LIGANDS. A) SIGNALLING BY ACTIVIN LIGANDS. B) SIGNALLING BY TGF-Β LIGANDS AND C) 
SIGNALLING BY BMP LIGANDS. IMAGE TAKEN AND MODIFIED FROM 
(HTTPS://REACTOME.ORG/PATHWAYBROWSER/#/R-HSA-9006936&DTAB=DT). ...................................... 176 
20 
 
FIGURE 4.3: DOMAIN STRUCTURE OF SMADS. MH1 DOMAIN OF SMAD2 CONTAINS AN ADDITIONAL 30 AMINO ACIDS (DARK 
GREEN BOX). SMAD3 CONTAINS A TRANS-ACTIVATION (TA) IN ITS LINKER REGION. SMAD2, 3 AND SMAD4 CONTAINS A 
NUCLEUS LOCALIZATION SIGNAL (NLS) IN THEIR MH1 DOMAIN. SMAD 7 LACKS MH1 DOMAIN. FIGURE TAKEN AND 
MODIFIED FROM SAMANTA AND DATTA, 2012 [234]. ............................................................................... 178 
FIGURE 4.4: TGF-Β/SMAD SIGNALLING PATHWAY FROM ACTIVATION UPON TGF-Β LIGAND BINDING TO TRANSLOCATION TO 
THE NUCLEUS AND EFFECT ON GENE EXPRESSION. IMAGE TAKEN AND MODIFIED FROM JIANG ET AL. 2015 [235]. .. 179 
FIGURE 4.5: SCHEMATIC DIAGRAM OF SNIP PROTEIN DEPICTING THE LOCATION OF THE TWO FUNCTIONAL DOMAINS ....... 180 
FIGURE 4.6: TGF-Β/SMAD SIGNALLING PATHWAY FROM ACTIVATION UPON TGF-Β LIGAND BINDING TO TRANSLOCATION TO 
THE NUCLEUS AND REPRESSION OF GENE EXPRESSION ON SNIP1 BINDING TO THE P300/CBP TRANSCRIPTION CO-
ACTIVATOR. IMAGE TAKEN AND MODIFIED FROM JIANG ET AL. 2015 [235]..................................................... 181 
FIGURE 4.7: SIMPLIFIED PEDIGREE OF THE FOUR AMISH FAMILIES INITIALLY INVESTIGATED SHOWING THE SIX AFFECTED 
INDIVIDUALS INITIALLY GENOTYPED USING A GENOME-WIDE SNP MICROARRAY. ............................................... 182 
FIGURE 4.8: PICTORIAL REPRESENTATION OF THE (A) IDENTIFIED 1.65MB DISEASE LOCUS ON CHROMOSOME 1 CONTAINING 
17 GENES, WITH SNIP1 INDICATED (RED CIRCLE).  (B) SEQUENCE CHROMATOGRAM CORRESPONDING TO THE SNIP1 
C.1097A<G VARIANT (C) MULTI-SPECIES AMINO ACID ALIGNMENT AROUND THE GLU366 REGION, SHOWING 
STRINGENT CONSERVATION OF THIS REGION (D) SCHEMATIC SHOWING DOMAIN ARCHITECTURE OF SNIP1 POLYPEPTIDE 
SEQUENCE WITH REGARD TO GLU366 , LOCATED ALONGSIDE THE FORKHEAD-ASSOCIATED DOMAIN (F). ............... 184 
FIGURE 4.9: THREE SIBLINGS DISPLAYING CHARACTERISTIC CRANIOFACIAL FEATURES. PHOTOGRAPH PROVIDED BY DR ZINEB 
AMMOUS FROM THE COMMUNITY HEALTH CLINIC, TOPEKA, US. WRITTEN CONSENT GRANTING PERMISSION FOR 
PUBLISHING WAS OBTAINED LOCALLY. ...................................................................................................... 185 
FIGURE 4.10: AXIAL BRAIN MRI OF A NORMAL CONTROL (LEFT) COMPARED TO AN AFFECTED PATIENT (RIGHT) SHOWING 
SKULL DYSPLASIA AND HYPOMYELINATION. ................................................................................................ 187 
FIGURE 4.11: A) INFANT PATIENT WITH TRACHEOSTOMY TUBE FITTED AS A RESULT OF RESPIRATORY COMPLICATIONS. 
ATYPICAL FEATURES TALIPES EQUINOVARUS (B) AND CRANIOSYNOSTOSIS (C, D). PHOTOGRAPH PROVIDED BY DR ZINEB 
AMMOUS FROM THE COMMUNITY HEALTH CLINIC, TOPEKA, US. WRITTEN CONSENT GRANTING PERMISSION FOR 
PUBLISHING WAS OBTAINED LOCALLY........................................................................................................ 187 
FIGURE 4.12: GENE EXPRESSION FOR SNIP1 IN MULTIPLE HUMAN TISSUES. THE DATA USED FOR THIS ANALYSIS OBTAINED 
FROM: HTTPS://GTEXPORTAL.ORG/HOME/GENE/SNIP1, THE GTEX PORTAL ON 21/10/2019 USING GTEX ANALYSIS 
21 
 
RELEASE V8 AND DBGAP ACCESSION NUMBER PHS000424.V8.P2 ON 21/10/2019.   SORTED ACCORDING TO TISSUE 
TYPE WITH THE OUTLINER FUNCTION SWITCHED OFF. ................................................................................... 198 
FIGURE 4.13: SHOWING THE LOCATION OF SYNAPTIC PROTEINS IN THE SYNAPSES. HIGHLIGHTED () ARE THE TWO FAMILIES 
OF PROTEINS IDENTIFIED DUE TO GENES OF THEIR FAMILY MEMBERS BEING UPREGULATED IN OUR DISEASE GROUP 
(COMPARED TO CONTROLS) VIA ENRICHMENT ANALYSIS. IMAGE TAKEN (AND MODIFIED) FROM OSIMO ET AL. [257].
 ........................................................................................................................................................ 201 
FIGURE 4.14: A) SCHEMATIC DRAWING OF A SYNAPSE INDICATING THE LOCATION OF THE ACTIVE ZONE (IMAGE ADAPTED FROM 
SÜDHOF [263]). B) A SCHEMATIC VIEW OF SYNAPTOTAGMIN1, WITH EACH FUNCTIONAL DOMAIN IS COLOURED 
DIFFERENTLY, SHOWING THE LOCATION OF CA2+ BINDING TO THE C2A AND C2B DOMAINS (IMAGE REPLICATED AND 
MODIFIED FROM BRACHYA ET AL. [260]). ................................................................................................. 202 
FIGURE 4.15: THE SYNAPSIN FAMILY PROTEIN DOMAINS. DOMAIN A, A SHORT N-TERMINAL REGION, IS SHARED BY ALL 
SYNAPSIN ISOFORMS AND CONTAINS A PHOSPHORYLATION SITE THAT CONTROLS THE REVERSIBLE ASSOCIATION WITH 
SYNAPTIC VESICLES. DOMAIN B IS RICH IN SMALL AMINO ACIDS, VARIES BETWEEN ISOFORMS AND IS CONSIDERED AS A 
LINKER REGION CONNECTING DOMAIN A TO DOMAIN C. DOMAIN C IS A LARGE REGION (~300 AMINO ACIDS) BELIEVED 
TO STABILISE THE INTERACTION WITH THE SYNAPTIC VESICLE BY PENETRATING ITS LIPID BILAYER. AFTER DOMAIN C, THE 
AMINO ACID SEQUENCE DIVERGES IN THE DIFFERENT SYNAPSIN GENE PRODUCTS. HOWEVER, ALL ISOFORMS BEAR A 
PROLINE-RICH DOMAIN WITHIN THE C-TERMINAL REGION (WITHIN DOMAINS D, G, H OR J). THE AMINO ACID SCALE IS 
SHOWN ALONG THE TOP. IMAGE TAKEN AND MODIFIED FROM CRESCA ET AL. [268]. ......................................... 205 
FIGURE 4.16: THE MAJOR FUNCTIONS OF SYNAPSINS TAKEN FROM MIRZA AND ZAHID, 2018 [266]. ............................ 206 
FIGURE 4.17: THE SCHEMATIC STRUCTURE OF CHL1 DEMONSTRATING THE CHARACTERISTIC STRUCTURE OF A 
TRANSMEMBRANE IMMUNOGLOBULIN CELL ADHESION MOLECULES (IGCAMS) CONTAINING SIX IG-LIKE DOMAINS AND 
FIVE FN3 REPEATS. IMAGE MODIFIED FROM IRINTCHEV AND SCHACHNER, 2012 [279]. .................................... 209 
FIGURE 4.18: THE SCHEMATIC STRUCTURE OF ROBO FAMILY MEMBERS. ROBO1-3 SHOWING THE TYPICAL STRUCTURE WIHT 
FIVE IG DOMAINS, THREE FIBRONECTIN TYPE III (FN3) REPEATS AND FOUR CONSERVED CYTOPLASMIC DOMAINS AND 
ROBO4 COMPRISING OF ONLY THREE IG DOMAINS, TWO FN3 DOMAINS AND TWO CYTOPLASMIC DOMAINS. IMAGE 
MODIFIED FROM YPSILANTI ET AL., 2010 [283] AND YADVA AND NARAYAN, 2014 [282]. ............................... 211 
FIGURE 5.1: SCHEMATIC SHOWING AN OVERVIEW OF THE DIFFERENT SOURCES OF INFORMATION USED DURING THE PROCESS 
OF VARIANT CALL FILE ANNOTATION. ........................................................................................................ 218 
22 
 
FIGURE 5.2: SCHEMATIC ILLUSTRATING THE OVERALL AIMS OF THE NIH CLINGEN PROJECT DESCRIBING IT HOPES TO IMPROVE 
PATIENT CARE THROUGH GENOMIC MEDICINE REPRODUCED FROM HTTPS://WWW.CLINICALGENOME.ORG/ABOUT. 227 
FIGURE 5.3: MEMBER ORGANIZATIONS OF THE MME PROJECT REPRODUCED FROM 
HTTPS://WWW.MATCHMAKEREXCHANGE.ORG/......................................................................................... 228 
FIGURE 5.4: SUMMARY OF THE AMISH EXOME DATA ANALYSIS INCLUDING FILTERING CRITERIA, NUMBER OF VARIANTS AND 
LOCATION OF RESULTS. .......................................................................................................................... 232 
FIGURE 5.5: SCHEMATIC REPRESENTATION OF A COMMON SNVS CAUSING RECESSIVE DISEASE WHEN OCCURRING IN 
COMBINATION WITH A LOF VARIANT IN A COMPLEX COMPOUND HETEROZYGOUS FASHION. ................................ 265 
FIGURE 7.1: ANTIBODY STAINING OF THE INNER MOUSE EAR (E16.5) A) WITH THE ANTIBODY RAISED AGAINST SLC15A5 AND 




LIST OF TABLES 
TABLE 1.1: ADVANTAGES OF STUDYING GENETICS IN THE AMISH. TAKEN [24] ............................................................ 37 
TABLE 1.2: PHRED QUALITY SCORES WITH ASSOCIATED Q SCORE. Q SCORES ARE LOGARITHMICALLY LINKED TO ERROR 
PROBABILITIES ....................................................................................................................................... 53 
TABLE 2.1 BUFFERS, REAGENTS AND STOCK SOLUTIONS REQUIRED FOR MOLECULAR DNA TECHNIQUES AND THEIR 
CONSTITUENTS. ..................................................................................................................................... 60 
TABLE 2.2: COMPONENTS OF A 10µL AND 20µL LABTAQ PCR REACTION .................................................................. 72 
TABLE 2.3: LABTAQ PCR REACTION THERMOCYCLER PROGRAM .............................................................................. 73 
TABLE 2.4: SEQUENCING REACTION COMPONENTS AND QUANTITIES ......................................................................... 76 
TABLE 2.5: SEQUENCING REACTION THERMOCYCLER PROGRAM ............................................................................... 76 
TABLE 2.6: SOLUTIONS FOR MOLECULAR CLONING TECHNIQUES ............................................................................... 81 
TABLE 2.7: DETAILS OF CUSTOM DESIGNED PRIMERS .............................................................................................. 82 
TABLE 2.8: COMPONENTS PFU PCR REACTION MIXTURE ........................................................................................ 86 
TABLE 2.9: LIGATION REACTION MIXTURE ............................................................................................................ 89 
TABLE 2.10: TRANSFECTION MIXTURE COMPOSITION ............................................................................................. 91 
TABLE 2.11: DETAILS OF PRIMARY ANTIBODIES USED FOR IMMUNOCYTOCHEMISTRY (ICC) AND WESTERN BLOT (WB) 
ANALYSIS .............................................................................................................................................. 92 
TABLE 2.12: DETAILS OF SECONDARY ANTIBODIES USED FOR IMMUNOCYTOCHEMISTRY (ICC) AND WESTERN BLOT (WB) 
ANALYSIS .............................................................................................................................................. 93 
TABLE 2.13: SDS-PAGE GEL PERCENTAGE RECOMMENDATION BASED ON PROTEIN SIZE. .............................................. 96 
TABLE 2.14: SDS-PAGE GEL COMPOSITION. ....................................................................................................... 96 
TABLE 3.1: CHARACTERISTICS FOR CLASSIFYING HEARING LOSS [128-130]. .............................................................. 109 
TABLE 3.2: SUMMARY OF GENES ASSOCIATED WITH SYNDROMIC SNHL HEARING LOSS IDENTIFIED IN THE AMISH. ............ 124 
TABLE 3.3: SUMMARY OF GENES ASSOCIATED WITH SYNDROMIC, CONDUCTIVE AND MIXED HEARING LOSS IDENTIFIED IN THE 
AMISH. .............................................................................................................................................. 125 
TABLE 3.4: SUMMARY OF FAMILIES IN WHICH GJB2 VARIANTS WERE FOUND DURING INITIAL SCREENING. ...................... 134 
TABLE 3.5: REGIONS OF SHARED HOMOZYGOSITY BETWEEN AFFECTED SIBLINGS. ....................................................... 139 
TABLE 3.6: ALLELE FREQUENCY DATA FOR SLC15A5 VARIANT DETERMINED FROM AN AMISH POPULATION COHORT OF 167 
UNAFFECTED INDIVIDUALS. ..................................................................................................................... 141 
24 
 
TABLE 3.7: SUMMARY OF GENES ASSOCIATED WITH HEARING LOSS IDENTIFIED IN THE AMISH COMMUNITY. ALLELE FREQUENCY 
WAS DETERMINED FROM AN AMISH POPULATION COHORT OF 167 UNAFFECTED INDIVIDUALS ............................. 151 
TABLE 4.1: THE CLINICAL PRESENTATION IN THE 33 AFFECTED INDIVIDUALS; ADHD, ATTENTION DEFICIT HYPERACTIVITY 
DISORDER ........................................................................................................................................... 186 
TABLE 4.2: TOP TEN PATHWAYS AND ASSOCIATED GENES IDENTIFIED BY ENRICHR AS BEING UPREGULATED IN THE DISEASE 
GROUP COMPARED TO CONTROLS ............................................................................................................ 189 
TABLE 4.3: TOP TEN PATHWAYS AND ASSOCIATED GENES IDENTIFIED BY ENRICHR AS BEING DOWNREGULATED IN THE DISEASE 
GROUP COMPARED TO CONTROLS ............................................................................................................ 190 
TABLE 4.4: COMPARISON OF THE CLINICAL PRESENTATION IN THE 33 AFFECTED INDIVIDUALS AND SYT1- ASSOCIATED NDD.
 ........................................................................................................................................................ 203 
TABLE 5.1: CLINVAR REVIEW STATUS, ASSIGNMENT OF STARS AND DESCRIPTION OF EACH WHEN EACH STATUS IS AWARDED.
 ........................................................................................................................................................ 223 
TABLE 5.2: SUMMARY OF THE SIX VARIANT CLASSES USED BY HGMD [305]............................................................. 225 
TABLE 5.3: NONSENSE VARIANTS CLASSIFIED AS PATHOGENIC OR LIKELY PATHOGENIC IN CLINVAR OR WITH A DISEASE-CAUSING 
MUTATION (DM) IN HGMD® REPORTED TO CAUSE AN AR DISORDER/PHENOTYPE. VARIANTS PREVIOUSLY REPORTED 
IN THE AMISH ARE HIGHLIGHTED IN BLUE. THE VARIANT IN FRY IS SHOWN IN GREY THERE IS LESS ROBUST EVIDENCE IN 
SUPPORT OF ITS PATHOGENICITY. ............................................................................................................ 235 
TABLE 5.4: FRAMESHIFT VARIANTS CLASSIFIED AS PATHOGENIC OR LIKELY PATHOGENIC IN CLINVAR OR WITH A DISEASE-
CAUSING MUTATION (DM) IN HGMD® REPORTED TO CAUSE AN AR DISORDER/PHENOTYPE. VARIANTS PREVIOUSLY 
REPORTED IN THE AMISH ARE HIGHLIGHTED IN BLUE. ................................................................................... 236 
TABLE 5.5: CANDIDATE NOVEL HETEROZYGOUS NONSENSE VARIANTS IDENTIFIED IN GENES PREVIOUSLY ASSOCIATED WITH AN 
AUTOSOMAL RECESSIVE DISORDER IN HUMANS IDENTIFIED IN OUR AMISH AGGREGATED EXOME DATASET. ............. 238 
TABLE 5.6: CANDIDATE NOVEL HETEROZYGOUS FRAMESHIFT VARIANTS IDENTIFIED IN GENES PREVIOUSLY ASSOCIATED WITH AN 
AUTOSOMAL RECESSIVE DISORDER IN HUMANS IDENTIFIED IN OUR AMISH AGGREGATED EXOME DATASET. ............. 241 
TABLE 5.7: RARE (AF ~1% OR LESS) HETEROZYGOUS MISSENSE VARIANTS IDENTIFIED IN THE AGGREGATED AMISH EXOME 
DATA THAT HAVE PREVIOUSLY BEEN ASSOCIATED WITH AUTOSOMAL RECESSIVE DISEASE IN HUMANS AND ARE REPORTED 
AS PATHOGENIC OR LIKELY PATHOGENIC IN CLINVAR. GROUPED BY PRIMARY SYSTEM AFFECTED. VARIANTS PREVIOUSLY 
REPORTED IN THE AMISH IN ASSOCIATION WITH THE DISEASE ARE HIGHLIGHTED IN BLUE. .................................... 245 
25 
 
TABLE 5.8: ALLELE FREQUENCY ANALYSIS OF THE MOST COMMONLY OBSERVED VARIANTS WITHIN DIFFERENT AMISH 
COMMUNITIES. .................................................................................................................................... 247 
TABLE 5.9: ALLELE FREQUENCY ANALYSIS OF HETEROZYGOUS VARIANTS ONLY OBSERVED WITHIN ONE AMISH COMMUNITY 
WITHIN OUR COHORT. ........................................................................................................................... 248 
TABLE 5.10: ALLELE FREQUENCY DATA FOR VARIANTS IN PUTATIVE DISEASE GENES IN DIFFERENT AMISH SETTLEMENTS














Indiana - 0 0
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1.1 The Amish  
 
1.1.1 A brief history of the Amish  
The Amish are a distinct group of rural-living Anabaptist Christians whose 
heritage dates back to 16th century Europe. Setting out to revive the Anabaptist 
movement one leader, Jakob Amman, suggested the implementation of stricter 
practices including; more regular communions, forbidding the trimming of beards, 
the wearing of fashionable clothes and advocating the shunning of    
excommunicated members. The practice of shunning or “Meidung” was not 
intended to be a punishment but instead used to show to an individual that they 
needed to repent their sin. Shunning could be demonstrated in a number of ways 
including; avoiding the individual, refusal of goods from offenders or refusing to 
share a meal with them. In 1693 these proposals caused a schism within a group 
of Swiss Anabaptists in Alsace; those members choosing to follow Amman 
became known as the Amish. 
Since the formation of the Anabaptist church, during the Protestant Reformation 
in 16th century Europe, the religious convictions of these individuals has created 
a social and cultural divide. Their rejection of infant baptism and belief in adult 
baptism, was one such division. The name Anabaptist itself means “rebaptisers” 
due to their practice of baptising adults who had previously been baptised as 
infants in a Catholic or Protestant church. The rapid spread of the Anabaptist 
movement and their request for a voluntary church separate from the state 
angered other religious leaders and civil officials. This unfortunately led to the 
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persecution of many Anabaptist followers and culminated in the social, cultural, 
and subsequently genetic, isolation of Anabaptists from the rest of the Europe. 
In 1737, as a consequence of continued persecution, twenty-one Amish families 
migrated to the USA, originally settling in the Mid-west, particularly Pennsylvania, 
Ohio and Indiana. Between 1815 and 1860, there was a second wave of 
immigration resulting in approximately 3000 Amish individuals from Europe 
settling in the US.  
 
1.1.2 Population bottleneck and the founder effect in the Amish 
These migrations created an ancestral bottleneck (Figure 1.1Figure 1.1) which 
further reduced the genetic diversity of the already modest gene pool that has 
established the now large Amish population, estimated to be 308,000.  
 
 




As a result of a limited number of founder individuals the frequency of autosomal 
recessive (AR) alleles, present in these founders, may increase within that 
population meaning any two individuals, selected at random, from the community 
have an increased chance of being a carrier for a particular variant [1].  
As with any community arising in this way, including other genealogically-related 
Anabaptist communities, such as the Mennonites and Hutterites, a number of 
causal genetic variants have become enriched within the population. This has 
unfortunately led to a higher incidence of particular genetic diseases, compared 
to the general population, caused by a phenomena known as the “founder effect”. 
Dwarfism (Ellis–van Creveld syndrome) [2], Angelman syndrome [3] and various 
metabolic disorders, including maple syrup disease [4] and phenylketonuria [5] 
are examples of genetic diseases that have become enriched within the Amish 
population.  
 
Despite no longer being persecuted for their beliefs the Amish are still considered 
to be isolated, both culturally and geographically. The Amish are relatively 
immobile as a result of religious constraints on transportation (Figure 1.2). Very 
few members join their communities and the Amish advocate endogamous 
marriages, the practice of marrying within a specific social group rejecting those 
from others. This has resulted in little gene inflow into the population meaning 





Figure 1.2: Amish horse and buggy transportation. Personal photograph provided 
by Professor Andrew Crosby, taken in Ohio, June 2014. 
 
The Amish Population has increased dramatically since the initial migrations; 
expanding by 18% between 2011 and 2016 [6]. It is estimated that the population 
doubles approximately every 18-20 years.  The driving force behind this growth 
can be attributed to the large nuclear families, frequently having more than five 
children, and the high retention rate of around 85% within the Amish faith. As a 
result of this growth the number of settlements (geographical communities) 
continues to increase with 138 new settlements being established from 2009 to 
2018. This included six new settlements in Canada and surprisingly two 
settlements in South America located in Argentina and Bolivia [6]. The 
establishment of new settlements is not solely to accommodate the increasing 
population. New settlements can arise for a variety of reasons including; the 
availability of affordable farmland or non-farm work in specialised occupations, to 
achieve rural isolation that supports the Amish lifestyle in terms of social and 
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physical environments, to move closer to family or similar Amish church groups 
(demes) or to resolve church or leadership conflicts. Conflicts can arise due to 
differing opinions on the practices within a particular group or affiliation (collection 
of church districts that have similar practices). 
As with any religious following there is diversity between the different groups 
within the Amish faith. One of the greatest sources of this variety is the differing 
views regarding the acceptance of technology. It is a common misconception that 
all Amish reject all forms of modern technology. Some affiliations choose to use 
battery powered lights and sewing machines where the more conservative decide 
to use kerosene lanterns and only permit the use of treadle (foot-powered) sewing 
machines. A more accurate description of the use of technology within the Amish 
is that is it used selectively in a manner that preserves their traditional way of life 
and prevents the introduction of foreign values into their communities. For these 
reasons many Amish groups reject technology that enables access to the mass 
media including the use of televisions, radios and the internet. 
There are four groups that carry the Amish name: Beachy Amish, Amish 
Mennonites, New Order Amish and Old Order Amish. Although practices 
between these groups display large amounts variation they can largely be 
separated into two distinct classes. The Beachy and Mennonite Amish own 
automobiles and use public utility electricity whereas the New and Old Order 
Amish use horse-and-buggy transportation and do not use public utility electricity. 






1.1.3 Amish demes 
One aspect of this study involved undertaking the first large scale investigation of 
carrier frequencies within different Amish demes for the most commonly occurring 
pathogenic variants seen in the Amish. These studies have the potential to 
expedite diagnostic testing for families by helping identify the most likely 
causative genetic variants based on the community in which the affected 
individual belongs. 
Due to the circumstances under which new demes are typically formed 
(discussed above) each deme included in this study occupied a different 
geographical location. We hypothesised the allele frequencies observed in each 
region would reflect the ancestral histories and migration patterns of each deme. 
For this reason, the allele frequency data was grouped depending on the region 
in which an individual originated. This gave rise to four cohorts within our allele 





1.2 Other population isolates 
Population isolates can arise as a result of a founder effect, where a new 
population is established by a (relatively) small number of individuals from a 
larger population, or from the extreme reduction in size of a population resulting 
in a genetic bottleneck [7]. The Amish are not the only founder population that 
display an enrichment of particular diseases. Other founder populations include 
the Finns, the Samoans, the Orkney islanders and the Ashkenazi Jews.  
 
1.2.1 The Finnish population 
The Finnish population has been a target of extensive genetic studies since the 
1950s [8]. In 1973 a “landmark paper” describing 10 'Finnish' disorders was 
published and coined the term 'Finnish Disease Heritage' (FDH) to describe a 
group of rare hereditary diseases that are overrepresented in Finland [8, 9]  
The unique Finnish genetic architecture is explained by repeated population 
bottlenecks that have subsequently given rise to the large current day Finnish 
population of 5.5 million [10] from a small founder population. The initial founder 
effect arose as a result of two waves of colonisation that took place between 
4000-2000BP (years before present) in southern and western Finland. These 
areas remained populated at a low density until internal emigration occurred in 
the 15-16th century when small family groups, from the original colonisations of 
southern Finland, moved into the northern and eastern areas [10, 11]. These 
movements formed sub-isolate populations, isolated through distance, that are 
believed to be behind the presence of more than 35 recessive monogenic 
illnesses including Finnish nephropathy (NPHS1) and cartilage hair hypoplasia 
(RMRP) [9], that are more commonly seen in the Finnish population, particularly 
in eastern Finland [11]. These movements are also assumed to explain the 
34 
 
exceptionally low prevalence of other diseases such as cystic fibrosis, with an 
incidence a 10th of that in other parts of Europe, and phenylketonuria, which was 
reported at a carrier frequency of 1:180 [8]. 
Like the Amish, the Finnish population is well suited for gene mapping studies 
due to its reduced diversity and increased homogeneity. However, studies have 
reported substantial differences in genetic composition between different parts of 
Finland [11].   
 
1.2.2 The Samoan population 
It has been suggested that the Samoan populations of the Western Pacific are 
one of the best examples of an isolated population given the archaeological, 
cultural and linguistic evidence supporting the long-distance migration 
undertaken by the ancestors of today’s islanders [12, 13]. Samoan settlement is 
believed to have occurred 5000-4000BP after rapid migration from Southern 
China [12].  After ~1000years (3000BP) island culture was reportedly thriving and 
supporting an estimated population of 100,000 to 300,000 people [12, 14]. After 
European contact in the 1700s Samoa suffered significant population declined, 
attributed to the introduction of disease [12]. By 1900 the population was 
estimated to be as low as 30,000 people. After numerous epidemics throughout 
the 18th century the population recovered to an estimated 69,000 by the 1940s 
[12]. These historical events are likely to have influenced the Samoan genome.  
Over the last 35 years there has been a documented rise in the prevalence of a 
number of non-communicable diseases, including Type 2 diabetes mellitus (TD2) 
and cardiovascular disease (CVD) in addition to high levels of adiposity (obesity) 
[14, 15]. Although obesity is a complex phenotype with genetic and environmental 
factors impacting its presentation the relative isolation, large family sizes and 
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recent exposure to modernization of the Samoan population provide a unique 
opportunity to identify novel genetic contributors to obesity [14, 16].  
In the last decade a number of susceptibility loci for obesity have been identified 
within the Samoan population [14]. More recently one study has identified a 
variant (NM_153607.2:c.1370G>A, p.Arg457Gln) in the CREBRF gene 
associated with an extreme increase in body mass index (BMI), very rare in other 
populations but common in Samoans, that selectively decreases energy use and 
increases fat storage in adipocyte cell studies [16, 17]. Interestingly there is 
evidence that this variant has been positively selected in Samoan genomes, 
supporting the “thrifty” variant hypothesis proposed by James Neel in 1962, 
suggesting that this variant may historically have been an asset to the population 
during historical periods of “feast-or-famine” [18].  
 
1.2.3 Orkney Island population 
Located in an isolated position off the northern coast of Scotland, geographic 
distance has acted as a barrier to migration resulting in minimal movement in to 
and out of the Orkney Islands [19]. This has impacted the genetic structure of the 
population and led to individuals displaying higher levels of genetic similarity than 
would be expected in a non-isolated population [20]. This relatively low genetic 
variability, in addition to the comparatively low environmental variability, means 
this population is well suited to identify risk factors of diseases found within the 
community at a higher than expected prevalence [19].  
Over 30 years ago high rates of multiple sclerosis (MS) were reported in the 
Orkney Islands and northern Scotland. MS, a complex inflammatory autoimmune 
disorder, is the most common disabling neurological disorder in young adults [21] 
with strong evidence suggesting both genetic and environmental risk factors 
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effect disease susceptibility [19]. Recent epidemiological studies have shown that 
the prevalence of this condition on the island has continued to increase with 
Orkney now reporting the highest prevalence rate of MS in world [22, 23]. As a 
result the communities of the Orkneys have been involved in a number of studies 
investigating the role of both genetic [19] and environmental [21] factors on the 




1.3 Genetic studies in the Amish 
In 1962 the first genetic studies of the Amish were undertaken by Victor 
McKusick, a prominent figure in the formation of the medical genetics field, 
investigating dwarfism within the community. These investigations were based 
on ideas he had developed from reading an article written by David Krusen, a 
local family doctor, and a manuscript entitled “Amish Society” submitted by John 
Hostetler. The article mentioned achondroplasia was extremely common in the 
Amish and the manuscript highlighted the many characteristics of the Amish 
community that are advantageous to the study of genetic traits (Table 1.1) [24]. 
 
Table 1.1: Advantages of Studying Genetics in the Amish. Taken [24]  
Advantages of Studying Genetics in the Amish 
The Older Order Amish are a self-defined population 
It is a closed population; gene flow is almost exclusively centrifugal 
The Western European origins of the population are well known 
Extensive genealogic records 
The standard of living is high 
The standards of medical care are relatively high 
An evident interest in illness (and its cause) 
There is a high coefficient of inbreeding due to the relatively small number of founder 
couples 
The illegitimacy rate is apparently low 
The Amish are interested and knowledgeable about the health of their relatives. They 
seek out information on rare disorders shared by other Amish families 
Socio-economic and occupational circumstances are notably uniform 
Because of constraints on transportation, the Amish are relatively immobile 
Most Amish families are large, with an average of seven to nine children 
Children with birth defects or genetic disorders are usually kept at home rather than 
institutionalized 
The existence of several Amish isolates makes comparisons of sub-populations 
possible 
 
Taken together these factors greatly facilitate the discovery of genes responsible 
for inherited disease, which might otherwise have been impossible in studies of 
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other populations due to the genetic and environmental complexities of a 
condition. 
 
In 1962 McKusick was approached by a young doctor, Dr Harold Cross, who was 
raised in an Amish community in Indiana and wished to undertake a PhD. The 
resulting studies focused on neurological conditions in the Ohio Amish and 
produced publications describing a number of disorders including Troyer 
syndrome [25] and Mast syndrome [26] two novel forms of complex hereditary 
spastic paraplegia. However, at the time, it was not possible to identify the 
causative genes for these novel conditions.  
 
The work of McKusick in the early 1960’s led to the development and publication 
of the Mendelian inheritance in Man (MIM). First published in print in 1966 as a 
“comprehensive knowledge base of human genes and genetic disorders” [27] it 
contained a trilogy of catalogues detailing autosomal dominant (AD), autosomal 
recessive (AR) and X-linked phenotypes. Twelve print editions of this 
compendium were released between 1966 and 1998. These print versions have 
been superseded by an online version, the Online Mendelian Inheritance in Man 
(OMIM) which was first made available in 1987. Since 1995, and its distribution 
by the National Centre for Biotechnology Information (NCBI), it has been updated 
daily and become a critical, frequently used resource for anyone involved in the 
field of medical genetics [28]. 
 
Professor Andrew Crosby, who has a particular interest in neurological 
conditions, contacted Dr Cross in 2000 to suggest a collaborative research 
project with the aim of using genetic technologies, developed since the original 
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study, to identifying the underlying genetic causes of these conditions. These 
studies successfully identified the causative genes for both Troyer syndrome 
(SPG20) in 2002 [29] and Mast syndrome (SPG21) in 2003 [30].  
As a result of these successful investigations and realising the potential impact 
to the Amish community Crosby and Cross established the Windows of Hope 
Project (WoH) [31] which conducted the largest survey of inherited conditions 
amongst the Amish communities. In partnership with the non-profit Amish-led 
Windows of Hope Genetic Information Centre (WHGIC) the project has made a 
significant contribution to determining the underlying molecular causes and 
clinical manifestations of inherited diseases amongst the Ohio Amish community.  
 
1.3.1 Windows of Hope Project 
The Windows of Hope Project is a long-running, non-profit community genetic 
research program which has undertaken the largest survey of inherited conditions 
within Anabaptist communities. By working closely with the Anabaptist 
communities and local healthcare and special educational needs providers in 
both Ohio and Wisconsin the group has made significant progress in determining 
the molecular causes and clinical manifestations of inherited diseases. To date it 
has assisted in the identification and description of the genetic cause of over 30 
inherited disorders, including 16 novel conditions being described as a direct 
result of their work [31]. Almost all of these disease genes, initially identified in 
the Amish, have subsequently been found worldwide in other populations causing 
similar diseases. Highlighting the global significance of studying inherited 
conditions in genetic isolates such as the Amish.  
The high number of undiagnosed childhood development disorders among the 
Holmes County Amish population places a significant social and financial burden 
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on the community. Whilst community schemes are available to help with medical 
expenses, the rising costs of medical care means many Amish families are not 
supported so do not undergo important clinical investigations or receive 
treatment.  
The primary aim of the WoH project is to utilise modern genomic technologies, 
combined with clinical expertise, to advance the understanding of inherited 
disease within Anabaptist communities, improve healthcare outcomes and 
provide substantial cost savings for families affected by these conditions. 
Genomic findings from research studies enable these improved outcomes by 
empowering molecular diagnostic services, enabling focused disease-specific 
clinical management strategies and the development of new treatment strategies. 
The WoH undertakes studies of a wide range of inherited conditions including 
neurological, cardiovascular and developmental disorders. Clinical and 
diagnostic laboratory collaborations, supported by the WoH, have assisted 
families in receiving much-needed diagnoses for previously unrecognized 
conditions.  
 
The WoH Project now has a mature infrastructure including an Amish-led regional 
centre, WHGIC located in Ohio, the second largest Amish settlement in the US. 
The centre is a source of information and support for local families which, through 
collaborations with clinical partners, has developed an extensive community-
appropriate educational programme including family information days and 
disease-specific leaflets, and practical educational symposia.  In addition to this 
the WoH has established an extensive searchable clinical online database to 
provide information to medical practitioners about all the conditions currently 
known to be present in the Plain communities [31].  
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1.4 Genomic technologies  
The advent and widespread availability of next-generation sequencing (NGS) has 
decreased the cost and associated timelines of genetic and biological research 
[32]. A significant number of studies undertaken by the WoH project within the 
Amish have utilised various high-throughput NGS techniques including 
autozygosity mapping, in combination with whole exome sequencing (WES) to 
identify causative pathogenic variants.  
Outlined in this project is the first time the WoH project has employed the use of 
the PLEXseq process, to determine the allele frequencies of the most commonly 
occurring pathogenic variants seen within the various Amish communities. 
 
1.4.1 Autozygosity mapping 
Rare recessive mutations are predicted to occur in every population but are 
unlikely to achieve homozygosity in the general population. However, unions 
between closely related (consanguineous) or distantly related (endogamous) 
individuals dramatically increases the probability of resultant offspring being 
homozygous at any given genetic locus [33]. Endogamous and consanguineous 
unions often result in autozygosity, a special form of homozygosity, where two 
copies of a section of DNA, shared by two or more people, are identical by 
descent (IBD) as they have been inherited from a common ancestor, without any 
intervening recombination (Figure 1.3) [34]. 
The use of ‘autozygosity mapping’ to define the chromosomal location of a 
disease locus was first proposed in 1987 using consanguineous families based 
on the principle that affected individuals will be IBD for the disease causing 
variant and surrounding haplotype [35]. Over the last 30 years this approach has 
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become a powerful method for identifying recessively inherited disease genes 
within genetically isolated populations, such as the Amish.  
 
 
Figure 1.3: Simplified schematic presentation of the concept of autozygosity. An 
ancestral haplotype (red box) containing a variant of interest () is transferred 
through the generations. In each generation different haplotypes enter the 
pedigree represented with a different coloured bar. Recombination events 
(shown by dotted lines) in each generation shorten the size of the haplotype. 
(Modified from [36] and [34]). 
 
Advances in the experimental techniques used to generate and analyse data has 
dramatically increased the speed of detecting autozygous regions [37].  Early 
methods used highly polymorphic microsatellite, or small tandem repeat (STR), 
markers to identify autozygous regions. Despite these markers being more 
powerful at detecting homozygous chromosomal segments than single-
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nucleotide polymorphisms (SNPs) the increased time, cost and inability to identify 
smaller autozygous sections, due to the increased distance (10–12cM) between 
markers, led to them being superseded by SNP microarrays [38].  
 
SNP microarrays are silicon chips (SNP-chips), originally designed by Affymetrix 
and Illumina that detect SNPs across the whole genome in a single hybridisation 
reaction making them much more time and cost efficient than microsatellite 
analysis. Although each SNP, as mentioned previously, is far less powerful at 
detecting a homozygous region than a microsatellite marker, they offer a number 
of other benefits that have encouraged their increased and extensive use.  
SNP-chips offer greater coverage of the genome, due to their increased number. 
For example an early chip containing 10,913 SNPs is reported to be equivalent 
to a 3–4cM microsatellite marker map [39], enabling the identification of smaller 
autozygosity regions. The increased number of SNPs also enables the detection 
of heterozygous regions more effectively than with microsatellite markers. A 
single average microsatellite marker was projected to have a 70% chance of 
detecting heterozygosity. A genomic region of the same size on a SNP-chip 
containing approximately 30 SNPs would have a 99% chance of detecting a 
heterozygous region [39]. 
More recently it was suggested that exome sequencing could be used to 
concurrently define autozygous regions and identify possible causative variants. 
However, initial investigations found poor coverage, compared to SNP-chip 
genotyping, due to the uneven distribution of coding regions across the genome 
[40] and suggested that shorter autozygous regions could be missed should they 




Today high-density and high-resolution SNP-chips, available from  Affymetrix and 
Illumina both containing more than 1 million genetic markers (Affymetrix SNP 
array 6.0 and Illumina 1M respectively), enable the detection of even the smallest, 
(54kb) structural changes [41, 42].  Copy number variation (CNV) is a type of 
genetic variation that is widely found in mammalian genomes and includes 
genomic deletion and duplication as well as complex rearrangements that range 
from 100 base pairs to several mega base pairs in size [43]. CNVs have been 
shown to have a significant impact on complex human diseases, such as autism 
[44] and cancer [45], due to the fact that they can disrupt gene structure and affect 
gene regulation. However, not all CNVs are linked to adverse phenotypes. To 
date, approximately 552,586 CNVs are included in the Database of Genomic 
Variants [http://dgvbeta.tcag.ca/dgv/app/home] [46]. A recent study mapping 
CNVs, not associated with disease, found around 100 genes that can be 
homozygously deleted without producing an adverse disease phenotype and 
estimated that up to 9.5% of the human genome contributes to CNV [47].  
 
These high-density SNP genotyping array platforms target biallelic SNPs. For 
each SNP, an array platform includes two types of hybridisation probes specific 
to two types of known alleles, usually coded as A and B, and the SNP genotype 
can be determined by the ratios of the hybridisation intensities for A and B probes. 
CNVs such as duplications and deletions increase or decrease the total 
measured intensities. Large CNVs, that span multiple SNPs, have intensity ratio 




Figure 1.4 CNV Analysis of Illumina Bead Chip Data. B allele frequency and log2 
R (normalised signal intensities) ratio are plotted over the entire genome for all 
SNPs. The plot exhibit diagnostic signature profiles of copy number. CN=2, 1; & 
3 shown (adapted from [48]). 
 
The number of SNP-chips now readily available allows users to select the array 
most suited to their research needs. The Illumina HumanCytoSNP-12 Bead Chip 
array was used in all studies outlined in this project. This platform permits the 
processing of up to 12 samples in parallel which increases sample throughput, to 
a level appropriate to the number of samples required for our studies, and 
decreases experimental variability [49]. It offers a low cost per sample, compared 
to other methods, and only requires 200ng of DNA per sample which is easily 
achievable when extracting DNA from whole blood lymphocytes and possible, 
though more variable, from extracting DNA from buccal swabs. Additionally this 
SNP-chip incorporates ~300,000 SNPs, offering dense coverage of ~250 disease 
regions shown to be important for detecting cytogenetic abnormalities most 
relevant to human disease.  
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Whilst it is generally accepted that SNP-chips are the best way to generate the 
data required to calculate regions of homozygosity (ROH) within samples and 
produce autozygosity maps there is currently a lack of consensus regarding how 
ROHs should be defined [50]. 
Although there are several computational methods for identifying ROHs within a 
dataset they can all be classified as either genotype-counting or model-based.  
 
Genotype-counting 
Genotype-counting software, such as PLINK [51], GERMLINE [52] or cgaTOH 
[53], all search for long, consecutive runs of homozygous genotypes that occur 
within a set of predefined parameters including the maximum number of 
heterozygous calls within a given region and the number of allowable missing 
genotypes.  
PLINK v.19, for example, uses a sliding window approach. This is where an 
algorithm scans each chromosome by moving a fixed sized window along the 
whole genome searching for consecutive homozygous SNPs [54]. To identify 
ROHs the location of each SNP is considered. This is achieved by calculating the 
proportion of completely homozygous windows that incorporate each SNP. If this 
proportion is higher than a defined threshold, a given SNP appears in more 
consecutive homozygous windows than expected, the SNP is considered to be 
in a ROH. The simplicity of this method permits large amounts of SNP data to be 
analysed efficiently [54].  
 
Model-based  
Model-based software, such as BEAGLE [55], FILTUS [56], BCFtools/RoH [57] 
and GARLIC [58], use probability to differentiate between autozygous and non-
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autozygous regions using the allele frequency of SNPs and recombination rate 
estimated from the data. Each of these methods utilise different algorithms which 
determines the achievable sensitivity, specificity and false positive rate of the 
resulting analysis. However, all current model-based methods use statistical 
modelling in the form of hidden Markov models (HMMs) to account for 
background levels of linkage disequilibrium [54]. 
HMMs were first introduced to computational biology during the late 1980s and 
are a class of probabilistic models [59] that represent probability distributions over 
linear sequences [60] and offer a consistent mathematical basis for assigning 
position-specific residue scores [61]. The central idea behind a HMM is that it is 
a finite model describing the probability distribution across an infinite number of 
possible sequences [61]. Being described as the “Legos of computational 
sequence analysis”, HMMs are now central to a diverse range of analysis 
programmes including; multiple sequence alignment, gene finding and regulatory 
site identification [62].  
 
In addition to the lack of consensus in how ROHs are delineated there is also a 
lack of standardisation regarding the sizing of ROHs which can be expressed 
using either a physical distance, in kilobases (kb) or megabases (Mb) or a genetic 
distance expressed in centimorgans (cM). A centimorgan is a measure of 
recombination frequency, with 1cM corresponding to a recombination frequency 
of 1% [63]. Whilst it has been suggested that the use of genetic distances to 
describe ROHs is preferable due its capacity to mitigate the effect of linkage 




LD refers to the non-random association of alleles at two, or more, genetic loci 
[65]. Loci are said to be in LD when the frequency of association of their different 
alleles is higher or lower than what would be expected if the loci were 
independent and associated randomly. The degree of LD varies greatly across 
the human genome. Regions that have undergone little to no historical 
recombination, displaying high LD, are often referred to as “haplotype blocks” [66] 
and are commonly bordered by recombination hotspots [64]. As a result of these 
different regions it is not possible to accurately compare ROHs located in different 
genomic locations based solely on physical distances.  
A population that has accumulated many recombinations at every position in the 
genome would display little LD as there would be no correlation between the 
inheritance of alleles at any particular loci [67]. The amount of LD between two 
alleles is related to the time of the mutation event, the genetic distance between 
alleles and the history of the population in which they are located. Relatively 
young (<2000 years) populations arising from a small founder population, such 
as the Amish, tend to display higher levels of LD [67]. This means the genomes 
of individuals from this population are more likely to contain longer ROH, or 
haplotype blocks, compared to the general population.  
 
The ROHs in the studies outlined in this project where measured in physical 
distances and determined using an in-house genotype-counting method which 
allowed for regions to be confirmed manually, taking into consideration potential 
miscalled or missing genotypes. Regions >1Mb in size were preferentially 




1.4.2 Whole exome sequencing 
Since the completion of the Human Genome Project (HGP) in 2001, at a cost of 
~$3billion and in excess of 200 scientists working for over a decade [68], 
substantial improvements have been made in the approach to genome 
sequencing [32]. Current methodologies are far less laborious and offer 
significantly cheaper costs per sample when compared to BAC (bacterial artificial 
chromosome) based sequencing, used by the HGP, and first generation 
sequencing techniques such as chemical sequencing [69] and dideoxy chain 
terminator, “Sanger”, sequencing [70]. Second generation, or next generation 
sequencing (NGS) technologies implement massively parallel sequencing 
(MPS), the simultaneous sequencing of multiple variants within multiple samples, 
of short-read lengths of DNA (50–500bp) which are amplified then assembled, by 
alignment to a reference sequence, using a bioinformatic pipeline [71, 72]. The 
high-throughput nature of these short-read technologies has enabled the cost of 
sequencing, per megabase, to reduce at a rate exceeding that of Moore’s Law 
(which proposed technology reduces microprocessor costs by half every 18 
months) [73]. Recently the lowest cost of whole genome (WGS) and whole exome 
(WES) sequencing was estimated to be $1906 per genome and $555 per exome, 
which has facilitated their increased application within both a research and clinical 
setting [74]. There are now several types of NGS tests available for use in a 
clinical setting; exome, genome, and panel NGS, which offer varying degrees of 
genome coverage [75]. 
 
Despite WGS investigating sequence changes such as; single-nucleotide 
variants (SNVs), insertions and deletions (indels), chromosomal rearrangements 
and copy-number variation (CNVs), across the whole genome, WES is reported 
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to be the more popular technique [76] as it covers the “more actionable areas of 
the genome” [74].  
Protein coding genes only constitute ~1% of the human genome [76] but contain 
85% of disease-causing mutations responsible for Mendelian disorders [77] 
which result from the mutation of a single genetic locus. As WES only targets 
95% of the coding regions, or exons, of protein coding genes [77] across the 
genome it requires less sequencing space, allowing more samples to be 
analysed, and produces less, more interpretable data at a fraction of the cost of 
WGS [68, 76]. Even with the rapid and significant improvements in sequencing 
technologies identifying exonic variants that affect phenotypic expression through 
WGS is approximately four times more expensive than an exome sequencing 
approach [68, 74].   
Since its first successful use to diagnose and inform subsequent treatment of an 
infant patient with a rare form of inflammatory bowel disease [68] WES has been 
instrumental in revolutionising our understanding of rare and common human 
diseases and supporting the implementation of health-improvement projects 
throughout the world [77, 78].  With the increasing interest and drive towards 
personalised medicine the development of efficient targeted sequencing 
strategies is likely to continue. Currently WES methodologies can be classified in 
two ways; solution or array based [68].  
Array-based methods where the first used to enrich specific regions of the 
genome [79] and sequence a whole exome [80]. They involve the hybridisation 
of randomly sheared, adapter-ligated genomic DNA (target sequences) to 
synthetic oligonucleotides (probes) bound to a high-density microarray [81]. An 
additional array-based method, multiplex amplification, was also proposed that 
cleaved off and amplified, through a polymerase chain reaction (PCR), the 
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oligonucleotides synthesised on the microarray to perform a padlock and 
molecular-inversion reaction [82]. However, this method was initially reported to 
miss more than 80% of targeted exons, represent sequence targets unevenly and 
showed poor reproducibility between replicates [81]. Since these methods were 
introduced, increasingly powerful sequencing techniques requiring smaller 
amounts of template DNA and involving less manual work where in high demand 
[83].  
A solution-based method, proposed by Gnirke et al. in 2009 overcame some of 
the short-comings of previous methods utilising a hybrid-selection method for 
enriching specific genomic regions. It combines the robust performance of 
oligonucleotide synthesis on an array with the favourable kinetics of RNA-driven 
hybridisation in solution [81].  The first commercially available sample preparation 
kit using this method was the SureSelect Human All Exon capture kit (Agilent) 
closely followed by the NimbleGen with the SeqCap EZ Exome capture system 
(Roche). A systematic comparison of these two platforms, using the same 
Illumina sequencing machine and bioinformatics pipeline to annotate the 
sequences, found the NimbleGen kit aligned more accurately to the target regions 
whilst the Aligent kit had less duplicated reads. Alignment of the Aligent kit to the 
human reference genome was equal to that of the NimbleGen kit with neither kit 
capturing all of the consensus coding sequence (CCDS) exons [83].  
Available WES capture methods are constantly being improved and updated. 
Solution-based kits are currently the most commonly used with improvements to 
these platforms focusing on increasing the read depth, the number of aligned 
sequencing reads covering a specific genomic position [84], the coverage, the 
average raw or aligned read depth and the breadth of coverage, the percentage 
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of target bases that are sequenced a given number of times [85], increasing both 
sensitivity and specificity. 
Two solution-based WES platforms where used in this study; the SureSelect 
Human All Exon V4 (Agilent) exome enrichment kit sequenced on an Illumina 
HiSeq2000 sequencer and the BGISEQ-500 sequencing system both obtaining 
mean read depths and breadth of coverage sufficient for accurate variant calling 
for clinical purposes.  
Current technologies now generate accurate and reliable sequencing data 
covering the majority of the genome [75], removing the historical “sequencing 
bottleneck” [86], where the sequencing of genetic variants was the most time, 
labour and cost intensive aspect of providing a genetic diagnosis. This has 
allowed these technologies to be widely integrated into clinical settings but has 
posed several new challenges including [87]; 
 The setup, validation and implementation of appropriate bioinformatic 
analysis to accurately determine genotypes  
 The standardisation of variant interpretation and classification  
 The development of polices and guidelines to inform the identification and 
disclosure of secondary variants (incidental findings) not directly linked to 
the patient’s phenotype under investigation 
 The storage, accessibility and dissemination of sequencing data 
 
Quality control (QC) is an essential step in the analysis of sequencing data to 
ensure accurate genotyping when defining a variants pathogenicity. It can be 
difficult to determine a genotype due to errors introduced in the base-calling 
process, which can vary significantly across different sequencing platforms. In 
addition genotype calls are extremely dependent on the achieved read depth; 
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only genotypes with many reads can be reliably assigned [88]. A Phred, or Q, 
score (Error! Reference source not found.) is calculated using several 
predictors of possible errors and widely used by all major sequencing platforms 
to measure the probability that a base has been called incorrectly [88].   
 
Table 1.2: Phred quality scores with associated Q score. Q scores are 
logarithmically linked to error probabilities 
Phred Quality Score 
Probability of 
incorrect base call 
Base call accuracy 
Q10 1 in 10 90% 
Q20 1 in 100 99% 
Q30 1 in 1000 99.9% 
Q40 1 in 10,000 99.99% 
Q50 1 in 100,000 99.999% 
 
 
Once the reliability of the genotyping calls has been calculated the next important 
step of interpreting sequence variants is to determine their frequency in large 
population databases. The Genome Aggregation Database (gnomAD) is one 
such database which has complied the data of 125,748 exomes and 15,708 
genomes from human sequencing studies [89]. Pathogenic variants are expected 
to occur at extremely low frequencies or not have been previously observed in 
the general population. It has become widely accepted that for a variant to be 
considered rare it must have a frequency of <1% in the general population [71]. 
However, it has been reported that genetic studies show a high degree of 
population bias with a greater representation, ~80%, of participants being of 
European decent which should be considered when interpreting variants from 
underrepresented populations [90, 91]. 
Good quality variants occurring at a low frequencies can then be analysed 
through the use of in silico prediction tools such as SIFT [92], PolyPhen-2 
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(Polymorphism Phenotyping v2) [93] or MutationTaster2 [94] to establish if the 
variant is likely to alter protein function through disruption of the amino acid 
sequence. Whilst it is possible to undertake these investigations in isolation, 
investigating all variants from an individual’s exome sequencing data via a 
number of tools, would be far too laborious. It is far more common for the VCF 
files which is the standard  bioinformatics format for storing gene sequence 
variations, containing WES and WGS data to be annotated using a software 
application that integrates several prediction tools. In these studies the Alamut 
Software Suite (v1.4.4) was used to assess variants so that a small number of 
candidate variants could be selected to undergo further interrogation. Alamut 
complies with ACMG/AMP variant interpretation guidelines [95] and as a result is 
used extensively within clinical settings. 
 
 
1.4.3 The future of sequencing technologies 
NGS technologies have dramatically reduced the cost of DNA sequencing 
increasing its accessibility [96] and making the use of gene panels, WES and 
WGS in clinical diagnostics possible [72]. Despite this, the short-read sequences 
used by these techniques are not without issue. The dependence on clonal 
amplification and creation of clusters of DNA molecules requires read lengths to 
be short (50-500bp), providing an opportunity for errors in base incorporation to 
occur thus increasing noise within samples [72]. Furthermore these short lengths 
then require extensive assembly which can cause difficulties for complex regions, 
particularly those containing a high number of repeated sequences by producing 
misalignments or misassemblies and impairing the phasing of variants [71, 72].  
In 2011, Pacific Biosciences (PacBio) released the first commercially available 
third-generation sequencing (TGS) technology employing single molecule real-
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time sequencing (SMRT) [97] which has proved to be useful in sequencing 
extended repetitive regions of the genome [71]. 
The key differences of TGS is that sequencing is done in real-time, unlike NGS 
where sequencing is paused after the incorporation of each base, and that it 
utilises long-read technologies which are reported to be revolutionising genomics 
research [98].  
One such example is the development of nanopore sequencing introduced in 
2014 by Oxford Nanopore Technologies (ONT) [99] which identifies nucleotides 
by measuring their electrical conductivity as they pass through the nanopore 
membrane. In addition to its innovative sequencing chemistry an attractive 
feature of this sequencer is its incredibly small size and USB port connectivity 
making it the first fully portable DNA sequencer [71].  
 
Alongside the continued development and innovation in sequencing technologies 
there is growing interest in the increased incorporation of artificial intelligence (AI) 
platforms into clinical diagnostic practices. Being employed initially to cut costs 
associated with analysing the ever increasing volume of patient data by 
accelerating the annotation and prioritisation of sequence variants from WES. 
Whilst is it likely to be some time before AI technologies are commonplace in 
mainstream medicine a number of companies are already deploying aspects of 
AI technologies through clinician-friendly web-based interfaces that support the 




1.5 Aims  
The studies detailed in this thesis can be summarised by two distinct yet 
connected aims. The first aim was to identify the underlying molecular cause of 
developmental conditions within Amish communities which included; 
investigating congenital forms of hearing loss in multiple families to provide 
genetic diagnoses and defining the clinical phenotype and molecular basis of a 
novel complex autosomal recessive neurological disorder.  The second aim was 
to conduct a pilot, proof-of-principle study to characterise the architecture of the 
Amish genome which included; determining the carrier frequencies of pathogenic 
and potentially pathogenic variants known to be present in the Amish 
communities in addition to identifying potentially pathogenic variants known to 
cause disease but yet to be reported in the Amish community. In order to meet 
these aims the following objectives where pursued:  
 To undertake in-depth genetic studies, including autozygosity mapping, 
traditional and next generation sequencing technologies, to identify the 
underlying molecular cause of congenital hearing loss in two families with 
multiple affected individuals.  
 To functionally characterise putative disease genes and elucidate the 
effect of the pathogenic variants identified.  
 To investigate the allele frequencies of variants known to cause hearing 
loss in different Amish communities (demes).  
 To interrogate exome sequencing datasets to identify coincidentally 
carried, potentially deleterious, autosomal recessive variants found in 
genes known to cause disease but yet to be seen in the Amish community. 
 To utilise a PLEXseq sequencing approach to determine the prevalence 
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   Materials and Methods 
 
2.1 Family recruitment and sample acquisition  
 
2.1.1 Recruitment to the Amish Windows of Hope (WoH) project  
All the WoH project studies were reviewed and approved by the Institutional 
Review Board of the Office for Responsible Conduct of Research, University of 
Arizona (Tuscon, Arizona, USA) (reference 10-0050-01) and by the University of 
Exeter Research Ethics Committee (reference 14/04/048).  
Research was carried out in compliance with the Code of Practice for Human 
Tissue and Research (code E) provided by the Human Tissue Authority (HTA), 
which defines human tissue as relevant material consisting of, or containing cells, 
therefore includes blood and buccal samples.  All blood and buccal samples, and 
subsequent DNA extractions, used in this project where used and stored in HTA-
licensed premises with research carried out in accordance with the Human Tissue 
Act 2004.  
Recruitment to the WoH project requires submission of the appropriately signed 
consent, clinical details and a blood or buccal sample. Signed consent is given, 
in accordance with the HTA’s code of practice, only when individuals, or parents 
of individuals, feel they are sufficiently informed, about the purpose of the 
research, how their samples are to be stored and used and satisfied with the 




2.1.2 Phenotyping of affected individuals 
Full medical and family histories for the purposes of the research study was 
obtained for all individuals. Individuals were examined with clinical phenotypes 
assessed and described by a member of our research group, Dr Emma Baple, 
Consultant Clinical Geneticist at the Royal Devon and Exeter Hospital. 
Phenotypic data for each family was then collated and reviewed for the purposes 
of the studies outlined in this thesis.  
 
2.1.3 Data management 
On receipt of blood or DNA samples each sample was assigned a sample ID. 
The tubes containing the samples were anonymised and labelled with the 
relevant sample ID. The clinical and molecular information was recorded 
alongside the samples ID in a password protected database.  
Family pedigrees are constructed using the online Swiss Anabaptist 




2.2 Molecular DNA methods  
All general-purpose chemicals were acquired from Fisher Scientific. All primers 
where supplied by IDT (Integrated DNA Technologies). Specialist kits, chemicals 
and consumables purchased from alternate sources are noted in the text where 
appropriate. Components of solutions made in-house are detailed in Table 2.1. 
 
All plastic ware was acquired from StarLabs or Sarstedt. Kits for DNA extraction 
where purchased from Promega. 
 
2.2.1 Buffers, Reagents and Stock Solutions 
 
Table 2.1 Buffers, reagents and stock solutions required for molecular DNA 
techniques and their constituents. 
Solution Constituents 
Agarose loading buffer 
40% (w/v) ficoll 
0.2% (w/v) xylene cyanol  
0.1% (w/v) bromophenol blue 
ExoSAP 
For 1 millilitre: 50 U/ml Exonuclease I, 50U/ml 
shrimp alkaline phosphatase (both bought from 
New England BioLabs), ddH2O to final volume 
50X LAB 
5.1% (w/v) lithium acetate dihydrate 
3.1% (w/v) boric acid 
ddH2O to final volume 
 
 
2.2.2 DNA extraction from whole blood 
DNA was extracted from whole blood lymphocytes using the ReliaPrepTM Blood 
gDNA Miniprep system (Promega) according to the manufacturer’s instructions 
which is summarised below.  
 
On arrival blood samples were stored at -20°C. Prior to extraction, blood samples 
were thawed completely and mixed thoroughly for 10 minutes at room 
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temperature on a rotisserie shaker. Filter tip pipette tips were used at all stages 
during the procedure to prevent contamination of samples and equipment. 
For each sample, 20μl of Proteinase K (10U/µl) was dispensed into a 1.5ml 
microcentrifuge tube. 200μl of blood was added to the Proteinase K and mixed 
by repeat pipetting. 200μl cell lysis buffer was added to the tube. The tube 
contents were vortexed for 10 seconds then incubated at 56°C for 10 minutes. 
Following incubation, 250μl of binding buffer was added to the tube with the 
contents vortexed for 10 seconds. The lysate was checked to ensure that it was 
dark green in colour. The contents of the tube were added to a ReliaPrepTM 
binding column placed in a collection tube and centrifuged at 16,200xg 
(13,000rpm), max speed of microcentrifuge) for 1 minute. If the lysate was still 
visible at the top of the membrane following centrifugation, the column was spun 
for a further 1 minute. The column was moved to a fresh collection tube, and the 
flow through from the old one was discarded as hazardous waste. The column 
was then washed by adding 500μl of column wash solution to the column and 
centrifuging it at 16,200xg (13,000rpm) for 3 minutes. If any of the solution 
remained visible on the membrane, the column was spun for a further minute. 
The flow through was again discarded as hazardous waste. This wash step was 
repeated a further two times to make a total of three washes. The column was 
then transferred to a clean 1.5 microcentrifuge tube and 50μl of 70°C nuclease 
free water added to the column which was centrifuged at 16,200xg (13,000rpm) 
for 1 minute to elute the DNA. The binding column was discarded.  
The DNA concentration and purity of the sample was measured using the 
NanoDrop 2000c UV-Vis Spectrophotometer (Thermo Scientific) by measuring 
absorption at 260nm (A260) in 1-2μl of undiluted sample. The NanoDrop software 
automatically uses a modified Beer-Lambert equation to calculate the 
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concentration (in ng/μl). DNA purity was assessed simultaneously by measuring 
absorption at 280 nm (A280). A ratio of A260 to A280 of ~1.8 indicates “pure” 
DNA. A secondary measure of absorbance at 230nm (A230) was also taken, 
values for a “pure” nucleic acid are often higher than the respective A260/A280 
values being within the range of 1.8-2.2. 
An aliquot of working stock of 10-30ng/μl was prepared by diluting the DNA with 
molecular grade water. Samples were then stored at -20oC. 
 
2.2.3 DNA extraction from buccal swabs 
DNA was extracted from buccal swabs using the Xtreme DNA Kit (XME-5/50, 
Isohelix) according to the manufacturer’s instructions which is summarised 
below. The composition of the buffers and solutions used in this protocol is 
proprietary information.   
 
Prior to extraction a hot block was preheated to 60oC. The proteinase K was 
reconstituted by adding 550μl ddH2O before first use (then stored at 4oC after 
reconstitution) and 60ml of 98-100% ethanol was added into the WB solution 
before first use. 
 
500µl LYS buffer was added to each sample which was then vortexed to ensure 
the solution covers the swab head. 20µl Proteinase K solution was added to each 
sample then mixed immediately by vortex. The tubes where then incubated at 
60oC for a minimum of 10minutes to lyse the sample. Following incubation, the 
liquid was transferred to a 5ml tube. 750µl CB buffer was then added to the 
samples and mixed by vortexing for 30 seconds. 1.25ml of ethanol was added to 
each sample then vortexed to mix. 
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100µl of EB buffer per sample, was preheated in a hot block, at 70oC. 
An Xtreme DNA column was placed into a collection tube, one per sample, with 
750µl of the sample was carefully added to the column without touching the rim. 
Samples were then centrifuged at 16,200xg (13,000rpm) for 1 minute. The flow 
through was discarded as hazardous waste. This step was repeated until all of 
the samples had been loaded onto the columns.  
The columns were then washed by adding 750µl of WB solution and centrifuged 
for 1 minute at 16,200xg (13,000rpm).  The flow through was again discarded as 
hazardous waste. This was step was then repeated, again discarding the flow 
through.  
Following the wash steps the columns were then placed into clean collection 
tubes and centrifuged at 16,200xg (13,000rpm) for 3 minutes to remove all traces 
of ethanol.  
The columns were then placed into clean 1.5ml microcentrifuge tubes. 100µl of 
preheated EB buffer was then added to the centre of the membrane of each 
column. The columns were left to stand at room temperature for 3 minutes then 
centrifuged at 16,200xg (13,000rpm) for 1 minute to elute the DNA.  
 
The DNA concentration and purity of the sample was measured using the 
NanoDrop 2000c UV-Vis Spectrophotometer (Thermo Scientific) as previously 
described with an aliquot of working stock of 10-30ng/μl prepared by diluting the 




2.2.4 Single nucleotide polymorphism (SNP) genotyping 
SNP genotyping was carried out using Illumina CytoSNP-12v2.1 arrays following 
the Infinium® HD Assay Ultra manual protocol and assistance from Dr Barry 
Chioza, University of Exeter.  
The assay requires 200ng of DNA per sample at a concentration of 50ng/µl with 
each chip holding 12 samples. The protocol is carried out over three days 
following the Infinium HD Assay Ultra Manual Workflow which is summarised 
below. 
 
Day 1: DNA samples were denatured using a buffer containing 0.1N NaOH and 
then neutralised in preparation for amplification. Samples were incubated 
overnight at 37oC to amplify.  
 
Day 2: Amplified DNA samples were enzymatically fragmented using the Illumina 
FMS buffer which utilises end-point fragmentation (to avoid over-fragmentation). 
The DNA was then precipitated using 2-propanol and the Illumina solution PM1, 
then collected via a 20 minute centrifugation carried out at 4oC. Following 
resuspension, using the Illumina solution RA1, the DNA was denatured at 95oC 
for 20 minutes. The denatured samples were cooled then 12µl of each sample 
was loaded onto the BeadChip. This was then incubated in the Illumina 
Hybridisation Oven at 48oC for a minimum of 16 hours (but no more than 24 
hours).  
 
Day 3: The BeadChips were prepared for the staining process. This involved 
washing away any un-hybridised and non-specifically hybridised DNA using the 
PB1 Illumina buffer. Following the wash step, labelled nucleotides were 
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dispensed onto the BeadChip through the Flow-Through Chambers to perform 
single-base extension of primers hybridised to the DNA. The BeadChips where 
then stained using the Illumina XStain HD BeadChip process then imaged on an 
Illumina iScan Reader.  
The iScan Reader uses a laser to excite the fluorophores of the single-base 
extension product on the beads of the BeadChip. Light emissions from the 
fluorophores are recorded by the reader, taking high-resolution images of the 
BeadChip. The data from these images were analysed using the Illumina 
GenomeStudio Integrated Informatics Platform allowing for the genotype to be 
determined. Further analysis was then undertaking by exporting the data into 
Microsoft Excel and using a macro to highlight notable regions of homozygosity 




2.2.5 Whole-exome sequencing (WES) 
DNA Whole-exome sequencing of individuals was performed using two different 
sequencing platforms, Otogenetics and BGI, summarised below;  
 
Whole-exome Otogenetics sequencing platform Otogenetics Corporation using 
the SureSelect Human All Exon V4 (Agilent Technologies) 
Patient DNA was sent to Otogenetics Corporation (Norcross, GA, USA) where 
whole exome sequencing of genomic DNA was performed on an Illumina 
HiSeq2000 using the Agilent SureSelect Human All ExonV4 (51Mb) enrichment 
kit and a paired-end (2 × 100) protocol at a mean coverage of 30X. The exome 
sequencing produced 31,783,299 mapped reads, corresponding to 93% of 
targeted sequences covered sufficiently for variant calling (>10X coverage, mean 
depth 45X). 
 
Whole-exome BGI sequencing platform 
WES was also performed by BGI Tech Solutions (Hong Kong) on the BGISEQ-
500 sequencing system. A total of 1,403,229,858 clean reads were aligned to the 
human reference genome (GRCh37) using the Burrows-Wheeler Aligner (BWA). 
On average, 99.79% of the whole genome excluding gap regions had at least 
99.40% had at least 4X coverage and 98.20% at least 10X coverage. Average 
sequencing depth across the genome was 45.73X. 
 
Bioinformatics Pipeline 
The FASTQ files obtained from Otogenetics and BGI were mapped to the 
reference genome using the Burrows-Wheeler Aligner BWA-MEM algorithm [100, 
101]. This algorithm was used due to its improved performance, compared to 
67 
 
other BWA algorithms, being faster and more accurate than previous versions as 
well as providing higher quality queries. The sequence alignment map (SAM), 
was converted to binary SAM format (BAM) to produce a smaller file and to 
increase the processing speed. 
Duplicate reads were marked by Picard (version 1.46). The BAM file was then 
realigned, to account for indels, with variants called using GATK-HaplotypeCaller 
and subsequently quality filtered based on; mapping quality (MQ40), read depth 
(QD2), strand bias (FS60), the average position of a variant in a read (RPRS-8) 
and SNP quality (MQRankSum-12.5). The variant call file (VCF) file was 
annotated using the Alamut Software (v1.4.4) Suite. Variants were quality control 
(QC) checked and filtered for rare, non-synonymous exonic or splice variants, 
with a population frequency of <0.005 in control databases (including the 
Genome Aggregation Database; gnomAD, the Exome Aggregation Consortium; 
ExAC, and the 1000 Genomes Project) (Interactive Biosoftware). Annotated vcf 
files were then interrogated depending on the condition(s) under investigation 
(Figure 2.1).  
Support for analysis of exome sequencing data was provided by Matthew 











2.2.6 PLEX-seq sequencing  
The genotyping of 176 Amish individuals for 165 variants commonly seen in the 
Amish communities (see Appendix A) was performed using the PlexSeq process 
by Plexseq Diagnostics. This process, previously described by Kayima et al [102], 
uses a multiplexed approach to amplify regions surrounding each SNP. The 
primers contain an additional sequence at the 5’ end to which universal barcoded 
Illumina primers were annealed during a secondary amplification reaction.  All 
samples, including negative and positive controls, were uniquely barcoded and 
sequenced simultaneously using the first DNA-to-data sequencing platform, 
MiSeq (Illumina). Genotype calls for all SNPs in each sample where determined 
through analysis of sequence data, in the form of FASTQ files, using Plexcall 
software (PlexSeq Diagnostics).  
 
2.2.7 Primer design 
The Ensembl Genome Browser (December 2013 (GRCh38/hg38) assembly) was 
used to obtain the gene sequences (website http://www.ensembl.org/index.html). 
Primers used for PCR amplification were designed using Primer3 software 
version 0.4.0 (website http://frodo.wi.mit.edu/primer3/).  
Primers were designed using the following criteria: 
 Primer sizes were between 18 and 22 nucleotides. 
 The difference in melting temperatures for the forward and reverse 
primers were no more than 1oC and between 55-65oC. 
 Guanine-cytosine (GC) base content was kept between 40-60%. 
 The primer sequences selected were specific and a 100% 
complimentary and unique to the region of interest to ensure only that 
region is amplified.  
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 Use of self-complimentary primers with inter or intra-primer efficiency 
extending more than 3 bases were avoided to reduce the formation of 
primer dimers and prevent the formation of secondary structures. 
 
In silico PCR and BLAST analysis were performed using the UCSC Genome 
bioinformatics website to ensure primers where specific to the region of interest 
and to confirm the corresponding primer sequence (available in Appendix B) 
contained no common SNPs (>1%). 
 
2.2.8 Resuspension of lyophilised primers 
Primers, designed as described in section 2.2.7, arrive lyophilised. They are 
resuspended in molecular grade water to a concentration of 100µM to produce a 
master stock, which is stored at -20oC. Before use in PCR reactions a 10µM 
working stock is produced by diluting the master stock 1 in 10 with molecular 
grade water. 
 
2.2.9 Optimisation of primer conditions 
To determine the optimal annealing temperature for a primer pair a PCR reaction 
was carried out using a temperature gradient of 52-64oC across the PCR block 
of an Eppendorf Mastercycler thermocycler.  
This involved setting up 12 reactions for each primer pair; each reaction had a 
different annealing temperature which increased incrementally across the PCR 
block from 52°C to 64°C by approximately 1°C. For these reactions a control DNA 
of high concentration and quality which had amplified well in a previous reaction 
was used.  
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If the PCR reaction produced weak or no product across the range of 
temperatures the contents of the mix and amplification conditions were altered. 
This might involve increasing the primer concentration or if the GC content was 
high, above 60%, a second gradient using 10% dimethyl sulfoxide (DMSO, Fisher 
Scientific) was performed. DMSO is an organic sulphur compound which binds 
to cytosine residues on DNA, this changes its conformation making it more liable 
to heat denaturation. Fortunately the primers used in the studies included in this 
thesis (Appendix B) did not require the conditions to be altered, standard 10µm 
concentrations of each primer were used without the addition of DMSO.  
 
2.2.10 LabTAQ Polymerase Chain Reaction (PCR) 
PCR is an in vitro laboratory technique used to selectively amplify DNA 
sequences. The process involves subjecting a small quantity of DNA to repeated 
temperature cycles permitting the exponential amplification of specific sequences 
of DNA, located between the forward and reverse primers, by up to 109 times.  
 
A master reaction mix was made for each primer pair, which includes all of the 
reaction components, with the exception of the sample DNA. The master mix 
volume is dependent on the number of reactions required. This is dictated by the 
number of samples (patients) plus positive and negative controls. The PCR 
reaction for each sample was either 10 or 20µl depending on further downstream 
analysis required (for example Sanger sequencing or sequencing by restriction 










ddH2O 6.85 13.7 
5x labTAQ  reaction 
buffer 
2 4 
10µM forward primer 0.3 0.6 
10µM reverse primer 0.3 0.6 
labTAQ enzyme 0.05 0.1 
DNA 0.5 1 
Total volume 10µl 20µl 
 
 
The master reaction mix was aliquoted into reaction tubes (individually, on a strip 
or on a plate, depending on the number of samples). The sample (patient) DNA 
was then added to the master reaction mix. For the negative control, ddH2O was 
added in place of DNA to ensure that the desired DNA template was being 
amplified, and not DNA from a contaminant in one of the reaction constituents. 
 
The PCR mix was then placed in an Eppendorf 96-well Mastercycler thermocycler 
and exposed to repeated heating cooling in order to separate the strands the 
template DNA (denaturation), allow the primers to bind to their complementary 
sequence (annealing) and permit the Taq enzyme to replicate the DNA strands 
within the region of interest through the addition of dinucleotides (elongation).  
To reduce the amplification of non-specific products, and therefore improve 
specificity of primer binding, a touchdown (TD) PCR protocol was implemented. 
This involves using an initial annealing temperature 4oC higher than the optimum 
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annealing temperature (Tm), then incrementally lowering the annealing 
temperature by 2oC every two cycles until the desired Tm is reached (Table 2.3). 
 
Table 2.3: LabTAQ PCR reaction thermocycler program 
NUMBER OF CYCLES TEMPERATURE (OC) TIME (S) 





















1 72 120 
 
 
2.2.11 Agarose gel electrophoresis 
To determine if the amplification of the DNA was successful, and adequate for 
sequencing, the resulting PCR products underwent agarose gel electrophoresis. 
Agarose gel electrophoresis is a technique used to separate DNA (PCR 
products), according to their size, using an electric current. The agarose gel forms 
a matrix through which the negatively charged DNA travels when an electric 
current is applied across the gel. The smaller DNA molecules migrate faster 
towards the positive electrode so therefore travel further down the gel than the 
larger molecules in a given time.  
 
For resolving smaller DNA fragments, such as PCR products which are typically 
500bp a 1% agarose gel was made by mixing 1g of agarose powder (Sigma-
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Aldrich) with 100ml 1X LAB (Table 2.1) and heating the mixture in a microwave 
for 2-3 minutes. After checking the powder had completely dissolved, 2µl of 
10mg/ml ethidium bromide solution was added to the gel and swirled gently to 
mix evenly. Ethidium bromide (EtBr) is a DNA intercalating agent that fluoresces 
brightly when exposed to ultraviolet (UV) light.  
 
The gel was then left to cool while the casting tray was set up. This involved 
securing a rubber gasket to each end of the gel tray and placing a 28-toothed 
comb at the top of the gel (the number of rows of combs is dependent on the 
number of samples being run). The molten gel was then carefully poured into the 
casting tray and left to set for 10-15 minutes. Once set, the rubber gaskets and 
comb(s) were removed from the gel creating the wells. The gel was then placed 
into an electrophoresis tank and submerged in 1X LAB.  
The first well of each row (if using multiple combs) was then loaded with 2µl DNA 
ladder (Gene Ruler 100bp DNA Ladder, Thermo Scientific) to allow the size of 
PCR product to be estimated. 5μl of each PCR product was mixed with 2μl 
agarose loading buffer, and loaded into one of the wells alongside the DNA 
ladder.  
A power pack was used to apply a 130V across the gel for 20 minutes. The gel 
was removed from the gel tank and the gel plate then placed on the illuminator 
(UV light box with a camera). This causes the EtBr to fluoresce under the UV light 
visualising the PCR products in which it is intercalated.  
The PCR reaction can be deemed as successful if a band, of the correct size, is 
seen in the lanes containing sample DNA with no band being visible in the 
negative control lane. If a band (therefore DNA/PCR product) is visible in the lane 
containing the negative control it shows the presence of contamination. As the 
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source of contamination is not clear it must be assumed that all samples have 
been contaminated and therefore the reaction must be repeated.  
 
For larger DNA fragments (>500bp), PCR products a lower concentration 
agarose gel (0.8%) was used; prepared as above with less (0.8g) agarose 
powder dissolved in the same volume (100ml) of 1xLAB. 
 
2.2.12 PCR product purification 
Prior to sequencing a PCR product it is important to remove any unincorporated 
primers and dNTPs. This was achieved by undertaking an ExoSAP reaction 
containing exonuclease-1 (Exo) and shrimp alkaline phosphatase (SAP). 
Exonuclease-1 is an enzyme capable of degrading the single stranded DNA of 
the unincorporated primers in a 3’-5’ direction. This step produces dNTPs which 
are subsequently removed by the shrimp alkaline phosphatase.  
For this reaction 2µl of ExoSAP was added to 5µl of each of the PCR products. 
This mixture was then incubated at 37oC for 30 minutes, the optimum 
temperature for enzyme activity, and then at 85oC in order to inactivate the 
enzymes by denaturation.  
 
2.2.13 Sequencing reaction 
Purified PCR products underwent a sequencing reaction using the BigDye 
Terminator Cycle Sequencing Kit v3.1 (ABI, Applied Biosystems) which uses a 
classic chain termination PCR method to incorporate ddNTPs labelled with 
fluorescent dyes into the resultant PCR products. These dyes emit light at 
different wavelengths which are read by the sequencing machine. A master 
reaction mixture, containing the BigDye Terminator, BigDye Terminator buffer, 
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primer and ddH2O, was made for each region of interest. 7µl of this mixture was 
aliquoted into appropriately labelled 0.2ml tubes and mixed with 3µl of the 
appropriate PCR product. For each sample two separate 10µl sequencing 
reactions were carried out for the forward and reverse primers ( 
Table 2.4).  
 
Table 2.4: Sequencing reaction components and quantities 








(Forward or reverse) 0.5 
ddH2O 4.3 
Cleaned PCR product 
3.0 
Total Volume 10 
 
The reaction mixtures where placed into an Eppendorf 96-well Mastercycler, 
thermal cycler machine and run through following programme (Table 2.5) for 25 
cycles: 
 
Table 2.5: Sequencing Reaction Thermocycler Program 
Process Temperature (oC) Time 
Denaturation 96 30 seconds 
Annealing 50 15 seconds 




2.2.14 Sequencing reaction purification 
In order to prepare the sequencing reaction products for automated DNA 
sequencing, they were first be purified. Purification of was carried out using the 
BigDye® XTerminator™ Purification Kit (Applied Biosystems) according to the 
manufacturer’s instructions. 
Unincorporated BigDye, salts and other charged molecules from sequencing 
reactions may interfere with base calling and electrokinetic sample injection 
during DNA sequencing. The BigDye® XTerminator™ Purification Kit cleans 
samples by utilising two reagents; XTerminator™ Solution which scavenges 
unincorporated dye terminators along with other charged molecules and SAM™ 
Solution that enhances the performance of the XTerminator™ Solution and 
stabilises the post-purification reactions.  
 
Sequencing reaction products were loaded into a 96-well plate with 5μl 
XTerminator™ Solution aliquoted into each well (containing the sequencing 
reaction products) and vortexed briefly. 30μl of SAM™ Solution was then added 
to each well. The plate was sealed using clear adhesive film (Thermo Scientific) 
and vortexed for 30 minutes then briefly centrifuged. The plate was then placed 
into a 16-capillary 3130xl Applied Biosystems® Automated DNA Sequencer for 




2.2.15 Genotyping by restriction digest 
A restriction digest can be used to detect variation in a DNA sequence providing 
a genotype. This method can only be used for DNA polymorphisms that create 
or destroy the restriction site of a restriction enzyme, commonly known as a 
restriction fragment length polymorphism (RFLP). 
RFLP analysis can be a cheap and effective way to genotype a large number of 
samples. As the polymorphism under investigation will interrupt the palindromic 
recognition sequence of a restriction enzyme, DNA fragments of differing lengths 
are produced depending on the presence or absence the variant. After carrying 
out the restriction digest reaction, at the optimum conditions, agarose gel 
electrophoresis can be used to size the fragments and then determine the 
genotype of individuals.  
 
A restriction digest reaction mixture contains PCR product of the area of interest, 
the appropriate 10X restriction digest buffer, the appropriate restriction 
endonuclease and ddH2O.  
To determine the most appropriate restriction enzyme to use the sequence, 
containing the variant and the wild type sequence, was entered into NEBcutter 
V2.0 online software (http://tools.neb.com/NEBcutter2/).  
A restriction digest master mix was made with all the constituents, except for the 
PCR product with 12.5μl aliquoted into appropriately labelled 0.2ml 
microcentrifuge tubes. 2.5μl PCR product was then added to each tube, and the 
tubes were incubated at 37˚C overnight (8+ hours). In addition to sample DNA, a 
negative control (water replacing DNA) and a known homozygote and 
heterozygote for the variant were included to provide control bands to confirm 
digestion and aid the interpretation of results. Following incubation samples were 
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loaded, along with a loading buffer, onto a 3% agarose gel (3g Agarose powder, 
100ml 1XLAB) and were electrophoresed for 60mins at 100V. The resultant 
bands were visualised in an illuminator to identify if the specific variant under 
investigation was also present any DNA samples.   
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2.3 Molecular cloning techniques 
The pCMV6-entry-SLC15A5 clone was transformed into E.coli DH5-alpha 
bacteria through the incubation of the bacteria with the clone and applying a heat 
shock. Liquid bacterial culture was inoculated to amplify the plasmid DNA which 
was then extracted through mini and midi preps. Restriction digests of the plasmid 
DNA where undertaken to check the plasmid DNA was what it was expected to 
be which can be determined by the fragment pattern seen after digestion.  
Initial immunocytochemistry experiments were undertaken using the pCMB6-
entry vector but due to low levels of expression a construct using a pCAGGs 
plasmid was produced, to increase mammalian expression, this included a YFP 
tag in place of the Flag (DDK) tag, to avoid potential issues with SLC15A5 
antibody binding. The transfection process was repeated with the new pCAGGs-
SLC15A5-YFP plasmid DNA.  
The methods used for these experiments are detailed below. 
 
2.3.1 Buffers, reagents and stock materials 
All general-purpose chemicals, with exception of alcohols (purchased from Fisher 
Scientific) were acquired from Sigma-Aldrich. All solutions for cell culture were 
supplied by Lonza, except and penicillin/streptomycin from PAA laboratories. 









Table 2.6: Solutions for molecular cloning techniques 
Solution Constituents 
10% APS 10% (w/v) APS 
10% SDS 10% (w/v) SDS 
100X SOC 
2M glucose, 1M MgCl2, 250mM KCl, sterilised by push 
filtration (0.22µm filter)  
2X PFA 8% (w/v) paraformaldehyde, in PBS, pH adjusted to 7.4 
3X Laemmli sample 
buffer 
10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) β-2 
mercaptoethanol, 0.002% (w/v) bromophenol blue, 
0.125M Tris-Cl (pH 6.8) 
Ampicillin 100 U./ml 
Destain 40% (v/v) MeOH, 10% (v/v) acetic acid, in dd.H20 
DMEM 10 % serum 
(HEK) 
10% (v/v) heat-inactivated FBS, 100 U./ml penicillin, 
100ug/ml streptomycin, in DMEM 
6X DNA loading 
buffer 
30% (v/v) glycerol, 0.25% (w/v) bromophenol blue, 0.25% 
(w/v) xylene cyanol 
HE lysis buffer 
25 mM HEPES, 5 mM EDTA, 1 mM MgCl2, 10% (v/v) 
Glycerol, 1% (v/v) Triton-X100, 100 μM PMSF 
Kanamycin 50 μg/ml 
LB agar 15 g/L agar, 10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast 
extract 
Luria Bertani Broth 10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract 
Lysine block 
5% (v/v) horse serum, 5% (v/v) goat serum, 50 mM poly-
D-lysine, 0.2% (v/v) Triton X-100 
Running buffer 25 mM Tris-base, 192 mM glycine, 0.1% (w/v) SDS 
TAE 40 mM Tris-base (pH 7.6), 20 mM acetic acid, 1 mM EDTA  
TBS 20mM Tris-Cl, 150mM NaCl 
TBS-T 20mM Tris-Cl, 150mM NaCl, 0.1% (v/v) Tween-20 
Transfer buffer 
25mM Tris-base, 192mM glycine, 0.1% (w/v) SDS, 20% 
(v/v) MeOH 
 
Plastic ware for tissue culture was acquired from Greiner Bio-one, with other 
general laboratory consumables purchased from Alpha-Labs and Fisher 
Scientific. Kits for deoxyribonucleic acid (DNA) amplification and gel extraction 
were purchased from Qiagen, restriction enzymes were supplied by Promega 
and New England Biolabs.  
Specialist kits, antibodies, chemicals and consumables bought from alternate 
sources are noted in the text where appropriate. 
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2.3.2 DNA Plasmid preparation  
 
Constructs 
The SLC15A5 plasmid for expression studies was purchased from Origene. 
SLC15A5 fusion genes were subcloned by PCR (primer details outlined in  
Table 2.7) from its original cytomegalovirus (CMV) vector into a pCAGGS 
backbone (gift of Dr John Chilton) to increase expression efficiency [103]. Full 
length SLC15A5 was excised from the pCMV6-Entry vector by HindIII overnight 
digestion and inserted into the corresponding sites of pCAGGS-mycFLAG. Maps 
for key expression vectors and cloning schemes can be found in Appendix C. 
Constructs were checked at all steps by restriction enzyme digest using unique 




Table 2.7 describes all primers that were designed, following the general rules of 
primer design [104], to have flanking sequences containing convenient sites for 
restriction digest and to omit the proteins native stop codon. 
 






digest site Forward Reverse 
CMV6BamF 
GAC TGG ATC CGG 
TAC CGA GGA G 
  22 BamH1 
FLAGSalR 
ATA TGT CGA CTT AAA 
CCT TAT CGT CGT CAT 
C 
  31 Sal1 
SLC15BamF 
ATA TGG ATC CAT 
GTC TGT TAC AGG 
CTT TAC C 




AAT TGT CGA CTC ATA 
GGG CTG TCT CCC 
AAA GAT C 
  34 Sal1 
2.3.3 Mini preps: Inoculating a liquid bacterial culture and recovering 
plasmid DNA from bacterial culture  
Small amounts of plasmid DNA, usually around 10μg per ml of bacterial culture, 
were extracted using the QIAprep Spin Miniprep Kit. These plasmids were used 
for restriction mapping, ligations and transient transfections to confirm 
fluorescence for fluorescent protein-tagged plasmids. 
 
A 5ml culture of bacteria was grown overnight in LB broth (Sigma) with 5μl of 
kanamycin (30mg/ml) selective antibiotic. This produced a LB broth with a final 
kanamycin concentration of 0.03. 
A 1.5ml aliquot of overnight bacterial culture was removed and centrifuged at 
16,200xg (13,000rpm) for 1 minute at 20oC. The supernatant was discarded and 
the pellet resuspended in 250μl of Buffer P1 (a resuspension buffer; 50mM 
Tris.HCl, pH8.0; 10mM EDTA; 100μg/ml RNAse A, without LyseBlue reagent). 
250μl of Buffer P2 (a lysis buffer; 200mM NaOH; 1% w/v SDS) was added to the 
suspension, and mixed via 4-6 inversions, to rupture the bacteria by alkaline lysis. 
Cellular debris was precipitated by the addition of 350μl Buffer N3 (a proprietary 
neutralization Buffer) and mixed by further 4-6 inversion until the flocculent 
precipitate was evenly dispersed. The mixture was then centrifuged at 16,200xg 
(13,000rpm) for 10 minutes. The supernatant was removed then added to a 
QIAprep spin column and centrifuged at 16,200xg (13,000rpm) for 1 minute. The 
column was washed by addition of 500μl Buffer PB (a proprietary binding buffer) 
which was then centrifuged at 16,200xg (13,000rpm) for 1 minute. A second wash 
was undertaken by the addition of 750μl Buffer PE (a low salt, high ethanol 
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proprietary solution) to the column which was then centrifuged at 16,200xg 
(13,000rpm) for 1 minute.  The flow through was discarded and the column 
centrifuged for a further 1 minute at 16,200xg (13,000rpm) (to remove residual 
ethanol). The column was then transferred to a fresh microcentrifuge tube. 55μl 
of molecular biology grade water (Sigma-Aldrich) was added to the column which 
was then incubated for 1 minute before a final spin at 16,200xg (13,000rpm) for 
1 minute to elute the DNA. Molecular biology grade water is 0.1mm filtered, has 
been analysed for the absence of nucleases and proteases and has undergone 
bioburden analysis.  
 
2.3.4 Midi preps: Inoculating a liquid bacterial culture and extracting 
plasmid DNA from bacterial culture  
Midipreps were used in the purification of up to 300μg of plasmid DNA using 
HiSpeed Midi Prep Kit (Qiagen) which was then used for expression and 
functional studies. 
 
A 5ml starter culture was grown overnight in LB broth with kanamycin a selective 
antibiotic. This was diluted 1:1000 in 50ml of LB broth with the kanamycin 
selective antibiotic and grown overnight. The bacteria were harvested by 
centrifugation at 1,900xg (4,500rpm) for 15 minutes at 4oC then resuspended in 
6ml of Buffer P1 (without LyseBlue added). The bacteria were lysed by the 
addition of 6ml of Buffer P2, mixed thoroughly by 4-6 inversions and incubated at 
room temperature for 5 minutes. Cellular debris was precipitated by the addition 
of 6ml of Buffer P3 (a neutralization Buffer; 3M potassium acetate, pH5.5) and 4-
6 inversions. This was then added to a QIAfilter Midi Cartridge and incubated at 
room temperature for 10 minutes. During this incubation, an anion-exchange 
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resin column (Qiagen HiSpeed Midi Tip) was prepared by the addition of 4ml 
Buffer QBT (an equilibration Buffer; 750mM NaCl; 50mM MOPS, pH 7.0; 15% v/v 
isopropanol; 0.15% v/v Triton X-100) which was allowed to empty under gravity. 
The cell lysate was push filtered in to the column and allowed to move through 
under gravity. The column was washed by the addition of 20ml Buffer QC (a wash 
buffer; 1M NaCl; 50mM MOPS, pH7.0; 15% v/v isopropanol). 5ml Buffer QF (an 
elution buffer; 1.25 M NaCl; 50 mM Tris.HCl, pH 8.5; 15% v/v isopropanol) was 
added to the column to elute the DNA and precipitated by the addition of 0.7 
volumes of isopropanol, inverted 4-6 times and incubated at room temperature 
for 5 minutes. Precipitated DNA was bound to a QIAprecipitator module, washed 
with 2ml 70% v/v ethanol and dried by pushing air through the module. DNA was 
recovered by the addition of 350μl of Buffer TE (a resuspension and storage 
buffer; 10 mM Tris.HCl, pH 8.0; 1 mM EDTA). 
 
The concentration of DNA recovered was quantified using a NanoDrop 2000c 




2.3.5 Pfu PCR of extracted bacterial DNA 
DNA, containing the gene of interest, was amplified via PCR using Pfu DNA 
polymerase (Promega). The highly thermostable DNA polymerase (from the 
hyperthermophilic archaeum Pyrococcus furiosus) was used in placed of labTAQ 
DNA polymerase due to its 3’5’ exonuclease (proofreading) activity, which 
enables the Pfu polymerase to correct nucleotide incorporation errors. 
 
The reaction mixture (outlined in Table 2.8) was combined in a sterile, nuclease-
free microcentrifuge tube on ice. It is critical to add Pfu DNA Polymerase after the 
addition of dNTPs or the proofreading activity of the polymerase may degrade the 
primers which may result in nonspecific amplification and reduced product yield. 
 




Pfu DNA Polymerase 10X Buffer with MgSO4 5μl 1X 
dNTP mix, 10mM each 1μl 200µM (each) 
Upstream primer 25 pmol 0.1–1.0µM 
Downstream primer 25 pmol 0.1–1.0µM 
DNA template Variable <0.5µg/50µl 
Pfu DNA Polymerase (2–3u/µl) Variable 1.25u/50µl 
Nuclease-Free Water (to final volume of 50μl) Variable  
 
 
The mixture was mixed gently then placed into the SimpliAmp Thermal Cycler 
(Applied Biosystems by Life Technologies) and heated to 95oC for an initial 2 
minute denaturing step. This was followed by 35 cycles of; 30 second DNA strand 
melting, 30 second annealing at 50oC, 2 minute extension at 72oC (which required 
1 minute per kilobase (Kb) of final PCR product). Finally a 5 minute extension 
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step at 72oC was carried out before samples were cooled to 4oC until the tube 
was collected. A 5μl aliquot of PCR product was mixed with 6X Agarose loading 
buffer (Table 2.1) and loaded onto a 0.8% w/v agarose gel to undergo 
electrophoresis and a verify the amplicon was of the predicted size. 
 
2.3.6 PCR product purification 
QIAquick PCR Purification Kit was used to remove any impurities such as salts, 
unincorporated nucleotides, agarose, or dyes and unincorporated nucleotides 
which can affect subsequent processing.  
Five volumes of buffer PB to one volume of PCR product was added to 10µl was 
added to 3M sodium acetate (pH5) and mixed by slowly pipetting up and down. 
The sample was when added to a QIAquick column which was placed inside a 
collection tube. The sample was centrifuged at 16,200xg (13,000rpm) for 13 
minutes. The flow through was discarded and the column placed back into the 
collection tube. 750µl buffer PE was added to the column then centrifuged at 
16,200xg (13,000rpm) for 1 minute. The flow through was again discarded. This 
time the column was placed into a clean 1.5ml centrifuge tube with 50µl of 
molecular grade water added to the centre of the QIAquick membrane. The tube 
was then centrifuged for a further minute at 16,200xg (13,000rpm).  
 
Purified PCR products underwent overnight restriction digest with an appropriate 
restriction enzyme at 37oC. The digested product was combined with 6X DNA 
loading buffer and loaded onto a 0.8% w/v agarose gel which was run for 40 
minutes at 80V to undergo electrophoresis. Afterwards the gel was stained in 




2.3.7 Gel purification of DNA  
QIAquick Gel Extraction Kit was used to clean the DNA fragments from enzymatic 
reactions and remove unwanted impurities such as salts, agarose, or dyes which 
can affect subsequent processing. 
After suitable restriction digestion, DNA was electrophoresed at 100V on a 0.8% 
w/v agarose gel in TAE buffer containing 1:20,000 Sybr Safe (Life Technologies) 
until DNA bands could be resolved and the appropriate fragment excised and 
placed into a microcentrifuge tube. The DNA was purified using a QIAquick Gel 
Extraction Kit. 
The volume of gel was estimated by weight, with 100 mg ≈ 100 μl. Three volumes 
of buffer QG were added and incubated at 50oC for 10 minutes, vortexing every 
3 minutes. If the colour of the mixture is orange or violet, then 10μl of 3M sodium 
acetate was added to the dissolved gel solution to ensure the correct pH as 
indicated by a yellow colour. The solution was then added to a QIAquick column 
and spun at 16,200xg (13,000rpm) for 1 minute. The column was washed with 
750μl buffer PE (a low salt, high ethanol proprietary solution) and the column 
centrifuged at 16,200xg (13,000rpm) for 1 minute. The flow through was 
discarded and the column was spun for a further minute at 16,200xg (13,000rpm) 
to remove residual ethanol. The column was transferred to a fresh 
microcentrifuge tube and 30μl of molecular biology grade water was added to the 
column and incubated for 1 minute before a final spin at 16,200xg (13,000rpm) 




2.3.8 Ligation  
The reaction mixture (Table 2.9) was made up to a total of 10μl in molecular 
biology grade water then incubated overnight at 14oC.  
 
Table 2.9: Ligation reaction mixture 
Component  Final Concentration 
10X T4 ligase buffer* (Promega) 1 μl  
Restriction digested backbone  ~80ng 
Restriction digested insert  ~240ng 
T4 DNA ligase (Promega)  2U 
*(300mM Tris.HCl, pH 7.8; 100 mM MgCl2; 100 mM DTT and 10 mM ATP) 
 
The amount of cDNA was estimated by comparison to known amounts of DNA in 
standard size marker ladders in an agarose gel. 1μl of ligation product was used 
to transform bacteria.  
 
2.3.9 Bacterial transformation 
All bacterial transformations were carried out using standard sterile practice in a 
designated category 2 laminar flow containment hood. A 40μl aliquot of competent 
DH5α Escherichia coli (E.coli, NEB) was thawed on ice. 1μl of plasmid DNA was 
then added and mixed to the E.coli and mixed by gentle tapping. The bacteria 
were left on ice for a further 15 minutes.  
A heat shock method was used to allow the bacterial cells to take up the plasmid 
DNA. During heat shock transformation a sudden increase in temperature 
creates pores in bacterial plasma membranes allowing for plasmid DNA to enter 
the cell. This method involved cells being incubated at 42oC for 45 seconds, then 
returned to the ice for a further 2 minutes.  
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The bacteria were then added to 1ml of SOC (LB containing 20mM glucose, 
10mM MgCl2 and 2.5mM KCl) and placed in a shaker at 37oC for 1 hour, to allow 
expression of antibiotic resistance proteins. The bacteria cells were collected by 
centrifugation at 1,500xg (4,000rpm) for 2 minutes at 4oC. 800μl of the 
supernatant was removed, the bacteria were gently resuspended in the 
remaining liquid which was then plated out on an agar culture plate containing 
the ampicillin selection antibiotic.  
 
2.3.10 Human Embryonic Kidney (HEK) 293 cell culture 
HEK 293 cells were originally transformed in 1977 by Frank Graham, a post-doc 
in Alex Van der Eb’s laboratory. They are named after the cell type, human 
embryonic kidney, and the fact that this transformation was Graham’s 293rd 
experiment. The cells were transformed through exposure to sheared fragments 
of human adenovirus type 5 (Ad5) DNA which lead to the incorporation of Ad5 
into chromosome 19 of the kidney cell genome [105].  
 
Cell lines used were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM), 
containing 100U/ml penicillin and 100μg/ml streptomycin and 10 % (v/v) foetal 
calf serum. HEK 293 cells were incubated at 37oC, 5% CO2, and were routinely 
passaged at 80-90 % confluency.  
The plasmid DNA was then used to transfect HEK 293 cells.  After cells had been 
grown to 80-90 % confluency they were counted using a Neubauer chamber then 
seeded onto cover slips at a concentration of 30x104. Overnight lipofectamine 
transfections were carried out with cells then fixed to the cover slips (4% PFA at 
room temperature for 15 minutes). Immunocytochemistry was then carried to 
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stain the cells ready for visualisation under the confocal microscope. Details of 
the methods used are outlined below; 
 
2.3.11 Transient transfection 
Lipofectamine LTX (Invitrogen) transfections where undertaken following the 
manufacturer’s protocol. Cells were grown until 40-80% confluency. An 
appropriate amount of sterile DNA (2.5µg per 35mm dish) was diluted in Optimem 
(Gibco), to a suitable volume for the size of the culture dish being used. If multiple 
constructs were to be expressed, plasmids were combined prior to addition to 
enhance co-expression efficiency. The specified amount (3.75-8.75μl) of 
Lipofectamine LTX reagent required was added and the contents mixed by gently 
tapping the microcentrifuge tube. The transfection mixture was incubated for a 
minimum of 30 minutes at room temperature (Table 2.10).  
 
Table 2.10: Transfection mixture composition 
Component  
Volume (µl) 
per 35mm dish 
Plain DMEM 493 
DNA (1µg/µl) 2.5 
Lipofectamine LTX 4.5 
Total  500 
 
 
Following incubation, the transfection mixture was added to the cell culture 





Cells were seeded on to coverslips at a density of approximately 1 x 104 cells per 
13mm diameter coverslip, and cultured for a minimum of two days prior to 
staining. All washes were carried out at room temperature. Cells were fixed by 
adding matching volume of 4% w/v paraformaldehyde (PFA), pre-warmed to 
37oC, to the culture medium. This was then removed and replaced with fresh PFA 
(pre-warmed) with cells fixed for 15 minutes at 37oC.  
 
After fixing, the coverslips underwent three 5 minute washes with PBS. Non-
specific binding was pre-blocked by incubation at room temperature in lysine 
block for 1 hour. The primary antibodies (Table 2.11) was diluted in lysine block 
with 50μl applied to each coverslip to cover it completely. This was then left for 1 
hour at room temperature.  
 
Table 2.11: Details of primary antibodies used for immunocytochemistry (ICC) 
and Western blot (WB) analysis 
Antigen Host Dilution Supplier Application 
SLC15A5 Rabbit 1:100 Atlas Antibodies ICC & WB 
Myc Mouse 1:100 Abcam ICC & WB 
FLAG Mouse 1:100 Abcam ICC & WB 
 
The coverslips were then underwent three further 5 minute washes with PBS. 
The appropriate fluorescently conjugated secondary antibodies (Table 2.12) were 
diluted in lysine block and applied as with the primary antibodies and incubated 




Table 2.12: Details of secondary antibodies used for immunocytochemistry 
(ICC) and Western blot (WB) analysis 
Target Host Conjugate Dilution Supplier Application 
Rabbit IgG Goat AlexaFluor 568 1:400 Invitrogen ICC 
Mouse IgG Goat AlexaFluor 488 1:400 Invitrogen ICC 
Mouse IgG Goat AlexaFluor 633 1:400 Invitrogen ICC 
Rabbit IgG Goat 
Horseradish 
Peroxidase 
1:5000 Sigma WB 
Mouse IgG Goat 
Horseradish 
Peroxidase 
1:5000 Sigma WB 
 
Coverslips were then washed three more times with PBS for 5 minutes. When 
appropriate the final wash was replaced with 4, 6- diamidino-2-phenylindole 
(DAPI, Invitrogen) at 1:1000 in PBS to stain nuclei. After removing excess PBS, 
by blotting, coverslips were mounted on Superfrost slides (VWR) in Fluorsave 
(Calbiochem) and left to cure for 24 hours, in the dark, at room temperature. 
Images were captured using a Leica SP8 confocal microscope.   
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2.4 Western blotting 
To detect and analyse endogenous proteins and expression of fusion protein 
products from exogenous DNA transiently transfected in cell lines as previously 
described, the proteins were first extracted then subjected to Western blot 
analysis.  
 
2.4.1 Preparation of cell lysates 
Cells were typically seeded in 6-well plates one day prior to experimentation. 
Where appropriate, cells were transfected and allowed to express the exogenous 
constructs for 18-24 hours. Growth media was removed from culture vessel prior 
to being placed on ice. Cells were washed with chilled PBS then 150μl of HE lysis 
buffer was added. The dish was swirled to ensure coverage then left on ice for 
10 minutes. The bottom of the culture vessel was scraped, the lysates collected 
in 1.5ml microcentrifuge tube and then spun at 16,200xg (13,000rpm) for 10 
minutes at 4oC. The supernatant was carefully transferred to a fresh 
microcentrifuge tube, without disturbing the pellet of non-solubilised cellular 
material. The supernatants were retained for further analysis. 
 
2.4.2 Protein quantification  
A Pierce bicinchoninic acid (BCA) Protein Assay Kit (Thermo Scientific) was used, 
according to the manufacturer’s protocol to estimate the amount of protein 
present in cell lysates.  
Working reagent was prepared by combining 50 parts of BCA reagent A with 1 
part of BCA reagent B. Bovine serum albumin protein standards (0.2-1.2 μg/ml) 
were prepared in a 96-well plate by diluting 2mg/ml stock with the same diluent 
as the samples. As HEPES-EDTA (HE) lysis buffer contains more EGTA than the 
95 
 
microplate assay can accommodate, it was necessary to first dilute the lysis 
buffer 1:10 with PBS before preparing the standards. The samples were also 
diluted 1:10 in PBS and 10μl of both samples and standards were loaded into 
wells in triplicate.  
Following an 8 minute incubation at room temperature on an orbital shaker (LSE 
Low Speed Orbital Shaker, Corning), absorbance was measured at 562nm using 
a PHERAstar FS microplate reader (BMG Labtech). Concentrations of each 
sample were calculated against the standard curve. Each sample was then 
diluted in appropriate lysis buffer and 1x Laemmli sample buffer to give 1mg/ml. 
Samples were then stored at -20oC until required.  
 
2.4.3 SDS-PAGE separation of proteins  
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (SDS-PAGE) 
was used to separate proteins according to their molecular weight. 
SDS is an anionic detergent with a net negative charge across a wide pH range 
that denatures proteins, eliminating the influence of the structure and charge of a 
polypeptide. During electrophoresis proteins are separated based solely on chain 
length when a voltage is applied and they migrate through the acrylamide gel 
matrix towards the positively charged electrode.  
The resolution of the resolving gel required is determined by the length of the 
polypeptide (Table 2.13). A 10% resolving gel was used to investigate SLC15A5 
due to its size of 65.2kDa (65,263Da).
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Table 2.13: SDS-PAGE gel percentage recommendation based on protein size. 







The 10% SDS-PAGE gels were prepared according to the recipe outlined in 
Table 2.14 using the Mini-PROTEAN™ Tetra Handcast System (BioRad). 
Ammonium persulphate (APS) and N,N,N',N'-tetramethylethane-1,2-diamine 
(TEMED) were added last to initiate polymerisation (setting) of the acrylamide. 
 
Table 2.14: SDS-PAGE gel composition. 
Component Stacking Gel (4%) Resolving Gel (10%) 
40% Acrylamide/Bis 0.7 6.3 
1M Tris-HCl pH 6.8 0.88 - 
1.5M Tris-HCl pH 8.8 - 6.25 
10% SDS 0.07 0.25 
10% APS 0.07 0.125 
ddH2O 5.28 12.1 
TEMED (μl) 2.5µl 2.5µl 
Total volume*  7 25 
*Volumes (in ml, unless otherwise stated) are for 40% Acrylamide/Bis solution 
37.5:1 ratio and makes 2 gels.
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Each well was loaded with 25μg of protein in Laemmli sample buffer and 5μl 
BLUeye Prestained Protein Ladder (Gene Flow) was loaded at either end of the 
gel. The loaded gel was then immediately run at 200 mA on ice for 90 minutes in 
running buffer (detailed in Table 2.6).  
 
2.4.4 Membrane transfer 
Following the separation of proteins by SDS-PAGE, gels were incubated in 
transfer buffer for 10 minutes to reach stability. This step was required to allow 
expansion of the gel as the polyacrylamide takes on water. Gels that do not 
undergo this equilibration step can swell during transfer resulting in poor protein 
resolution.  
Proteins were then transferred to Immobulon-P polyvinylidene difluoride (PVDF) 
transfer membrane (Merck) by sandwiching the two together between 
chromatography-grade blotting filter paper (GE Healthcare) and applying a 
constant current of 200mA over the stack to enable efficient migration of the 
proteins towards the anode and binding to the PVDF membrane. 
 
2.4.5 Immunodetection and visualisation  
After transfer, PVDF membranes were blocked with 5% (w/v) skimmed milk in 
tris-buffered saline with 0.1% Tween-20 (TBS-T) for 1 hour at room temperature 
to prevent non-specific binding of the detection antibodies. Blocked membranes 
were then incubated in primary antibody solution (primary antibodies listed in 
Table 2.11). 
Membranes were then removed from the primary antibody and washed in TBS-T 
three times for 5 minutes. Incubation for 1 hour at room temperature with 
appropriate secondary antibody (detailed in Table 2.12) conjugated to horse-
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radish peroxidase (HRP) followed with another set of washes. Proteins were 
visualised using enhanced chemiluminescence (ECL) detection reagent. This 
method involves the breakdown of the ECL detection reagent by the HRP 




2.5 Gene expression methods 
 
2.5.1 RNA extraction 
RNA was extracted from whole blood collected in PAXgene Blood RNA Tubes 
(BRT) and purified for sequencing using the Qiagen PAXgene blood RNA kit 
according to the manufacturer’s instructions. 
The RNA concentration of samples was measured using the NanoDrop 2000c 
UV-Vis Spectrophotometer (Thermo Scientific), as previously described, with the 
quality of the RNA measure by the Agilent 2200 TapeStation System (Agilent 
Technologies).  
Assessing RNA quality is a critical step as the integrity of the RNA determines 
the success of downstream experiments including cDNA library construction and 
qPCR. The Agilent 2200 TapeStation System compares relative ratios of signals 
to produce an RNA integrity number (RIN) equivalent (RINe) score. This RINe 
uses the 1-10 scale as RIN where a score of 10 describes the highest quality 
RNA and 1 indicates the RNA is completely degraded. 
 
2.5.2 Whole transcriptome sequencing  
Experiments outlined below were undertaken by the Exeter Sequencing Service 
(Exeter Sequencing Service and Computational core facilities at the University of 
Exeter. Medical Research Council Clinical Infrastructure award (MR/M008924/1). 
Wellcome Trust Institutional Strategic Support Fund (WT097835MF), Wellcome 
Trust Multi User Equipment Award (WT101650MA) and BBSRC LOLA award 
(BB/K003240/1). 
Reverse transcription is the process by which single stranded complementary 
DNA (cDNA) is synthesized using a reverse transcriptase enzyme and an RNA 
100 
 
template. A TruSeq stranded total RNA sample preparation with RiboZero Globin 
kit (Illumina) was used to prepare whole-transcriptome sequencing libraries from 
blood-derived RNA by depleting rRNA, via a bead-based method, and 
synthesising cDNA. The quality of the cDNA was checked using the High 
Sensitivity D1000 ScreenTape system (HS D1000) (Aligent).  
Accurate quantification of the library was undertaken using the NEBNext® Library 
Quant Kit (Illumina) in conjunction with the StepOnePlus™ Real-Time PCR 
System prior to undergoing NGS sequencing. This quality control (QC) step is 
vital to obtain maximum, high quality NGS sequencing data.  
The NGS data was then analysed by Dr Ryan Ames (University of Exeter) to infer 
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3.1.1 The mammalian ear 
Consisting of the three basic parts; the outer ear, the middle ear and the inner 
ear [106], the mammalian ear is an intricate physiological apparatus that collects 
a wide spectrum of sounds of various frequencies and intensities from the 
environment. By transferring this information to the brain, as an electrical signal, 
it facilitates the interpretation of sound enabling them to not only be identified but 
their relative distance and direction to be determined [107].  
The outer ear consists of the visible auricle and the ear canal (Figure 3.1a). Its 
primary function is to collect sound waves from the environment, funnel them into 
the ear canal and onto the tympanic membrane (ear drum), a thin, circular layer 
of tissue. Sound waves cause this thin membrane to vibrate, passing the sound 
waves into the middle ear.   
The middle ear contains three small bones, or ossicles, called the malleus 
(hammer), the incus (anvil) and the stapes (stirrup). The malleus, being attached 
to the inside surface of the tympanic membrane, vibrates when sound waves hit 
the membrane. This is turn causes the subsequent bones to vibrate, passing the 
waves through the middle ear. Upon vibration the stapes makes contact with the 
oval window, a membrane covered opening leading into the cochlear, that divides 




Figure 3.1: Schematic illustration of the human ear. (a) The ear consists of the 
outer, middle and inner ear. (b) A section through the cochlear. (c) The organ of 
Corti. Image adapted from [107]. 
 
The inner ear occupies the cavity in the temporal bone and houses the sensory 
organs for hearing and balance. This location serves as an acoustic chamber 
enabling the capture of low intensity sounds [107].  
The cochlear is a snail-shaped organ consisting of a spiral canal that turns 2.5 
times around an axis, the modiolus, ending in the helicotrema [108]. This canal 
is divided by two membranes the Reissner’s, or vestibular, membrane and the 
basilar membrane which forms three fluid-filled ducts; the scala vestibular and 
the scala tympani, filled with perilymph, and the scala media (Figure 3.1b). The 
scala media, also called the cochlear duct, is an endolymph-filled cavity that 
houses the organ of Corti, commonly referred to as the organ of hearing, which 
sits on the basilar membrane (Figure 3.1c). 
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Mechanical vibration of the oval window, initiated by the stapes, causes the 
endolymph to move through the cochlear duct and vibrate the basilar membrane 
against the tectorial membrane [107]. Embedded within the basilar membrane 
are specialised cells called hair cells which, through a process of 
mechanoelectrical transduction (MET), are responsible for transferring this 
mechanical stimuli into an electrochemical signal which is the basis of hearing. 
 
3.1.2 Mechanoelectrical transduction in the mammalian ear 
There are two types of hair cell; inner hair cells (IHC) and outer hair cells (OHC) 
that are arranged in a highly order pattern [109] consisting of one row of IHCs 
and three rows of OHCs supported by various other non-sensory cells [110] 
forming the organ of Corti (Figure 3.1c). The IHCs are the main sensory cells 
which convert the sound-induced motion of the endolymph into an 
electrochemical impulse that is transmitted to the auditory cortex of the brain, via 
the auditory nerve, capturing information regarding the frequency, intensity and 
timing of sounds. The role of the OHCs is to act as amplifiers modifying the 
sensitivity and selectively to sound [111].   
 
Both hair cell types have a hair bundle located on its apical surface, consisting of 
between 20-300 actin-rich projections called stereocilia and a single microtubule-
based kinocilium, [112]. The hair bundles of the IHCs extend into the scala media 
whereas the stereocilia of the OHC bundles are connected to the tectorial 
membrane [111].  
The stereocilia undergo a precise assembly process that gives the hair bundle an 
asymmetric, staircase appearance [113] (Figure 3.2a). Each stereocilia within in 
a hair bundle is connected to an adjacent stereocilia via a cadherin tip link (Figure 
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3.2bi) which connects the tops of the small and middle row stereocilia with the 
sides of the taller neighbouring stereocilia [110]. These connections are 
considered to be an essential part of the MET machinery [114, 115].  
 
 
Figure 3.2: (a) Scanning electron microscopy showing the organisation of the 
IHCs viewed from the top of the organ of Corti. Schematic representation of an 
IHC with relaxed tip links and closed MET channels (bi) and with tip links under 
tension and MET channels open as a result of mechanical deflection by a sound 
wave (bii). Adapted from Benjamin Cummings, Pearson 2008. 
 
Small (1-100nm) mechanical deflections of the hair bundle in the direction of the 
taller stereocilia [110, 116] increases tension in a gating spring [114] that leads 
to the opening of MET ion channels located atop the stereocilia (Figure 3.2bii). 
Although much is known about the MET channels of the HCs, the molecular 
identity of the gating spring and the MET channel protein and how these channels 
are activated is yet to be confirmed [114, 116]. However, current literature 
suggests the MET channel may belong to the transient receptor potential (TRP) 
channels [117].  
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The opening of these channels initiates an influx of sodium (Na+), potassium (K+) 
and calcium (Ca2+) ions into the hair cells. This depolarises the basolateral 
membrane of the hair cells and triggers the calcium dependent exocytosis of the 
neurotransmitter glutamate [111] via synaptic ribbons. These ribbons tether 
synaptic vesicles permitting synchronous auditory signalling [118]. The release 
of glutamate into the synaptic cleft excites adjacent afferent auditory neurones 
signalling the auditory centres in the brain [111].  
 
 
3.1.3 Ion Homeostasis in the mammalian ear 
Ion homeostasis is the maintenance of highly asymmetric concentrations of the 
major inorganic ions [119]. MET is heavily reliant on ion homeostasis to maintain 
the specific ionic gradient between the perilymph and endolymph, unique to the 
inner ear [120]. The ion composition of the perilymph is similar to other 
extracellular fluids, such as cerebrospinal fluid and blood plasma, consisting of 
5mM K+ and 150mM Na+. However, the endolymph, in addition to protein, Mg+ 
and Ca2+, comprises of high (150mM) K+ and low (5mM) Na+ which results in a 
highly positive endocochlear potential (EP) of +80mV compared to the perilymph 
[121, 122].  The function of IHCs is highly dependent upon this EP [123] which 
greatly enhances the flow of ions into the cells during MET permitting greater 
sensitivity to sound [121].  
The non-sensory epithelium cells of the stria vascularis generate the high 
concentration of K+ and in turn the highly positive EP with virtually no input of 
metabolic energy [120]. These cells also play a key role in the recycling of the K+ 





Figure 3.3: Potassium ion (K+) recycling in the inner ear. MET of the IHCs causes 
an influx of K+ into the hair cells. These ions are then secreted back into the 
endolymph by the stria vascularis (SV) via supporting cells and the spiral ligament 
(SL). Image taken from [114]. 
 
Several recycling pathways have been suggested comprising of a system of 
channels, transporters and gap junctions with many of the molecules involved 
identified via mutations in mice and humans that have led to hearing loss [120].  
Any genetic mutation leading to an imbalance of K+ in the endolymph and loss of 





3.2 Hearing Loss 
The World Health Organisation has reported that ~466 million people worldwide 
experience disabling hearing loss and predict this to rise to over 900 million by 
2050 [124]. Hearing loss is the most prevalent sensory deficit disorder in 
developed societies [125] with congenital hearing loss affecting at least 1 in 500 
new-borns [126, 127] and more than 50% of the population over the age of 80 
suffering from presbyacusis (age-related hearing loss) [107].  
 
3.2.1 Types of hearing loss 
Hearing loss is an extremely heterogeneous condition [128, 129] and can be 
classified in a number of ways depending on the age of onset, type, severity, 
progression, frequency affected and laterality, if it affects one (unilateral) or both 
(bilateral) ears. It can also be grouped according to its aetiology (genetic or 
environmental factor) and whether the hearing loss occurs with (syndromic) or 




Table 3.1: Characteristics for classifying hearing loss [128-130]. 
Classification Description of hearing loss 
Age of Onset 
Congenital (present at birth), prelingual (0-5years of 
age), or postlingual (>5 years of age) 
Type Sensorineural, conductive or mixed 
Severity 
Mild (20-40dB), moderate (41-55dB), moderately 
severe (56-70dB), severe (71-90dB), or profound 
(>90dB) 
Progression Progressive or stable 
Tone frequency affected 
Low (<1000Hz), middle (1000-2000Hz) or high 
(>2000Hz) 
Laterality Unilateral or bilateral 
Aetiology Environmental/acquired or genetic 
Additional clinical features Syndromic or non-syndromic 
Inheritance Recessive, dominant, X-linked or mitochondrial 
Presence of vestibular 
disorder 
Hearing loss with or without vestibular dysfunction 
 
 
Sensorineural hearing loss (SNHL) occurs when the conversion of mechanical 
sound waves into an electrical signal is impaired due to malfunction of the inner 
ear [131] including the membranous labyrinth, the organ of Corti or the 
vestibulocochlear nerve [132]. SNHL most commonly has an underlying genetic 
cause. There are currently over 6000 causative variants in more than 110 genes 
linked to non-syndromic SNHL (NS-SNHL) [131] with additional genes being 
responsible for syndromic hearing loss. Conductive hearing loss is caused by 
abnormalities of the outer ear or the ossicles of the middle ear preventing the 
conduction of sound waves and is most commonly caused by an environmental 
factor [131]. Mixed hearing loss is when both the sensorineural and conductive 
parts of the ear are impaired. 
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Environmental factors such as exposure to ototoxic chemicals, for example 
aminoglycosides, exposure to excessive noise and neonatal insults including 
prematurity, jaundice or prenatal infection [125, 133] account for approximately 
20% of prelingual hearing loss with genetic causes giving rise to the remaining 
80% [134] (Figure 3.4). 
 
 
Figure 3.4: Causes of prelingual hearing loss in developed countries figure 
adapted from [131].  
 
It is widely accepted that early identification and accurate diagnosis of the 
underlying genetic cause is crucial for selecting the most appropriate therapeutic 
option. This is of particular importance when assessing cochlear implant 
candidacy [111, 125] and when monitoring potential future health concerns of 
genetic syndromes allowing for the implementation of protective management 
strategies [132]. Discovering the underlying cause also allows families to receive 
more targeted genetic counselling and be provided with information on the 




3.2.2 Impact of hearing loss 
Despite hearing loss being ranked as the fifth leading cause of years lived with 
disability by the Global Burden of Disease Study in 2103, it receives limited 
funding and public awareness [135]. Elucidating the underlying genetic cause 
and pathophysiology of congenital hearing loss presents numerous benefits to 
affected individuals, their families and to communities as a whole.  
The social costs of untreated hearing loss is ~$1.1million dollars per individual 
[111], presenting a huge economic burden. Early intervention, in the form of 
Universal Newborn Hearing Screening (UNHS), is predicted to reduce these 
costs ~75% and most importantly improve the life opportunities of affected 
individuals [136]. The impact of hearing loss on an individual is profound effecting; 
speech development and language acquisition, cognitive and psychosocial 
development, independence and overall quality of life [135, 137, 138] resulting in 
substantial negative effects on educational achievement and work life 
opportunities [135, 138]. Interventions implemented before 6 months of age 
provide the greatest chance of developing age-appropriate speech and language 
skills, [137] making it imperative for the genetic cause to be identified as early as 
possible [125]. During the past 20 years UNHS has become a standard of care 
throughout the US and UK [139, 140] reducing the age of diagnosis, enabling the 
implementation of proactive intervention efforts [125, 137, 139, 141] and 
informing treatment options such as cochlear implantation candidacy [142].  
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3.2.3 Diagnosing hearing loss 
It is widely accepted that hearing loss is an extremely heterogeneous condition 
[143]. Approximately 1% of all human genes are predicted to be involved in the 
hearing process and therefore could be responsible for the diverse phenotypes 
observed in hearing loss [137].  
For a number of years this clinical and genetic heterogeneity slowed the 
discovery of new causative genes [125] and prevented comprehensive genetic 
testing and large scale population screening [133] thus making molecular 
diagnosis very difficult [128]. With more than 110 genes and in excess of 6000 
mutations [131] reported to cause NS-SNHL traditional strategies involving single 
mutation screening using Sanger sequencing were not feasible due to cost and 
time constraints [131]. The advent of next generation sequencing (NGS) 
technologies, whole exome sequencing (WES) and whole genome sequencing 
(WGS), has increased the speed and proficiency of detecting hearing loss genes 
with 21 new genes identified between 2010 and 2015 [125].  
In addition to expediting the discovery of causative genes these new technologies 
have also permitted the implementation of improved diagnostic testing increasing 
diagnostic rates by approximately 50% [128, 143]. This enables families to be 
counselled appropriately, with regard to the progression and prognosis of the 
condition, receive the most suitable treatment [111] and facilitates affected 
individuals in achieving optimal cognitive development [137].   
In the UK the British Association of Paediatricians in Audiology (BAPA), whose 
aim is to maintain standards in audio-vestibular medicine [144], have published 
guidelines to standardise the investigations undertaken to diagnosis childhood 
hearing impairment after a failed UNHS. These guidelines (summarised in 
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Appendix D) utilise a gene panel approach to identify causative mutations for 
non-syndromic and syndromic hearing loss [145].  
 
The new challenge for genetic investigations and genomic research no longer 
comes from the sequencing of variants, which has become the cheapest and 
simplest part, but instead resides in the accurate interpretation of identified 
variants which currently incurs the highest expense due to the time and expertise 
required from a number of highly qualified individuals [125].  
 
3.2.4 Treatments 
Hearing impairment is the only sensory defect that can be successfully treated, 
even when hearing loss is complete [137] due to the one of the most significant 
advances in modern medicine, the cochlear implant [146]. 
 
Cochlear implants 
Cochlear implants (CIs) are a surgically placed electronic stimulus prostheses 
that can restore the missing, or impaired, function of the IHCs by taking on the 
role of transforming an acoustic signal into an electrical impulse capable of 





Figure 3.5: A typical modern cochlear implant system that converts sound to 
electric impulses delivered. Image shows the location of the; microphone (1), 
speech processor (2), transmitter (3), receiver (4), stimulator (5),  electrodes 
(6&7) and the auditory nerve (8) [147].  
 
However, to achieve the maximum therapeutic benefit of this treatment, and to 
minimise the effect on language development, it is necessary to detect and 
diagnose hearing loss as early as possible [141]. Studies have observed a 
negative correlation between outcomes with CIs and the duration of hearing loss. 
This indicates that those individuals that experience prolonged periods of auditory 
deprivation, for example those with congenital hearing loss who are implanted 
after the age of three years or individuals with postlingual hearing loss that 
experience a long period of severe hearing loss prior to implantation, are more 
likely to experience negative outcomes compared to those implanted earlier in 
life or within a year of developing substantial hearing loss for individuals affected 
by postlingual hearing loss [148].  
Candidacy for CIs is comprehensively assessed via medical and audiological 
examination [146]. Conventionally children with severe to profound hearing loss 
with speech recognition <12-30% where considered CI candidates [149]. 
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However, due to improvements in CI technology and surgical approaches, the 
criteria for CI implantation has expanded, with the FDA now approving children 
as young as one year of age and individuals with residual low-frequency hearing 
impairment [146].  
 
Biological treatments  
Although there is currently no biological treatment for hearing loss there is an 
apparent need for a treatment that restores auditory function without the need for 
a prosthesis or at the cost of any residual hearing [150, 151]. Within the auditory 
research community there is increasing interest into a variety of techniques that 
look to regenerate mammalian hair cells and restore their function [151].  
 
For a number of years gene therapy, the treatment of human disease using 
genetic material, was the focus of many research groups (Reviewed in [151]). 
Recent advances in this field including improved methods of gene delivery and 
improvements in hair cell regeneration [150] have demonstrated exciting proof-
of-principle studies in animal models which continues to suggest gene therapy as 
a possible treatment for some forms of hearing loss [152].  
However, the clinical application of gene therapy, for hearing loss and other 
conditions, is currently limited by the perceived risk of side effects which are still 
under investigation [153]. With almost 2600 clinical trials, in 38 countries, having 
been completed, underway or approved [154] there is hope that the findings from 
these studies will aid the translation of gene therapy to human patients and the 




In addition to gene therapy, genome editing technologies are an exciting new 
area of research. Genome editing technologies modify the genome at a targeted 
locus to correct genetic variants, known to cause hearing loss (and other 
disorders), by restoring the wild-type sequence in native DNA through the use of 
programmable nucleases [151]. The CRISPR/Cas9 system, derived from 
prokaryotic immune systems, is the most recent and advanced programmable 
nuclease that is considered to be the most prevalent and easy-to-use system with 
multiple applications [153]. 
Currently there are considerable concerns about the use of this technology in a 
clinical setting due to the potential for off-target editing and the unknown resultant 
side effects [151]. Although, to date, there is no way to identify or prevent them 
given the increasing interest in this area it is likely these complications will be 
overcome in the future. 
 
Public Health Awareness  
In conjunction with developing therapies to treat hearing loss there a number of 
strategies that could be employed to help mitigate hearing loss in children. 
Improvements in public health awareness and the application of simple measures 
such as; avoiding the use of ototoxic drugs, immunisation and the early 
identification and intervention for acute and chronic ear conditions, have shown 
to reduce the contribution of environmental factors in the development of hearing 





3.3 The genetics of hearing loss 
 
3.3.1 Syndromic hearing loss 
There are 600 conditions, cited in the London Medical Database V.1.0.31, linked 
to SNHL [128]. These account for approximately 20% of genetic causes of 
hearing loss. In a number of cases the hearing impairment may be the most 
obvious symptom, and therefore the first to be diagnosed, with other clinical 
features developing later [129]. Often a genetic diagnosis is the only way to 
determine if an individual will develop future complications, such as renal failure 
in Alport syndrome [132]. 
Perhaps one of most important syndromes to diagnose is the autosomal 
recessive Jervell and Lange-Nielsen syndrome where congenital, profound 
hearing loss occurs in conjunction with Long QT syndrome [131]. This syndrome 
is associated with a high rate of syncope, where individuals lose consciousness 
as a result of a sudden drop in blood pressure, and if left untreated, can lead to 
sudden death [128]. 
Some of the most common syndromes, grouped by inheritance pattern, are 
summarised in Appendix E.  
Interestingly mutations in some genes associated with syndromic forms of 
hearing loss can also cause non-syndromic forms such as CDH23 and MYO7A 
(Usher syndrome), SLC26A4 (Pendred syndrome), WFS1 (Wolfram syndrome) 
and COL11A2 (Stickler syndrome). 
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3.3.2 Non-syndromic hearing loss 
Determining the underlying genetic cause of an individual’s hearing loss can 
exclude the presence of a hearing loss syndrome or confirm the presence of non-
syndromic hearing loss. This information is useful for determining and 
implementing the most effective management strategy including potential 
treatments and for providing informed genetic counselling to families.  
 
There are currently over 110 genes linked to non-syndromic hearing loss which 
can be referred to by the genes involved or by the genetic locus. Non-syndromic 
deafness loci are referred to by DFN (DeaFNess) followed by a letter, which 
classifies the mode of inheritance (DFNA autosomal dominant, DFNB autosomal 
recessive, DFNX X-linked) and a number representing the order of gene 
mapping/discovery [131].  
 
GJB2 
The most common genetic cause of congenital NS-SNHL are mutations in the 
gap junction beta 2 (GJB2) gene [130], which was first identified as a cause of 
hearing loss in 1997 [155] and is commonly referred to as DFNB1. For European 
populations, mutations in this gene account for approximately 50% of hearing 
loss cases [130]. The GJB2 gene is located at 13q12.11 and encodes the gap 
junction protein connexin 26 (Cx26) which is expressed in the non-sensory 
epithelial cells of the inner ear [155].  
Connexins are integral membrane proteins which are generally referred to by 
their predicted molecular weight. For example, connexin 26 is predicted to be 
~26kDa [156] and exhibits the characteristic topological structure of a connexin 
protein containing; four transmembrane domains, two extracellular loops and one 
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intracellular loop, with both the N- and C- termini exposed to the cytoplasm 
(Figure 3.6) [157]. 
 
 
Figure 3.6: Topological structure of a typical connexin protein. Showing the four 
transmembrane (TM) domains, the two extracellular loops (E1 and E2) and the 
single cytoplasmic loop (CL). 
 
Six connexin molecules join to form a pore-like transmembrane oligomer called 
a connexon, or hemichannel [107] (Figure 3.7). These gap junctions are 
intercellular channels that permit the passage of ions and small molecules (up to 
~1.5kDa) [158]. It is widely accepted that these molecules play an important role 
in the recycling of K+ during the process of ion homeostasis, which is essential 





Figure 3.7: Connexins, connexons and gap junctions. Simplified diagram showing 
the assembly of a gap junction from the intercellular joining of two connexons, on 
adjacent membranes, each consisting of six single connexin molecules [156].  
 
More than 100 mutations located within GJB2 have been associated with hearing 
loss [158]. Most GJB2 mutations display a recessive (DBFB1) inheritance pattern 
with a few being dominant (DNFA3) in nature [155, 159]. A wide spectrum of 
hearing loss phenotypes ranging from profound congenital deafness [158] to 
mild, progressive, late-onset hearing loss starting in childhood [160] are 
observed. This diversity in phenotype suggests that hearing loss arising from 
mutations in GJB2 may involve several different underlying pathological 
mechanisms [158]. However, to date, there is no clear, demonstrable relationship 
between specific changes in Cx26 function and the observed phenotypes [158]. 
New evidence suggests that congenital hearing loss caused by mutations in 
GJB2 are associated with cochlear development disorders, as opposed to EP 
generation [161] or K+ recycling impairment [162]. This means that disruption of 
121 
 
K+ recycling is not the principle mechanism causing Cx26 mutation-induced 
hearing loss as predicted [160, 161]. 
 
The most frequently occurring GJB2 mutation, c.35delG (NM_004004.5: 
c.35delG), accounts for ~70% of cases worldwide [163, 164] with almost 4% of 
the white population in Southern Europe reported to be heterozygous [165, 166]. 
The high frequency of the c.35delG mutation could be due to a mutational hotspot 
resulting from its position in a T(G)6T sequence which, during DNA replication, 
may favour slippage and mispairing [167]. However, data from multiple other 
studies show strong evidence of linkage disequilibrium [168, 169] suggesting that 
c.35delG represents a common founder mutation and not a mutational hotspot. 
Other common GJB2 mutations are observed in specific populations, including 
c.235delC in East Asia and Japan [170], c.167delT in Ashkenazi Jews [171], 
p.V37I in Southeast Asia [172], p.W24X in India [173], IVS1+1G>A in Mongolia 
[174] and del(GJB2-D13S175) in Russia [175]. 
 
Mutations in GJB2 are often classified as either truncating or non-truncating 
depending on their possible effect on Cx26 [166]. Large systematic analysis of 
the GJB2 genotype has determined that mutations in this gene do display 
genotype-phenotype correlation with the type of mutation significantly impacting 
the severity of hearing impairment [176]. Truncating, or inactivating mutations 
(nonsense, frameshift, indels) prevent synthesis of Cx26 and, in homozygotes, 
are associated with severe to profound SNHL [163]. Non-truncating mutations 
(missense, in-frame) only modify one or several amino acids meaning that the 
protein may retain its function [166]. Individuals with homozygous non-truncating 
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mutations, or compound heterozygotes with one non-truncating and one 
truncating mutation, typically express mild to moderate hearing loss [163]. 
 
Other genes responsible for NSHL 
In addition to those seen in GJB2, mutations in other connexin genes can also 
lead to NSHL including, Cx30 (GJB6), Cx31 (GJB3) and Cx43 (GJA1). As with 
GJB2, GJB6 is predominately expressed in the cochlea and is considered a major 
deafness gene [157]. Whilst mutations in both Cx26 and Cx30 can independently 
induce hearing loss, digenic Cx26 and Cx30 heterozygous mutations are more 
frequently observed and are the second most common cause of recessive 
hearing loss [162]. Interestingly mutations in GJB6 have been shown to be 
responsible for both recessive (DFNB1) and dominant (DFNA3) forms of hearing 
loss. Connexin 30 is 30kDa protein, containing 261 amino acids, with the typical 
structure of a connexin (Figure 3.7). It is involved in gap junctional intercellular 
communication (GJIC) and is essential for maintaining homeostasis of the 
epidermis and inner ear [157].  
Further to the connexion family, mutations in a wide array of other molecules 
have also been associated with inherited forms of hearing loss; information 
regarding these molecules may be accessed through extensive online databases 




3.4 Causes of HL known in the Amish community 
Genetic studies have previously defined a number of gene founder alterations as 
causes of inherited hearing loss in the Amish, including PCNA [177], SLITRK6 
[159, 178], HARS [179], YARS [180], KCNQ1 [181], ST3GAL5 (GM3 synthase 
deficiency) [182], LONP1 [183], HYAL2 [184] and COL1A2 [185, 186].  Details of 
these variants are summarised below (Error! Reference source not found. and 
Error! Reference source not found.) with a more detailed description of each 
variant available in Appendix F.
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Table 3.2: Summary of genes associated with syndromic SNHL hearing loss identified in the Amish. 






moderate to profound 
high frequency SNHL 
Ocular/cutaneous telangiectasia, premature aging, 
photophobia/photosensitivity with predisposition to sun-induced 







moderate to severe 
SNHL 







Childhood progressive visual impairment, horizontal nystagmus, optic 
pallor, photosensitivity, bull’s eye macula, retinitis pigmentosa, delay in 







Severe nystagmus, visual impairment, developmental delay, pancreatic 
insufficiency, cholestatic liver disease, hypoglycaemia and subcortical 





Variable onset & severity 
SNHL 
Refractory infantile onset epilepsy, developmental delay, developmental 
regression, generalised irritability, feeding difficulties, dystonic arm 






Mild to moderate SNHL 
Developmental delay, facial dysmorphism, bilateral cataracts, dental 
anomalies, short stature, delayed epiphyseal ossification, metaphyseal 
hip dysplasia, vertebral abnormalities, hypotonia, scoliosis, laryngeal 
obstruction, swallowing difficulties, imperforate anus, omphalocele, 
rectovaginal fistula, cryptorchidism and tongue hemiatrophy 
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Table 3.3: Summary of genes associated with syndromic, conductive and mixed hearing loss identified in the Amish. 
 
Gene Variant Hearing loss Other clinical features 





Mild to moderate, unilateral/ 
bilateral and pre or 
postlingual  
(one individual with SNHL) 
Cleft lip or palate (CLP), facial dysmorphism, congenital cardiac 
abnormalities, pectus excavatum, single palmar creases, 2,3 toe 
syndactyly, myopia, staphyloma and cataract 





Progressive mixed hearing 
loss 
Bone fractures with minimal or no trauma, bone deformity, short 





As part of the Windows of Hope Project families with multiple individuals 
affected by hearing loss, with no genetic diagnosis, were recruited into the 
Amish Hearing Loss Programme. The aim of the program was to provide 
diagnoses for the underlying genetic cause of the hearing loss within these 
families. To date 19 families with between one and four siblings affected by 
SNHL have been identified and recruited into the program through the use 
of a community-appropriate newsletter and family support groups. Although 
GJB2 gene mutations had not previously been described in the Amish, our 
initial studies included evaluation of this gene due to the high prevalence of 
GJB2-related hearing loss worldwide. The screening process for affected 
individuals was initially dependent on whether the hearing loss presented 
with or without additional clinical phenotypes (Figure 3.8).  
 
 
Figure 3.8: Initial screening strategy implemented for individuals recruited 
to the Amish Hearing Loss Programme. 
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Individuals presenting with no other clinical phenotypes (at the time of 
assessment) where considered to have a non-syndromic form of hearing 
loss so where screened, via Sanger sequencing, for variants within GJB2. 
If no variants were found further genetic investigations involving genome-
wide SNP mapping in combination with whole exome sequencing was 
undertaken. If individuals were presenting with additional clinical features, 
and considered to have to syndromic form of hearing loss, screening for 
GJB2 variants was omitted.  
 
3.5.1 Molecular studies of a large Amish family with multiple 
individuals affected by a neurodevelopmental disorder and hearing 
loss  
A family presented with six children affected by a neurodevelopmental 
disorder in form of intellectual disability (ID), four of whom also presented 
with pre-lingual SNHL (Figure 3.9).  
 
Figure 3.9: Simplified pedigree of the extended Amish family investigated 
for a syndromic form of hearing loss presenting with developmental delay. 




Hearing tests were carried out to confirm the individuals affected and to 
determine the extent of the hearing loss (Figure 3.10). Both air and bone 
conduction tests were carried out as part of these assessments. Although 
the audiograms do not display a characteristic audiometric configuration, so 
could not be used to aid the identification of an underlying genetic cause, 
they were able to confirm the type and severity of the hearing loss. 
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Figure 3.10: Audiograms showing the two 
siblings unaffected by hearing loss (A and 
B) and the four affected individuals (C-F). 
Different symbols are used to plot the 
results of the different conduction tests for 
each ear. Air conduction tests in the right 
() and left () ear are performed first 
with sounds being played through 
headphones. Masking can be used to 
prevent sound from the ear under test 
being detected by the other ear. This 
involves a noise being played into the left 
ear when the right ear is being tested () 
or the right ear when the left ear () is 
being tested. Bone conduction tests, used 
if the air conduction test identifies a 
hearing impairment, involve the use of an 
instrument that vibrates the bones of the 
skull and determines the function of the 
right (<) or left (>) cochlear. Again masking 
can be used to prevent the problem of 
“crossover” and ensures only the right ([) 
or left (]) ear is tested at one time. Sound 
field testing may be also be used, this is 
where a sound stimuli is played via a loud 
speaker, so is not ear specific, and can be 
conducted with (A) or without (S) masking. 
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Two of the audiograms (Figure 3.10, D-E) confirm the type of hearing loss 
as sensorineural (SNHL) as the thresholds for air ( and) and bone (<) 
conduction are similar. If normal thresholds (<25dB HL) were obtained in 
the bone conduction tests with the threshold for air conduction being poorer 
(>25dB HL) this would indicate the cochlear is still functional and a 
conductive form of hearing loss, where deformity of the outer or middle ear 
is preventing sound waves from entering the middle ear is responsible for 
the hearing impairment. If both thresholds where impaired, with the bone 
conduction thresholds being significantly better than those in air, this would 
suggest a mixed type of hearing loss [187].  
The thresholds obtained in these tests show that the hearing loss 
experienced ranges from moderate (41-55dB HL) to profound (>90dB HL).  
 
After confirming the degree of hearing loss in the four affected siblings a 
genome-wide SNP microarray, using the Illumina Human CytoSNP-12v2.1 
330K array, was undertaken on DNA from all six siblings. Interrogation of 
the resultant genotypes identified a 0.56Mb microdeletion delimited by 
markers rs2549956 to rs35967690 (NC_000016.10: g.29622891-
30188484) located on chromosome 16p11.2 common to all the affected 
family members (Figure 3.11).  
Deletions and duplications in this region are one of the most frequently 
reported genetic cause of autism spectrum disorder (ASD) and other 
neurodevelopmental disorders [188]. The 16p11.2 microdeletion syndrome 
is characterised by speech articulation abnormalities, limb and trunk 
hypotonia with hyporeflexia, abnormal agility, sacral dimples, 
seizures/epilepsy, large head size/macrocephaly, lower brain herniation 
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(Chiari I/cerebellar tonsillar ectopia) and an increased tendency to be 
overweight [188]. The affected individuals in this family were not overweight 
and did not display a number of these characteristic phenotypes however, 
they did exhibit hyperactivity and social communication issues. 
 
 
Figure 3.11: Output from KaryoStudio software (Illumina) showing ideogram 
of chromosome 16 and the presence of a hemizygous microdeletion at 
16p11.2. Microdeletion is 0.56Mb spanning rs2549956 to rs35967690.       
 
Whilst it is likely that this microdeletion is responsible for the 
neurodevelopmental delay seen in this family it is unlikely to be the cause 
of the inherited hearing loss. In order to identify other putative genetic 
causes of the hearing loss the CytoSNP microarray data was further 
investigated to identify regions of homozygosity specific to the four siblings 
affected by hearing loss. This lead to the identification of a 0.96Mb 
homozygous region on chromosome 13 (Figure 3.12, Aii) that encompassed 
the connexin 26 (GJB2) gene. Dideoxy sequencing analysis of the GJB2 
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gene identified a c.229T>C substitution (NM_004004.5:c.229T>C, p.W77R) 
(Figure 3.12, Ai) in exon 2. This is a well-established pathogenic variant that 
has been previously reported [155, 189] to cause autosomal recessive 
hearing loss so is the most likely cause of AR-SNHL observed in this family.   
 
 
These findings confirm the presence of two distinct genetic disorders in the 
same family. Thus highlighting; the challenge of disentangling the genetic 
cause of complex phenotypes within the Amish community and the need to 
screen all individuals, recruited into the Amish Hearing Loss Programme, 




Figure 3.12: (Aii) Simplified 
pedigree of the extended Amish 
family investigated with pictorial 
representation of genotypes 
across a ~8Mb region of 
chromosome 13 encompassing 
the disease locus. Bold red box 
denotes the 0.96Mb region 
unique to the four affected 
siblings (and four other more 
distantly related individuals; 
XIII:1, XIIII:2, XIII:3 and XII:3) 
affected by hearing loss 
containing GJB2. Dashed red box 
highlights a homozygous region 
shared by all affected individuals 
and one unaffected sibling. 
Patient XI:13 appears to have a 
recombination event occur 33kb 
away from GJB2 preventing him 
from developing hearing loss, this 
also permitted the shared region 
containing GJB2 to be refined to 
0.35Mb (Ai) Sequencing 
chromatograms showing the 




3.5.2 GJB2 gene mutation is a common cause of NSHL in the Amish 
Families recruited to the Amish Hearing Loss Programme presenting with non-
syndromic hearing loss where initially screened for variants in GJB2, the most 
common genetic cause of congenital NS-SNHL. This initial screening process 
identified seven families with variants in GJB2 (Table 3.4) including four families 
with affected individuals homozygous for NM_004004.5: c.229T>C; p.Trp77Arg 
variant and one family with an affected individual homozygous for the common 
NM_004004.5: c.35del; p.Gly12Valfs variant (Figure 3.13, Family 6,). In the 
remaining two families affected individuals were found to be compound 
heterozygotes for both c.35del and c.229T>C variants. 
 




Genotype Region  
Number of 
affected  





Geauga 1 Family 1 
Indiana 3 Family 3 
Indiana 4 Family 4 
Indiana 2 Family 5 
NM_004004.5:c.35del; 
p.Gly12Valfs 








Geauga 2 Family 7 
Geauga 2 Family 8 
 
Figure 3.13 details all families in the Amish Hearing Loss Programme where a 
variant in GJB2 has been found to be responsible for the observed hearing 
impairment, this includes the family with two distinct genetic disorders described 
in section 3.5.1 (Figure 3.13, Family 2).  
There have been no previous studies published reporting specific GJB2 variants 
and their frequencies in the Amish community. These findings suggest both the 
135 
 
c.35del and c.229T>C GJB2 variants are likely to represent founder mutations. 
Interestingly the p.W77R variant has previously been reported in two interrelated 
families of Israeli-Arab origin [189], where both homozygosity and compound 







Figure 3.13: Simplified pedigrees of eight Amish families with hearing loss caused by variants in GJB2. Hearing loss observed in families 
1-5 is caused by the c.229T>C variant. Family 1 reside in Geauga, Family 2 are from Wisconsin and Families 3-5 are located in Indiana. 
Genotypes of sequenced individuals are shown below (in green). A wildtype allele for this variant is shown by WT. Hearing loss in family 
6, from Geauga, is caused by a c.35del variant with the genotypes for sequenced individuals shown below (in black). A wildtype allele for 
this variant is shown by WT. Affected individuals in families 7 and 8, both located in Indiana, are compound heterozygous for both the 
c.229T>C (in green) and c.35del (in black) variants. 
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3.5.3 Investigating SLC15A5 as a candidate molecule responsible for AR 
NS-SNHL 
 
Genetic and Clinical data 
A family presented with two siblings affected by non-syndromic hearing loss 
(Figure 3.14). The two siblings were initially screened for variants in GJB2 but 
none were found. Due to the inheritance pattern observed in the family it was 
evident that the hearing loss experienced by the two affected individuals was a 
result of an autosomal recessive genetic abnormality. Hearing tests were 
conducted to determine the type and extent of the hearing loss (Figure 3.15).  
 
 
Figure 3.14: Simplified pedigree of the extended Amish family investigated for 





Figure 3.15: Audiograms showing the two siblings affected by hearing loss. 
Different symbols are used to plot the results of the different conduction tests for 
with sounds being played through headphones. Masking can be used to prevent 
sound from the ear under test being detected by the other ear. This involves a 
air conduction test identifies a hearing impairment, involve the use of an 
instrument that vibrates the bones of the skull and determines the function of the 
right (<) or left (>) cochlear. Again masking can be used to prevent the problem 
of “crossover” and ensures only the right ([) or left (]) ear is tested at one time. 
Sound field testing may be used, this is where a sound stimuli is played via a loud 
speaker, so is not ear specific, and can be conducted with (A) or without (S) 
masking. 
 
The audiograms (Figure 3.15Figure 3.10) confirm the type of hearing loss as 
sensorineural (SNHL) as the thresholds for air ( and) and bone (<) conduction 
are similar. The thresholds obtained in these tests indicate that the hearing loss 
experienced by sibling A ranges from mild (20-40dB) to moderately severe (56-
70dB) in their right ear and mild (20-40dB) to severe in their left ear (56-70dB). 
Sibling B appears to be experiencing a more severe hearing impairment with 




To define the genetic abnormality responsible, genome-wide SNP mapping on 
affected family members was undertaken, using the Illumina CytoSNP-12 (330k) 
BeadChip platform in combination with whole exome sequencing, on a carrier 
parent (due to limitations in DNA availability from affected family members),  
using the Agilent Human exome V4 (51Mb) capture. The genome-wide SNP data 
identified a number of homozygous regions. Table 3.5 details the size and 
location of the four largest regions of homozygosity shared by the siblings.  
 
Table 3.5: Regions of shared homozygosity between affected siblings. 
SNPs Flanking Region Genomic Positon of SNPs 
Size of Region of 
Homozygosity 
rs4763845;rs1472874 chr12:12728803-24575272 11.8Mb 
rs4736695;rs11167068 chr8:134556752-142549778 8Mb 
rs2824733;rs2830165 chr21:19689082-27676592 8Mb 
rs408307; rs4876938 chr9:136892523-141213431 4.1Mb 
 
Whole exome sequencing filtering for rare (frequency) and novel heterozygous 
variants in the carrier parent identified no candidate variants in known disease-
associated genes. However, cross-referencing these datasets identified a single 
candidate nonsense variant (NM_001170798.1:c.865G>T; p.Glu289Ter) (Figure 
3.16) located in a 8.2Mb homozygous block common to the affected individuals, 
in SLC15A5, a gene of unknown function not previously associated with inherited 
disease, as a candidate cause of this condition. The variant was validated using 





Figure 3.16: Sequencing chromatograms comparing the identified SLC15A5 
mutation to the wildtype reference sequence.  
 
In-silico investigations predicted the variant to be disease-causing as a result of 
nonsense mediated decay (NMD) of the protein product. Whilst the variant was 
listed in the Genome Aggregation Database (GnomAD) 16 times; in 14 individuals 
of European origin (MAF 0.0001989) and 2 of African descent (MAF 0.0001231), 
no homozygotes were reported. The variant was not reported in 1000 genomes 
database.  
 
Genotyping studies of the variant was initially undertaken in 164 unaffected 
control Amish samples using dideoxy sequencing and identified 15 heterozygous 
individuals, corresponding to an allele frequency of 0.0457. Additional genotyping 
studies of the variant in 167 unaffected control Amish from different Amish 
communities (Table 3.6), using PlexSeq, a multiplexed amplicon sequencing 
approach (Illumina) [102], as described in chapter five, identified eight 





Table 3.6: Allele frequency data for SLC15A5 variant determined from an Amish 





gnomAD Freq.  







Ohio Holmes 0.0221 
Ohio Geauga 0.0273 
Wisconsin 0.0400 
Total 0.0234 
*Allele frequency quoted from gnomAD refers to European (non-Finnish) AFs 
correct as of March 2019. 
 
Given this finding the SLC15A5 variant remained a candidate cause of the 
condition, although no other individuals with SNHL were found to be homozygous 
for the SLC15A5 variant.  
  
Existing functional information on the SLC15A5 protein 
Given the candidacy of SLC15A5 as a cause of this condition, additional 
bioinformatic and molecular information was sought regarding the function of this 
molecule. The solute carrier family 15 member 5 (SLC15A5) gene is located on 
chromosome 12p12.3 comprising nine exons. SLC15A5 predicted to encode a 
579 amino acid proton oligopeptide cotransporter within the superfamily of solute 
carriers. The SLC15A5 polypeptide sequence is predicted to contain 11 helical 





Figure 3.17: TMHMM Server v. 2.0 output. Showing the prediction of 
transmembrane helices in SLC15A5. 
 
Very little is currently known about the specific function of SLC15A5 [190] as very 
few studies have been undertaken to characterise or determine its expression. 
Reviews detailing the expression of other family members, particularly SLC15A1 
(PEPT1) and SLC15A2 (PEPT2), are available in the literature detailing their 
roles in; 
 the absorption and conservation of dietary protein digestion products 
 maintaining homeostasis of neuropeptides in the brain 
 the absorption and disposition of a number of pharmacologically important 
compounds [190-193]  
 
However, as the most distantly related member of the SLC15A proton-peptide 
exchange transporter family, sharing approximately only 50% amino acid identity 
with its other family members [194] it is hard to draw direct comparisons with 




Preliminary studies of SLC15A5 gene product  
Functional studies were carried out through a number of collaborations. Dr Morag 
Lewis, from The Wolfson Centre for Age-Related Diseases, King's College 
London, kindly undertook the Immunohistochemical investigations in the inner 
mouse ear and Dr Barbara Vona (University of Tübingen), undertook the RT-PCR 
studies. The aim of these studies was to ascertain the subcellular localisation of 
wildtype SLC15A5 to gain further insight into the molecular role of this molecule. 
 
Immunocytochemistry experiments in HEK293 cells 
A pCMV6-entry SLC15A5 clone was transformed into E.coli DH5-alpha bacteria 
via heat shock. Initial immunocytochemistry experiments in HEK293 cells 
transfected with epitope tagged SLC15A5 showed SLC15A5 in a vesicular 
pattern (Figure 3.18). However, wide-field microscopy showed that the 
transfection efficiency of this construct was low. As approximately 70% 
fluorescence is required to ensure enough protein is produced to carry out a 
Western blot it was necessary to take steps to improve the uptake of the construct 
into cells. To do this is was necessary to determine what was causing the low 
transfection rate.  
The first step was to rule out issues with the cell line being used for the 
transfections. To do this mouse fibroblast cells, NIH/3T3, where transfected with 
the pCMV6-SLC15A5 construct. This cell line, named after the number of days 
the cells were originally allowed to grow (3) and the number of hundreds of 
thousands of cells (3) transferred (T) onto a new plate during each passage,  are 
well known for being highly transfectable by DNA. Unfortunately, these 
transfections did not significantly improve the transfection efficiency indicating the 
cell type was not the cause of the low transfection rate.   
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To determine if aspects of the pCMV6-SLC15A5-myc-FLAG construct itself were 
affecting transfection a yellow fluorescent protein (YFP) tag was added to the C-
terminal of the protein in place of the FLAG epitope and sub-cloned into a 
pCAGGs vector, creating pCAGGs-SLC15A5-myc-YFP. This construct did 
produce higher transfection levels and permitted some co-expression studies to 
be undertaken. When co-expressed with Rab7-RFP, a widely used marker of 
recycling endosomes [195], SLC15A5 showed extensive, but not complete, 
overlap (Figure 3.19). This may indicate that SLC15A5 is associated with 
lysosomes and/or endosomal trafficking and not the outer cell membrane. 
However, due to persistently low expression of the SLC15A5 antibody it was 
proposed that constructs with the epitope tags at the N-terminus of the protein be 
created to rule out the possibility the large YFP epitope were preventing the 
antibody from binding properly and to determine if antibody binding to the C-
terminus of the antibody was affecting the protein’s native structure and/or cell 
localisation. 
Advice regarding the binding efficiency of the commercially available polyclonal 
SLC15A5 antibody was sought from Dr Francesco Rao, Chief Scientific Officer 
at Dundee Cell Products. It was suggested the peptide sequence being targeted 
by the commercial antibody was relatively long (28 residues) so may be 
condensing to form an aggregate structure thus preventing antibody binding. It 
was also reported that our protein of interest (SLC15A5) shared some similarities 
to a proton-coupled transporter, nitrate transporter (NRT1.1).  
Based on this information it was suggested further immunocytochemistry 
experiments be conducted using a custom monoclonal antibody targeting new 
epitope regions (Dr Francesco Rao, Dundee Cell Products/Dr John Chilton, 




Figure 3.18:  Distribution of tagged SLC15A5 in HEK293 cells. Cells were transfected with pCMV6-SLC15A5-myc-FLAG (origene) fixed in 4% PFA and 
immunolabelled with anti-FLAG (green) and anti-SLC15A5 (magenta) antibodies. Nuclei are counterstained with DAPI (blue). Scale bar = 7.5µm 
 
 
Figure 3.19: SLC15A5 partially associates with late endocytic structures in live cells. SLC15A5-myc-YFP (green) associates with Rab7-RFP (magenta). 
HEK 293 cells were transfected with SLC15A5-myc-YFP and viewed on the wide field microscope. Scale bar = 7.5µm
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Western blot analysis 
Western blot analyses were performed on lysed HEK 293 cells transfected with 
pCAGGs-SLC15A5-myc-YFP with membranes probed with rabbit polyclonal anti-
SLC15A5 and anti-cmyc to detect the presence of SLC15A5 in transfected cells. 
Unfortunately, no SLC15A5 protein was detected (Figure 3.20a). The membrane 
was then post stained with Anti-GAPDH (Figure 3.20b), a protein integral for 
glycolysis and plays many roles in nuclear function, known to be expressed in 




Figure 3.20: SLC25A5 Western blot 
 
A lack of signal being detected by the SLC15A5 antibody could be a result of 
there not being enough SLC15A5 protein in the samples as a result of the low 
transfection efficiency or antibody binding issues, mentioned previously, which 




Investigating the expression of Slc15a5 in the mouse ear 
Experiments to investigate the expression of murine Slc15a5 in mouse tissue 
sections at various time points of embryonic development in the mouse using RT-
PCR were undertaken (Figure 3.21). These experiments yielded promising 
results, showing cochlear expression. 
 
 
Figure 3.21: RT-PCR analysis of Slc15a5 in the P7 C57BL/6J mouse. A) RT-PCR 
amplification of Slc15a5 was obtained using primers in exons 5 and 6 
(NM_177787). A 294 bp product is observed in the cochlea, hippocampus, 
cerebellum, whole brain, kidney, eyes, and liver. B) PCR amplification of 
ubiquitously expressed Hprt is shown below as a positive control. Amplification 
products were confirmed via Sanger sequencing. Image depicts results obtained 
from investigations carried out by Barbara Vona. 
 
To investigate this further, studies were undertaken in collaboration with 
Professor Karen Steele’s lab to determine the expression of Slc15a5 in paraffin 
sections of inner ear mouse tissue at embryonic day 16.5 (E16.5). Unfortunately 
however, no protein could be detected (Appendix G). As the peptide sequence 
targeted by the custom antibody appears to be located within a transmembrane 
(residues 542-570)   
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New genotyping data as part of a high-volume sequencing program excludes 
mutation of SLC15A5 as a cause of NSHL.   
Towards the latter stages of this study, new information became available 
regarding the frequency of the SLC15A5 (NM_001170798.1:c.865G>T; 
p.Glu289Ter) variant in other Amish communities, through a recently developed 
data exchange collaboration with workers investigating the causes of inherited 
diseases in the Pennsylvanian Amish community. This study involved WES in 
>1000 Amish individuals from this community, including affected and unaffected 
individuals, in order to provide important gene variant annotation data. As part of 
this collaborative study, we recently received data which identified two individuals 
with no known NSHL to be homozygous for the c.865G>T; p.Glu289Ter variant. 






3.5.4 Genetic studies define variant frequencies of causative gene 
mutations in distinct Amish communities 
To learn more about the prevalence of the two GJB2 variants, and other founder 
gene mutations linked to hearing loss in different Amish communities, genotyping 
studies were undertaken of each variant in 167 unaffected control Amish 
individuals from Ohio (Holmes County), Ohio (Geauga County), Indiana, and 
Wisconsin communities using PlexSeq sequencing. As expected, this defined 
remarkably divergent allele frequencies (AF) for each gene (Table 3.7), reflecting 
the distinct ancestral histories of each Amish community. 
 
The most common genetic causes of hearing loss identified across all the Amish 
communities related to ST3GAL5 (GM3 synthase deficiency) and GJB2 gene 
variants. The severe neurodevelopmental disorder GM3 synthase deficiency is 
known to be common in both Ohio Amish communities, corroborated by the 
relatively high AF seen for this variant of 0.022% (Geauga County) and 0.055% 
(Holmes County). Corroborating our GJB2 gene data (above), GJB2 variants 
(c.229T>C; p.Trp77Arg and c.35del; p.Gly12Valfs) were also identified 
particularly in Amish families from Wisconsin and Ohio (Geauga County) in whom 
the combined AF for both GJB2 variants is approximately 0.08% and 0.02% 
respectively. However, it was notable that the p.Trp77Arg GJB2 variant, which is 
a common disease allele in white Caucasian families [196] was absent in controls 
from Ohio (Holmes County), indicative of a low incidence of NSHL due to this 
variant in this region.  
The HYAL2 founder variant (c.443A>G; p.Lys148Arg) is common in both Ohio 
communities with frequencies of 0.029% (Holmes County) and 0.018% 
(Geauga). Whilst hearing loss is not a cardinal feature the exclusion of any 
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known, or potentially deleterious, variants in all currently reported hearing loss 
genes, through the interrogation of WES from affected individuals, is highly 
suggestive that hearing impairment is a variable feature of this disorder 
(Appendix F).  
The most common single gene variant detected overall was the ST3GAL5 GM3 
synthase deficiency founder variant which underlies a syndromic form of infantile 






Table 3.7: Summary of genes associated with hearing loss identified in the Amish community. Allele frequency was determined from an 




3.5.5 Identification of novel hearing loss gene 
As the above data was being compiled for publication, ongoing studies in two 
interlinking Amish families comprising five affected individuals with autosomal 
recessive syndromic SNHL and neurodevelopmental delay, identified a gene 
variant as a putative candidate (Figure 3.22).  
Affected individuals underwent GJB2 screening which identified no known 
pathogenic variants within the gene. A combination of genome-wide SNP 
mapping and exome sequencing studies was then undertaken in these families. 
Interrogation of the WES excluded variants in all genes currently reported to 
cause hearing loss.   
A nonsense variant in a gene encoding a microtubule-associated molecule 
located on chromosome 13q was identified as the only candidate cause of the 
condition. The variant cosegregates as appropriate for an autosomal recessive 
condition in all family members, and is not listed in online genome databases 
(gnomAD, ExAC, 1000 genomes). Ongoing genotyping studies in the Amish has 
identified only two carriers of the variant in 300 Amish control chromosomes.  
Although not previously linked to hearing loss the gene has been linked to a 
recessive form of intellectual disability (ID) [198, 199]. Interestingly this variant 
was also, initially, identified as a potential cause of ID in the Amish, through a 
novel, proof-of-principle study described in Chapter 5 that set out to identify 
potentially deleterious coincidentally carried heterozygous variants, that had yet 
to be reported in the community.  
Further studies of this gene lie beyond the scope of this thesis, and are currently 











The work described in this chapter investigates the nature, aetiology and 
frequency of genetic causes of hearing loss in families from the Amish 
community.  
 
The Amish hearing loss programme itself stems from a long running clinical-
research study, the Windows of Hope programme which aims to learn more about 
the molecular basis of inherited disease, in this instance hearing loss, within the 
Amish community and provide important information to aid much needed 
diagnoses for affected individuals and their families. This is achieved through the 
translation of research findings to directly benefit patients in the form of improved 
diagnostic information, supporting genetic counselling and aiding the 
implementation, or development of novel, targeted therapies for use within this 
community and the general population.  
 
As a result of the work outlined here, and through previous studies carried out by 
this group [177, 178, 184], 11 of the 19 families recruited to the Amish Hearing 
Loss Programme, with no previous genetic diagnosis, have now received 
confirmed genetic diagnoses (Figure 3.23). Additionally, the genetic cause of the 
observed hearing loss in two further families is under investigation and likely to 
be confirmed in the near future (section 3.5.5). Investigations are ongoing within 




Figure 3.23: Summary of families recruited into the Amish Hearing Loss Programme. Variants responsible for the hearing loss have been 
detailed where possible. Green boxes denote families where the investigations undertaken form part of this thesis. The yellow box 
highlights a family where the variant believed to be responsible was identified as part of this thesis (Chapter 5) despite the family studies 
being carried out by another group member (not included in this thesis). Blue boxes denote families where novel variants where discovered 




Certain characteristics of the Amish population, including origins from relatively 
few founder individuals, endogamy, large family size, and detailed genealogical 
records, enabling the construction of impressive family pedigrees empower 
genetic studies. However, these characteristics may also result in certain 
disorders, particularly those inherited in an autosomal recessive pattern, 
occurring more frequently in the community. These factors, in addition to the 
reducing cost and increasing availability of NGS technologies and high density 
whole genome SNP mapping (and associated linkage analysis) greatly facilitate 
the discovery of genes responsible for inherited disease, which might otherwise 
have been impossible in studies of other populations due to the genetic and 
environmental complexities of a condition. All of the conditions known in the 
Amish and described in the current study are recessively inherited with the 
exception of COL1A2 and the mitochondrial disorders. As a result six new genes 
associated with HL in the Amish population (PCNA, HYAL2, SLITRK6, HARS, 
LONP1, ST3GAL5) have been discovered, several of which were identified by 
our group including a very recently discovered microtubule-associated molecule 
(section 3.5.5).   
 
3.6.1 Identification of two distinct genetic disorders within the same Amish 
family 
Neurodevelopmental disorders (NDD) are a group of disorders involving the 
abnormal development of the central nervous system. Affecting 1-3% of the 
population of children under 5 years of age it is one of the most common 
conditions presenting in paediatric clinics [200]. Due to its extreme heterogeneity 
and overlapping clinical outcomes of many distinct genetic causes of these 
conditions, reaching a specific diagnosis may be difficult. Although the diagnosis 
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of NDD has improved in recent years as a result of advances in genetic 
technologies [201] the cause of the condition remains undetermined in 
approximately half of affected individuals [202]. To ensure the best overall 
outcomes for affected children and their families it is important clinicians establish 
a diagnosis so they can implement the most appropriate therapeutic 
management strategy [200]. 
The Windows of Hope team were asked to assist in reaching a diagnosis for a 
family with six individuals displaying NDD, four of whom also had SNHL. Due to 
the broad range of genetic abnormalities known to result in a highly diverse 
spectrum of inherited neurodevelopmental disabilities, which often give rise to 
other disabilities, including visual and hearing impairment, it was not clear if the 
same, or two distinct genetic causes, were responsible for the difficulties 
observed in these children. Genome-wide SNP microarray identified a 0.56Mb 
microdeletion located on chromosome 16p11.2, previously shown to result in a 
clinically variable neurological phenotype [203], with dideoxy sequencing 
confirming the presence of a p.W77R GJB2 variant, a well-documented cause of 
AR-SNHL, common to all affected individuals. This confirmed the presence of two 
distinct genetic disorders in the same family. 
 
Copy number variations (CNVs) within 16p11.2 are one of the most common 
structural chromosome disorders [188] with a prevalence of ~3/10,000 in the 
general population [204]. Recurrent ~600kb deletions or duplications are the most 
common genetic aetiologies of NDD and autism spectrum disorders (ASD), with 
a prevalence of ~1% in ASD patients [188]. The phenotype is characterised by a 
spectrum of neurodevelopment impairments including; developmental delay, 
language impairments, mild to moderate intellectual disability, schizophrenia, 
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altered body mass index, epilepsy and ASD [203, 205]. Whilst hearing 
impairment, both SNHL and conductive, has previously been reported in up to 
11% of individuals with this microdeletion [204], a more recent study 
characterising the range and frequency of neurological variation within the 
phenotype did not associate hearing loss with this CNV. This study concluded 
that the a 16p11.2 deletion is characterised by; 
• Highly prevalent (>75%) speech articulation abnormalities 
• Hypotonia (low muscle tone) with hyporeflexia (below normal or 
absent reflexes. 
• Poor agility 
• Sacral dimples 
• Seizures/epilepsy 
• Large head size  
• Chiari I/cerebellar tonsillar ectopia [188] 
The affected individuals in this family were not did not display all of these 
phenotypes though they did display hyperactivity and social communication 
issues. The notable absence of any form of hearing impairment as a cardinal 
feature of this syndrome, indicated that it was unlikely to account for the hearing 
loss seen in the family which was subsequently shown to be due to GJB2 
mutation. 
 
Due to the unique genomic architecture of the Amish population, as a result of a 
genetic bottleneck leading to the enrichment of certain disease-associated 
alleles, the co-occurrence of distinct two genetic disorders in the same family is 
not uncommon and is likely to occur more frequently than in the general 
population. The Windows of Hope team have assisted a number of families in 
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which three distinct inherited conditions are present amongst different family 
members, with some individuals being affected by all three disorders 
(Crosby/Baple personal communication). Due to this, and the outcome of this 
study all families recruited into the Amish Hearing Loss Programme are now 
screened for variants in GJB2, irrespective of any additional clinical phenotypes 
reported in affected individuals. Figure 3.24 summarises the screening strategy 
now implemented for new patients recruited to the programme. 
 
 
Figure 3.24: Updated screening strategy implemented for individuals recruited to 
the Amish Hearing Loss Programme.  
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3.6.2 GJB2 variants in the Amish occur on a distinct SNP genomic 
haplotype 
In addition to these genes, other genetic causes of HL are also present in the 
Amish community. This work described in this thesis documents that GJB2 
variants are a common cause of NSHL, and within the HL cohort 8 of 19 families 
suffer hearing loss due to two previously reported GJB2 variants (c.35delG and 
p.W77R). The c.35delG variant has also been reported in Hutterite [206] and 
Mennonite populations [207], which are distinct Anabaptist groups originating 
from Europe at the time of the radical reformation of the 16th century.  
Mutations in GJB2 are recognised as the most common cause of NSHL 
worldwide, and account for ~50% of NSHL cases in European populations [130]. 
More than 100 mutations located within GJB2 have been identified [158], with the 
c.35delG mutation being the most common pathogenic variant in most Caucasian 
populations accounting for up to 70% of GJB2 mutations [163]. Notably several 
studies have confirmed through haplotype analysis that the c.35delG variant 
represents a common ancient founder that arose in European and Middle Eastern 
populations, rather than a mutational hotspot [168, 169, 208]. The p.W77R GJB2 
variant was originally identified in a family of Israeli-Arab origin [189] and has 
subsequently been described in other populations in Europe, Australia, South 
America and the Middle East [209, 210]. The genetic data here confirms that both 
GJB2 variants in the Amish occur on a distinct SNP genomic haplotype, indicating 
that each occurred, or more likely was introduced, via a single ancestor. Both 
gene mutations are also likely to represent the same ancestral mutations present 




3.6.3 Exclusion of the SLC15A5 variant as a cause of NSHL  
Genetic studies in families with individuals with forms of hearing loss excluded 
from known causes of disease identified SLC15A5 as a potential candidate gene 
for NSHL. Genome-wide SNP studies in two affected siblings identified only four 
notable (>1Mb) genomic regions of homozygosity common to both siblings. In 
parallel with this whole exome sequencing in a parental carrier identified only a 
single candidate variant, a nonsense variant in the SLC15A5 gene, located in the 
largest homozygous region. The family identified originated from Ohio, the 
community from which most families in this study were recruited, in which the 
SLC15A5 variant was detected at modest allele frequency. A notably higher allele 
frequency for the SLC15A5 variant was identified in the Wisconsin community. 
Although these studies relate to a single family, our exome and whole genome 
SNP mapping studies excluded other known genetic causes of HL, and identified 
the SLC15A5 as the sole candidate gene.  
 
While it currently has no known function and is the first SLC15A family member 
to be linked to hearing loss another family member, SLC15A2, has been shown 
to be expressed in the otic vesicle of zebrafish. The otic vesicle is an embryonic 
structure that goes on to form the auditory and vestibular organ of the fish which 
is the homolog to the inner ear of mammals [191].  
Work to characterise atypical solute carriers showed that SLC15A5 is only found 
in mammals which is suggestive of a function related to the specific features of 
vertebrates [194]. This study also revealed that SLC15A5 showed negligible 
expression in the pituitary, liver, spleen and thymus (Figure 3.25) and was one of 
only two genes to not be differentially expressed in the CNS. Additionally, a study 
carried out by Scheffer et al. in 2015 investigating gene expression in inner ear 
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mouse hair cells during development did report expression of SLC15A5 in 
utricular hair cells [211]. Furthermore, studies by our colleagues in Tübingen also 
detected SLC15A5 gene expression in mouse cochlea (section 3.5.3) supporting 




Figure 3.25: Results from quantitative real-time PCR data for SLC15A5. The data 
has been normalized against the detected expression levels for that particular 
gene in 25 ng of mouse genomic DNA (Taken from [194]). 
 
Due to very little being known about SLC15A5 preliminary functional studies were 
undertaken to discover more about the expression and function of the molecule 
and its potential role in hearing loss. As expected for the nature of the variant in 
silico prediction software analysis predicted the candidate variant 
(NM_001170798.1:c.865G>T; p.Glu289Ter) to be pathogenic, due to the 
introduction of a premature termination codon (PTC), likely leading to protein 
truncation. While transcriptional outcomes were not assessed such aberrant 
mRNA transcripts may typically be subjected to the sophisticated quality control 
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monitoring mechanism, nonsense-mediated mRNA decay (NMD), that prevents 
the production of truncated polypeptides that could be toxic to normal cellular 
functions [212] resulting in the absence of any functioning protein product.  
Initial immunocytochemistry experiments appeared to show a vesicular pattern 
inside the cell cytoplasm. This was not surprising due to the localisation of the 
SLC15A family member PEPT1 (SLC15A1) which was previously reported to 
localise primarily to the outer cell membrane and in adjacent vesicles [213]. Due 
to the lack of SLC15A5 in the cell membrane co-expression experiments were 
undertaken, alongside Rab7, a marker of recycling endosomes. The extensive, 
but not complete, overlap of SLC15A5 with Rab7 suggests it may be associated 
with lysosomes and/or endosomal trafficking and not the outer cell membrane. 
However, further investigations would need to be undertaken in order to 
reproduce and confirm these findings.  
 
The lack of expression detected during immunohistochemical analysis of paraffin 
sections of inner ear mouse tissue at embryonic day 16.5 (E16.5) could have 
arisen due to a variety of reasons. Firstly the protein may not be expressed as 
this specific embryonic stage. Preliminary ISH experiments carried out by Dr John 
Chilton indicated that low levels of the protein were expressed in chick embryos 
at stage 20, corresponding approximately to E9.5 in a mouse, seven days prior 
to the sections used in these experiments. It would have been preferable to 
conduct these experiments at an early time point as it is possible, due to what is 
now know about GJB2 [161], that a mechanism involved in the development 
hearing loss is likely to be disrupted during early development. Equally, the lack 




The inability to detect SLC15A5 protein via Western blotting could be due to a 
lack of SLC15A5 protein being expressed in the transfected HEK293 cells, which 
may have arisen due to the low transfection efficiency observed, or issues with 
antibody binding. However, this, coupled with a lack of detection in 
immunohistochemical experiments, indicates there may be an issue with the 
SLC15A5 antibody binding to the target sequence, epitope, on the protein. It was 
suggested that the target sequence used by the original (Origene) SLC15A5 
antibody was quite long and, despite having good solubility in water, may 
condense into a folded, or aggregate structure, leading to variable success in 
different applications. To overcome this, a custom antibody targeting two regions 
of the protein could be used in future studies.  
 
Another possible cause of the issues experienced with antibody binding may 
reflect a lack of conservation between human and murine protein sequences. 
Although it would be straightforward to identify regions that are similar between 
mouse and human, there would be a bias towards the more conserved 
membrane embedded portion of the protein, which means its use would be limited 
to experiments where the membranes are isolated/denatured. This may not help 
in determining the subcellular localisation of the protein, particularly given the 
initial results indicating the protein is not present on the outer cell membrane 
(Francesco Rao, Dundee Cell Products/Dr John Chilton, personal 
communication). 
Whilst these studies were ongoing, exclusion of the SLC15A5 variant as a cause 
of NSHL was achieved through a new collaborative arm providing additional 
genotyping data in other Amish communities as part of a high-volume sequencing 
program. This identified two individuals to be homozygous for the SLC15A5 
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variant, who apparently displayed no features of SNHL. Thus, while the specific 
cause of SNHL in this family remains unknown, this finding likely excludes the 
SLC15A nonsense variant as the likely cause.  
This study provides has important lessons to consider when investigating 
potential, novel candidate pathogenic variants in endogamous communities. This 
study provides important lessons to consider when investigating potential, novel 
candidate pathogenic variants in endogamous communities, in which it is 
important to remain cautious when defining candidate variants, including those 
likely to be deleterious (nonsense), identified via small family studies. It is 
imperative that allele frequency datasets, both from within and outside the 
community, are thoroughly and regularly investigated, as conducted in this study. 
This permits the identification of additional variants in other families to aid 
confirmation of a gene as causative. 
 
As demonstrated with this family, and other families within the Amish community 
[177], the interpretation and clinical significance of novel or rare variants may be 
challenging. This may be aided through the curation and dissemination of 
knowledge regarding rare gene variants. 
Initiatives such as the Anabaptist specific variation database and MatchMaker 
Exchange (MME), launched in 2013, has significantly expedited the matching of 
unrelated cases with variants in the same gene and overlapping phenotypes. 
Whilst the genomic data collected by the Windows of Hope programme over the 
last 19 years is an invaluable source of information to the Amish community itself, 
its importance extends far beyond this into the general population. This data can 
be utilised by the “matchmaking community” in both a clinical and research setting 
to facilitate human disease gene identification, to aid genomic variant 
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classification and provide a valuable source of phenotypic and prognostic data 
on otherwise rare inherited disorders.  
However, this study also demonstrates the utility of a community-specific dataset 
which shares, otherwise unpublished information on nonsense and frameshift 
variants that may have become enriched in the community but, like the SLC15A5 
variant, are known to be non-pathogenic.  These concepts are explored and 
highlighted further in chapter five of this thesis. 
 
3.6.4 Allele frequencies of SHL in the Amish population 
Several syndromic presentations of SNHL have also been identified in the Amish 
population, including the previously well characterised conditions Usher 
syndrome [214] infantile Refsum disease [215] Jervell-Lange-Nielson (JLN) 
syndrome[181], COL1A2-related osteogenesis imperfecta [186], metabolic and 
mitochondrial disorders. JLN syndrome was described in the Amish population 
by [181] who reported a family with two affected siblings both with SNHL and long 
QT syndrome (LQTS), with the parents displaying borderline LQTS and normal 
hearing. DNA sequencing identified a homozygous 2bp deletion in KCNQ1 
predicted to result in a frameshift and premature termination as the likely cause 
in the affected siblings (NM_000218.2:c.451_452del; p.Leu151fs). While at low 
frequency, our studies confirmed the presence of this gene variant in both the 
Holmes and Geagua county Ohio Amish communities. Given the serious 
implications of sudden cardiac death associated with this disorder, it is crucially 
important to consider this genetic diagnosis in individuals with congenital SNHL 




Several genetic causes of congenital SHL have also been identified in the Amish 
community in association with specific syndromic conditions. These include 
PCNA, SLITRK6, YARS, GM3 synthase deficiency and CODAS (Cerebral, 
Ocular, Dental, Auricular and Skeletal anomalies) syndrome (see supplementary 
paper), each of which should be considered depending on the accompanying 
clinical features. Mitochondrial disorders associated with SNHL have also been 
described within the Amish population [216] and this group of disorders along 
with infantile Refsum disease [215], should be considered particularly in the 
context of SNHL associated with neurological and ophthalmological features. In 
Mennonite and Hutterite groups other conditions associated with SHL have been 
described, including mutation of PCDH15 and MYO7A with Usher syndrome 
[214, 217], ALMS1 in Alstrom syndrome [218, 219] and EDNRB in Waardenburg 
syndrome [220]. It is likely that other well characterised causes of both SHL and 
NSHL have been identified within the Amish population by local clinicians and 
researchers which remain unpublished. 
 
 
3.6.5 Future work and considerations 
As the data reviewing the causes and frequencies of hearing loss in the Amish 
community was being compiled for publication, ongoing studies identified a 
candidate new cause of SNHL and NDD in a large extended Amish family 
(section 3.5.5). This study investigated the molecular cause of hearing loss in two 
interlinking families in which known genetic causes of NSHL had been excluded, 
comprising five affected individuals, due to a nonsense mutation in a microtubule-
associated molecule. The genetic power of this study was notably greater than 
the SLC15A5 family study, due to the greater size of this family. Additionally, the 
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same p.Arg1197Ter nonsense variant was identified as a candidate cause of 
hearing loss and NDD by a collaborator of the Exeter team investigating families 
from the Middle East. Together, these studies provide strong evidence that the 
microtubule-associated molecule is responsible for this syndromic form of 
hearing loss. While beyond the remit of this thesis, future studies should be 
tailored to corroborate these findings and further explore the cellular and 
developmental role of this molecule about which little remains currently 
understood.  
Such studies would entail undertaking molecular studies to more precisely define 
binding partners and subcellular localisation of the gene product to define its 
molecular role in hearing loss. In addition to this immunohistochemical and RT-
PCR studies in mouse brain and inner ear at different developmental time points 
would be carried out to describe the pattern of gene expression in different tissues 
known to be linked to the development of hearing loss. Finally, mouse knockout 
studies could be conducted to investigate the phenotypical outcome in 
comparison with humans. 
There are numerous significant benefits of elucidating the genetic basis of a 
condition such as HL in any community setting. These include providing a specific 
diagnosis for affected individuals and their families, identifying relevant therapies 
and treatments (for example consideration for CI), screening for the presence of 
other features that may develop in the condition, and to inform parents for 
reproductive counselling. As with other inherited conditions originally identified in 
the Amish, the identification and clinical and molecular definition of HL disorders 
in the community has been of notable benefit globally, enabling informed disease 
diagnosis, counselling and management for patients and families worldwide 
subsequently diagnosed with these conditions. With the exception of mutation of 
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PCNA, all conditions defined in the Amish have ultimately been described in other 
populations highlighting the global relevance and importance of studies of 
inherited conditions in such genetic isolates. Further studies to elucidate the 
molecular mechanisms of HL-related disorders is crucial, and will ultimately 
facilitate the development of new treatments to alleviate the burden associated 
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 Defining the phenotype and pathomolecular basis of 
a novel form of neurodevelopmental disorder 
associated with the missense mutation of Smad 
nuclear interacting protein 1 (SNIP1) 
 
4.1 Introduction 
As previously described, neurodevelopmental disorders (NDD) are a group of 
disorders involving the abnormal development of the central nervous system 
which often display a spectrum clinical features. Global developmental delay 
(GDD) is commonly observed in NDD and is defined as the failure of an individual 
to achieve developmental milestones within the expected age range. Whilst GDD 
can occur in isolation it is also often observed alongside other neurological (and 
potentially non-neurological) features including epilepsy and behavioural 
problems (autism spectrum disorder and attention-deficit hyperactivity disorder) 
[221]. 
 
A collaboration between five Amish-based clinics (The Windows of Hope, the 
Community Health Clinic, New Leaf Center, LaFarge Medical Clinic and The 
Clinic for Special Children) identified 35 individuals (20 males; 15 females) which, 
whilst displaying a broad spectrum of neurological phenotypes, also showed a 
striking number of overlapping clinical features. A review of the phenotypes 
displayed by these individuals identified global developmental delay, hypotonia, 
abnormal skull shape and the presence of seizures as the most consistent 
features. To investigate if a common genetic cause was responsible for the 
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difficulties experienced by these individuals a combination of autozygosity 
mapping and exome sequencing was undertaken on a small subset of families. 
This revealed a p.Glu366Gly missense mutation of SNIP1 (Smad nuclear 
interacting protein 1), a widely expressed transcriptional suppressor of the TGF-
β signal-transduction pathway, common to all affected individuals. This variant 
had previously been reported as a puatative novel candidate in three individuals, 
from a different Amish community, displaying phenotypes overlapping with 
individuals from our cohort including epilepsy and skull dysplasia [179]. This 
finding further corroborates the likely pathogenicity of this variant and its role in 
the observed disorder.  
Due to its role as a transcription regulator, gene transcript studies where 
undertaken to elicit the effect of this variant on gene expression. These studies 
showed altered gene expression profiles for a number of molecules with well 
characterised roles in neurodevelopment, providing potential explanations for the 
source of the clinical phenotypes observed.  This study consolidates phenotypic, 
genetic and gene expression data in support of the mutation of SNIP1 as the 
cause of a novel autosomal recessive neurodevelopmental disorder in addition 
to providing insight into the molecular basis of the disorder and the role of SNIP1 
as a transcription factor. 
 
4.1.1 Cell signalling 
Cell signalling, or signal transduction, is the fundamental process of cells 
communicating and responding to external cues in their environment [222]. Cells 
communicate via membrane-associated proteins or through the secretion and 
detection of molecules, such as hormones, cytokines, chemokines and growth 
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factors that influence cell behaviour and responses including proliferation, 
differentiation and metabolism [223].  
The transforming growth factor–β (TGF-β) family is a well-studied example of a 
secreted growth factors that govern many developmental processes. Aberrant 
signalling within this pathway is well characterised, and shown to be associated 
with a number of human disorders including cancer, cardiovascular and 
musculoskeletal disease [223, 224]. 
 
4.1.2 TGF-β signalling pathway  
In mammals, the TGF-β superfamily of growth factors are encoded by 33 genes 
that are widely expressed in a variety of tissues [223, 225]. They are essential 
throughout the life of an organism orchestrating critical processes ranging from 
gastrulation and the onset of body axis asymmetry in early embryonic 
development, to adult tissue homeostasis [226]. 
The TGF-β family contains a large group of cytokines , ~60 members [227], which 
can broadly be divided into four subgroups; TGF-βs that comprises of the three 
mammalian TGF-β isoforms, the Müllerian inhibitory factors (MIF), the 
activins/inhibins, and the bone morphogenetic proteins (BMP) and growth and 
differentiation factors (GDFs) which contains all 20 BMPs and the majority of 




Figure 4.1: Members of the TGF-β family. Major families of the TGF-β superfamily 
include TGF-β, BMP, MIF and activin–inhibin. Image taken and modified from 
Drabsch & Dijke, 2012 [229]. 
 
Control of over the broad range of functions associated with members of the TGF-
β family is achieved through signalling specificity and differential ligand affinities 
to different cell surface TGF-β receptors (TGFβR) as well as the co-regulation of 
the various pathways by a number of transcriptional co-activators and co-
repressors [224]. TGF-β signal transduction includes Smad transcription factor 
mediated pathways (section 4.1.3: Smad proteins) which induce a transcriptional 
response, and non-Smad mediated pathways which evoke transcriptional 
responses as well as other direct cellular responses, not involving the regulation 
of transcription [224]. 
There are three main types of TGFβR present in all cell types, TGFβRI, TGFβRII 
and TGFβR-III. TGFβRI and TGFβRII mediate Smad dependent signal 
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transduction and contain a serine/threonine kinase domain, a transmembrane 
domain and a ligand-binding domain which associate in a homo- or heteromeric 
complexes and act as tetramers. [228, 230]. Binding of a homodimer TGF-β 
ligand to TGFβRII initiates the formation of a stable hetero-tetrameric complex 
with TGFβRI, where TGFβRI receptors are activated through phosphorylation by 
TGFβRII. Once activated TGFβRI receptors phosphorylate cytosolic Smad2 and 
Smad3 (receptor-regulated Smads, R-Smad) proteins at C-terminal serines. 
Activated R-Smads then form a trimer with Smad4, a common-partner Smad (co-
Smad) enabling the complex to be imported into the nucleus. Inside the nucleus 
the R-Smad-co-Smad complex associates with sequence specific transcription 







Figure 4.2: TGF-β signalling pathway. Summarising the different signal 
transduction pathways initiated by the different TGF-β ligands. A) Signalling by 
activin ligands. B) Signalling by TGF-β ligands and C) signalling by BMP ligands. 
Image taken and modified from (https://reactome.org/PathwayBrowser/#/R-HSA-
9006936&DTAB=DT).   
 
4.1.3 Smad proteins 
Smad proteins are a small family of structurally similar intracellular proteins that 
act as transcription factors in the transforming growth factor-beta (TGF-β) 
pathway (Error! Reference source not found.B) [232]. The name originates 
from the contraction of the names of homologous genes, Sma and Mad, 
originally discovered in Caenorhabditis elegans (C.elegans) and Drosophila 




The Smads are a well characterised signalling pathway initiated by activated 
TGF-β receptors. There are eight Smad family members in mammals [233] 
which can be grouped into three classes; receptor-regulated Smads (RSmads), 
common-partner Smads (Co-Smads), and inhibitory Smads (I-Smads). All 
Smad proteins are 500 amino acids in length and contain two globular domains; 
Mad-homology 1 (MH1) and Mad-homology 2 (MH2), joined by an unstructured 
linker (Figure 4.3). The MH1 domain, involved in nuclear import and cytoplasmic 
anchoring, DNA binding, and regulation of transcription, is highly conserved in 
all R-Smads and Smad4 but is not present in I-Smads. Due to the addition of 30 
amino acids in the MH1 domain, encoded by an extra exon, Smad2 is unable to 
directly bind to DNA. The linker regions, whilst all containing important 
phosphorylation and recognition sites, are diverse in the different Smad 
proteins. For example the linker region in Smad3 contains a trans-activation 
(TA) domain which permits the binding of transcription co-regulators with the 
Smad4 linker region containing a nucleus export signal (NES). The MH2 
domain, responsible for the regulation of Smad oligomerization, cytoplasmic 
anchoring and transcription of target genes, is highly conserved and considered 







Figure 4.3: Domain structure of Smads. MH1 domain of Smad2 contains an 
additional 30 amino acids (dark green box). Smad3 contains a trans-activation 
(TA) in its linker region. Smad2, 3 and Smad4 contains a Nucleus Localization 
Signal (NLS) in their MH1 domain. Smad 7 lacks MH1 domain. Figure taken and 
modified from Samanta and Datta, 2012 [234]. 
 
As describe above, R-Smads are activated through phosphorylation by a TGFβRI 
receptor. Once activated, and in a complex with the co-Smad, Smad4, the 
complex is translocated into the nucleus where Smad4 associates with 
interacting transcription factors and p300/CBP enabling it to bind to the Smad 
binding element (SBE) in a target gene promoter driving transcription of these 






Figure 4.4: TGF-β/Smad signalling pathway from activation upon TGF-β ligand 
binding to translocation to the nucleus and effect on gene expression. Image 
taken and modified from Jiang et al. 2015 [235]. 
 
Defects in TGF-β proteins, or disruption of the Smad signalling pathway by other 
molecular means, has been linked to a number of human diseases including 
cancer [235], chondrodysplasias [236], chronic kidney disease (CKD) [237] and 





The SNIP1 (Smad nuclear interacting protein 1) gene is located at 1p34.3 and 
encodes a widely expressed nuclear protein, SNIP1, which acts as a 
transcriptional suppressor of the TGF-β signal-transduction pathway. This 
evolutionary conserved protein, consisting of 396 amino acids, contains a two-
part nuclear localisation signal (NLS) and a forkhead-associated (FHA) domain 




Figure 4.5: Schematic diagram of SNIP protein depicting the location of the two 
functional domains 
 
The C-terminal FHA domain has been shown to bind to the N-terminus of c-Myc, 
a key regulator of cell proliferation and transformation, enhancing its 
transcriptional activity by stabilizing it against proteosomal degradation and by 
bridging the c-Myc/p300 complex [240]. Functional studies have demonstrated 
the N-terminal NLS inhibits Smad-dependent transcription by binding to 
p300/CBP co-activators [238, 241]. This interaction prevents Smad4 in the R-
Smad-Co-Smad complex binding to the co-activators rendering it unable to bind 
to the Smad binding element (SBE) in target gene promoters [235], thus 
supressing transcription (Figure 4.6). 
 
Orthologues of SNIP1 have been identified in organisms ranging from Homo 
sapiens to Caenorhabditis elegans (C. elegans), displaying varying degrees of 
conservation with 86% homology observed in murine SNIP1 compared to only 
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47% homology with the C. elegans homologue (C32E8.5) [242]. The most highly 
conserved domain within the SNIP1 protein is the FHA domain which is 
consistent with a role in growth regulation. Knock-down experiments in C. 
elegans showed that loss of SNIP1 resulted in embryonic lethality with growth 




Figure 4.6: TGF-β/Smad signalling pathway from activation upon TGF-β ligand 
binding to translocation to the nucleus and repression of gene expression on 
SNIP1 binding to the p300/CBP transcription co-activator. Image taken and 





4.2.1 Identification of a pathogenic variant in SNIP1 
Assuming that a founder mutation was responsible a genome-wide SNP 
microarray, (Illumina Human CytoSNP-12v2.1 330k array) performed using DNA 
from six affected individuals (Figure 4.7), was undertaken in conjunction with 
WES, performed using the DNA from one affected individual.  
 
 
Figure 4.7: Simplified pedigree of the four Amish families initially investigated 
showing the six affected individuals initially genotyped using a genome-wide SNP 
microarray. 
 
Inspection of resultant genotypes identified a single notable region of 
homozygosity of 1.65Mb on chromosome 1p34.3 shared by the affected 
individuals, delimited by SNP markers rs6667450 and rs10889902 
(NC_000001.11: g.36, 492,230-38,143,653; (Figure 4.8) containing 17 genes and 
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likely to corresponding to the disease locus. No other notable regions (of >0.5Mb) 
of autozygosity were observed.  
 
In parallel with the genome-wide SNP mapping, DNA from a single affected 
individual (Figure 4.7) underwent WES, to identify variants within this region as 
well as other candidate variants located genome-wide. After filtering the identified 
variants for call quality, potential pathogenicity, population frequency, and 
prioritisation for localisation within the candidate interval, a single potentially 
pathogenic sequencing variant (NM_024700.3: c.1097A>G; p.Glu366Gly) in 
exon four of SNIP1 remained as the only candidate variant. Dideoxy sequence 
analysis of all family members confirmed that, as expected, all six affected 
individuals were homozygous for this variant, while the parents and unaffected 
siblings were all heterozygous. The variant, predicted to be disease causing in 
MutationTaster2 [94] and probably damaging in PolyPhen-2 [93], results in the 
substitution of a highly conserved (Figure 4.8) glutamic acid residue at position 




Figure 4.8: Pictorial representation of the (A) identified 1.65Mb disease locus on chromosome 1 containing 17 genes, with SNIP1 indicated 
(red circle).  (B) sequence chromatogram corresponding to the SNIP1 c.1097A<G variant (C) multi-species amino acid alignment around 
the Glu366 region, showing stringent conservation of this region (D) schematic showing domain architecture of SNIP1 polypeptide 
sequence with regard to Glu366 , located alongside the forkhead-associated domain (F).
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4.2.2 Defining the clinical phenotype of a neurological disorder displaying 
severe psychomotor delay with seizures, epilepsy and dysmorphic features 
A collaboration between Windows of Hope, the Community Health Clinic, New Leaf 
Center, LaFarge Medical Clinic, and Clinic for Special Children identified 35 
individuals originally diagnosed with a broad range of genetic disorders including 
glycogen storage disorders, sialidosis, Crouzon syndrome, mitochondrial 
disorder/myopathy, and GM3 synthase deficiency.  
The spectrum of clinical features of this condition includes severe psychomotor 
delay with seizures, (decreased muscle tone), absent reflexes, and strabismus 
(improper alignment of the eyes) with horizontal nystagmus (involuntary eye 
movement), as well as neonatal hypotonia with poor feeding and characteristic 
dysmorphic features (Figure 4.9). 
 
 
Figure 4.9: Three siblings displaying characteristic craniofacial features. 
Photograph provided by Dr Zineb Ammous from the Community Health Clinic, 






Dr Zineb Ammous, a Clinical Geneticist from the Community Health Clinic, Topeka, 
US, conducted a survey of all 35 individuals and through historical and physical 
examination was able to precisely define the clinical phenotype (Table 4.1).  
 
Table 4.1: The clinical presentation in the 33 affected individuals; ADHD, 
attention deficit hyperactivity disorder 
 
ADHD, attention deficit hyperactivity disorder. VSD, ventricular septal defect. 
ASD, atrial septal defect. CoA, coarctation of the aorta. Ao valve 
 
All affected individuals investigated displayed an abnormal MRI showing an 




Figure 4.10: Axial brain MRI of a normal control (left) compared to an affected 
patient (right) showing skull dysplasia and hypomyelination. 
 
Approximately 70% of patients suffered from respiratory complications such as 
laryngomalacia, stridor, and/or apnea which, in some cases, required a 
tracheostomy (Figure 4.11A). The condition also includes a number of additional 
features including talipes equinovarus (Figure 4.11B) and craniosynostosis (Figure 
4.11C&D). 
 
Figure 4.11: A) Infant patient with tracheostomy tube fitted as a result of respiratory 
complications. Atypical features talipes equinovarus (B) and craniosynostosis (C, 
D). Photograph provided by Dr Zineb Ammous from the Community Health Clinic, 




4.2.3 Effect of SNIP1 mutation on gene expression and cellular pathways   
The SNIP1 protein is an evolutionary conserved inhibitor of the TGF-β signal 
transduction pathway [238, 242]. However, it is not yet fully understood which 
genes it regulates specifically, nor which regulatory mechanisms it may be 
involved. To discern the impact of the SNIP1 p.Glu366Gly sequence variant on 
gene expression, and through which pathways it operates, whole transcriptome 
sequencing of RNA extracted from whole blood was undertaken on samples from 
six affected and six unaffected, age and sex matched control individuals. 
Whole transcriptome sequencing enabled the characterisation of all RNA 
transcripts present within the samples by identifying differentially expressed genes 
and produced data on genes where expression was either increased (upregulated) 
or decreased (downregulated) in affected individuals (disease group) compared to 
the control group. This RNA-seq data underwent gene set enrichment and pathway 
analysis using the integrative web-based software application Enrichr [243] which 
collates a summary of the most biologically relevant enriched genes within a 
dataset [244]. This is done by comparing the frequency of individual annotations 
in the each gene list, from 102 available gene set libraries, with a reference list of 
genes. As this study utilised genome-wide, whole transcriptome sequencing the 
reference list contained all genes in the genome. For this analysis the “Reactome 
2016” gene set library, the largest, most comprehensive and best characterised 
gene set list, was used to functionally annotate the differentially expressed genes 
within >2250 pathways. Table 4.2 and Table 4.3 summarise the top ten pathways, 
and associated genes, that were up- or down- regulated in the disease group 
compared to the control.  
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Table 4.2: Top ten pathways and associated genes identified by Enrichr as being upregulated in the disease group compared to controls 
Enrichr 
code 







Serotonin neurotransmitter release 
cycle 
SYT1 SYN3 0.002096 -2.01 12.41 
R-HAS-
212676 
Dopamine neurotransmitter release 
cycle 
















PTK2 0.01364 -1.99 8.55 
R-HAS-
373752 
Netrin-1 signalling PTK2  ROBO1 0.01112 -1.88 8.46 
R-HAS-
983695 
Antigen activates B Cell Receptor 
(BCR) leading to generation of 
second messengers 
BLK  BLNK 0.01379 -1.87 8 
R-HAS-
112310 
Neurotransmitter release cycle SYT1 SYN3 0.01611 -1.92 7.94 
R-HSA-
421270 
Cell-cell junction organisation CDH4 PARD3 0.02257 -1.94 7.35 
R-HAS-
000178 









0.04623 -2.17 6.68 
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Table 4.3: Top ten pathways and associated genes identified by Enrichr as being downregulated in the disease group compared to controls 
Enrichr 
code 














0.0002381 -1.92 16 
R-HSA-
418890 
Role of second messengers in 
netrin-1 signalling 
TRPC3 TRPC1 0.001334 -2.16 14.29 
R-HAS-
69298 
Association of licensing factors 
with the pre-replicative complex 
E2F3 RPS27A 0.003057 -1.91 11.03 
R-HAS-
2173791 
TGF-beta signalling EMT 
(epithelial to mesenchymal 
transition) 
F11R RPS27A 0.003482 -1.89 10.71 
R-HAS-
983712 







0.005615 -2 10.42 
R-HAS-
3295583 





Oncogene induced senescence  SGK1 RPS27A 0.01358 -1.96 8.42 
R-HAS-
6804757 
Regulation of TP53 degradation SGK1 RPS27A 0.01612 -2.09 8.66 
R-HAS-
6806003 
Regulation of TP53 expression 
and degradation 
E2F5 RPS27A 0.01701 -2.11 8.58 
R-HAS-
382551 










0.01767 -2.066 8.31 
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The pathways described in these tables were selected by obtaining the highest 
combined score ranking (>5) of all the pathways analysed by this gene set library. 
The combined score multiples the log of the p-value, a statistical method using the 
Fisher’s exact test to assess the probability of any gene belonging to any set 
(Fisher exact test based ranking), by the z-score, which computes the deviation 
from an expected rank (rank based ranking). This combined score ranking allows 
for the slight bias of the Fisher exact test which was reported to affect the ranking 
of terms based exclusively on the length of the gene sets in each of the gene-set 
libraries [243]. 
 
A number of the pathways identified through the Enrichr analysis are evidently, 
highly relevant to the observed phenotype. The two most impacted biological 
pathways, involving serotonin and dopamine release, showed the highest level of 
enrichment (highest combined score) within the upregulated gene list. Both 
serotonin and dopamine are monoaminergic neurotransmitters that have been 
associated in the regulation of seizures [245, 246], a cardinal characteristic feature 
of the condition observed in our cohort (Error! Reference source not found.). 
This makes two genes, SYT1 (synaptotagmin 1) and SYN3 (synapsin III), identified 
in these pathways interesting candidates.  
CHL1 (cell adhesion molecule L1-lLike) and ROBO1 (roundabout guidance 
receptor 1) also stand out as potential candidates as a result of their involvement 
in the developmental biology pathway. This pathway, which obtained the third 
highest combined score, is of interest due to the broad spectrum of phenotypic 




The genetic and gene expression data described in this study strongly implicates 
mutation of SNIP1 as the cause of a novel autosomal recessive 
neurodevelopmental disorder and offers insight into the potential underlying 
molecular mechanisms responsible for the observed phenotypes. The extensive 
review of available phenotypic data provided a unique opportunity to more 
precisely define the clinical spectrum and cardinal features of this novel disorder 
which was only possible due to the high frequency of the condition within the Amish 
community. These findings will ultimately aid diagnosis and treatment, and reduce 
the number of misdiagnoses of affected individuals within the Amish community. 
 
4.3.1 SNIP1 variant (p.Glu366Gly) responsible for novel autosomal recessive 
neurodevelopmental disorder  
This study was only possible due to the extremely high prevalence of this rare 
condition within the Amish, particularly the communities of Indiana where an allele 
frequency of 0.0870 has recently been estimated (Chapter 5). The large number 
of affected individuals with our cohort permitted the collection of robust genetic 
evidence supporting the pathogenicity of this SNIP1 variant (NM_024700.3: 
c.1097A>G; p.Glu366Gly). 
 
Although samples from only six affected individuals were available for genome-
wide SNP mapping the data identified a single, common, very modestly sized 
genomic region (1.65Mb) on chromosome 1. Assuming a founder mutation was 
responsible for the condition this region was believed to be the likely disease locus. 
Exome sequencing was undertaken on one of the genome-wide SNP mapped 
individuals. As expected, the cross-referencing of this data with the SNP mapping 
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data identified a single candidate variant in SNIP1 within the shared region of 
homozygosity. No other candidates, predicted to be deleterious by in silico 
prediction software tools, were identified within the region of interest or genome-
wide. A total of 17 genes were found to be located within the homozygous critical 
region (Figure 4.8). Whilst none have previously been reported to cause 
seizures/epilepsy, hypotonia/hyporeflexia or dysmorphic facial features, two 
genes, GRIK3 and MANEAL, within the region have been linked to a neurological 
phenotype.  
 
A 2.6-Mb microdeletion in 1p34.3, encompassing GRIK3, has been associated 
with severe developmental delay, presenting with mild retrognathia and down-
slanting palpebral fissures in a single female proband [247]. GRIK family members 
are described as playing an important role in synaptic potentiation, a crucial 
process for learning and memory. Therefore the reported haploinsufficiency of 
GRIK3, as result of the microdeletion, is likely to be the cause of the developmental 
delay in this individual [247]. Although GRIK3 is present in the 1.65-Mb region of 
homozygosity shared by all the affected individuals in our cohort (Figure 4.8) there 
is only a small overlap between these two regions. This, in addition to the absence 
of variants within GRIK3 in our exome sequencing data, excluded this gene as a 
possible candidate.  
 
The second gene, MANEAL, was previously suggested as a novel cause of a 
complex infantile-onset neurodegenerative disorder observed in a single male 
proband, born to consanguineous parents from Saudi Arabia. A loss-of-function 
variant in MANEAL was found to co-occur with a homozygous splice defect in 
OSTM1, considered likely to be responsible for infantile malignant osteopetrosis. 
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The neurological features of this phenotype are characterised by developmental 
delay, optic nerve atrophy, dyskinetic movement disorder and neurodegeneration 
determined through the appearance of brain iron accumulation (NBIA)-like pattern 
on a brain MRI. However, this small family study was the first, and currently only, 
association of this gene with a human disease. As such further investigation and 
evidence will be required to confirm the clinical significance of this variant. 
Examination of our exome sequencing data and the absence of variants within 
MANEAL, excluded it as a possible candidate.  
 
The finding that mutation of SNIP1 is causative of the neurodevelopment disorder 
described in our patients is in agreement with a previous study defining five 
candidate genetic causes of NDD in the Amish, including SNIP1. This study 
identified three affected individuals from two sibships with a condition referred to 
as ‘PMRED’ (psychomotor retardation, epilepsy, and craniofacial dysmorphism). 
Exome sequencing identified the SNIP1 c.1097A.G (p.Glu366Gly) alteration as a 
candidate genetic cause [179]. This, together with the data presented as part of 
this PhD thesis, corroborates the c.1097A.G SNIP1 variant as the cause of this 
condition. 
 
4.3.2 Defining the clinical phenotype of a neurological disorder displaying 
severe psychomotor delay with seizures, epilepsy and dysmorphic features  
The work undertaken by Dr Zineb Ammous and our collaborating clinical teams 
has been instrumental in precisely defining the clinical phenotype of this condition, 




The authors of the PMRED study described the characteristic phenotype of this 
condition as neonatal hypotonia with poor feeding [179]. Both of which are 
universal features observed within our cohort. Puffenburger et al., also reported 
characteristic dysmorphic features including; a bulbous nose, wide mouth and 
tongue, broad jaw with protuberant angles, short hands, short tapered fingers, and 
broad thumbs [179] with cranial MRIs showing irregular skull surface, white matter 
abnormalities and ventriculomegaly. All of these features were observed in at least 
50% of patients within our cohort (Table 4.1).  
 
Neurological and neurodevelopmental difficulties were major features of the 
disorder described by Puffenburger. This included the presence of psychomotor 
delay, epilepsy and absent reflexes. Affected individuals did not learn to walk, 
develop speech or engage socially and developed seizures by 6 months of age, 
with either focal or generalised seizures of varying types that may be intractable. 
Electroencephalograms (EEGs) showed multifocal spike-wave discharges from 
central, occipital and temporal regions [179]. Whilst most individuals in our study 
achieved independent ambulation it was significantly delayed, compared to 
unaffected individuals, and all individuals are non-verbal however, several can 
communicate through signs, gesticulation or sounds. Hypo- or areflexia were also 
observed to be universal features with our cohort.  
 
The three individuals described by Puffenburger et al. all displayed ophthalmic 
features described as strabismus with horizontal nystagmus [179]. Although not a 
universal feature in our cohort 45% of individuals we assessed displayed some 
degree of strabismus or nystagmus with myopia also being observed.  
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In addition to the features described above we identified a number of additional 
features, not identified in the Puffenburger study. Congenital cardiac defects are a 
common feature observed in 60% of individuals within our cohort. These defects 
include hypoplastic left heart syndrome (HLHS), with two individuals dying in the 
neonatal period, aortic stenosis and bicuspid aortic valve (BAV) of varying severity, 
coarctation (narrowing) of the aorta seen in one individual, aortic root dilatation, 
atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus 
(PDA), pulmonary artery stenosis and mitral valve regurgitation. In addition to 
these features 11% (4/35) of individuals presented with cardiomyopathy.  
Several respiratory difficulties were also observed in the 35 patients assessed as 
part of this study. Around 75% of individuals displayed upper airway respiratory 
difficulties in the neonatal period, including laryngomalacia, pharyngomalacia and 
subglottic stenosis of variable severity causing a weak cry, stridor and apnoea 
where also observed. Several patients required tracheostomy procedures and 
supplementary home oxygen. Another reported respiratory feature was asthma.  
Finally, approximately 25% of the individuals assessed as part of this study 
presented with endocrine features, that were not previously reported in the three 
PMRED patients including hypoglycaemia, hypothyroidism and, in one individual, 
dyshormonogenesis.  
 
4.3.3 Gene expression and cellular pathway data analysis 
The high frequency of this condition within the Amish provided the opportunity to 
investigate how mutation of SNIP1 affects its role as a transcriptional regulator, 
and define the impact of gene mutation on these functions, by undertaking whole 
transcriptome sequencing. RNA samples were extracted from whole blood 
obtained from six affected individuals, which were age and gender matched to form 
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a control group of six samples in which the presence of the SNIP1 gene alteration 
was excluded. While a relatively modest number of samples were available for 
whole transcriptome sequencing, we hypothesised that the unique genomic 
architecture and wider homogeneity of Amish individuals may likely be beneficial 
and increase the statistical power of this study, especially given the fact that all 
individuals are homozygous for the same founder gene mutation.  
As with any neurological or neurodevelopmental disorder it was not possible to 
undertake gene expression profiling on the primary tissue of interest, the brain, 
instead whole blood, an accepted proxy, was used. Since the first blood-based 
transcriptomic study of the neurological disorder Huntington’s disease in 2005 
[248] many gene expression studies using whole blood have been undertaken to 
elicit the pathophysiological mechanisms of neurological conditions supporting 
whole blood as a useful proxy measure for gene expression in the central nervous 
system [249].  
Further evidence in support of using whole blood to undertake gene expression 
studies to investigate the effect of the SNIP1 mutation is the expression profile of 
SNIP1 reported by the Genotype-Tissue Expression (GTEx) project. The GTEx 
project was supported by the Common Fund of the Office of the Director of the 
National Institutes of Health (and by NCI, NHGRI, NHLBI, NIDA, NIMH, and 
NINDS) which set out to create a resource enabling the study of genetic variation 
and the regulation of gene expression in multiple reference human tissues [250]. 






Figure 4.12: Gene expression for SNIP1 in multiple human tissues. The data used for this analysis obtained from: 
https://gtexportal.org/home/gene/SNIP1, the GTEx Portal on 21/10/2019 using GTEx Analysis Release V8 and dbGaP accession number 
phs000424.v8.p2 on 21/10/2019.   Sorted according to tissue type with the outliner function switched off. 
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The data obtained from the GTEx portal indicates that whole blood provides a 
median TPM (transcript per million) for SNIP1 expression of 3.795 obtained from 
755 samples. These values are within the broad range of median TPM units 
(2.929-9.948) obtained from the 13 different types of brain tissue analysed from 
a minimum of 139 samples as part of the GTEx project. It has been suggested 
that genes expressing more than two transcripts per million transcripts (TPM>2) 
are highly likely to be actively transcribed genes [251]. A reported TPM of 3.795 
for SNIP1 expression in whole blood indicates that SNIP1 is being actively 
transcribed in blood. This data supports the approach taken in this study and 
validates the use of RNA extracted from whole blood to investigate the impact of 
SNIP1 mutation on transcription and gene expression.   
 
Despite the limitations of sample size and the use of a proxy tissue sample, this 
gene expression study has been valuable in providing further insight into the key 
molecular signalling pathways potentially influenced by SNIP1 mutation. 
Importantly, the developmental and biological pathways which were found to be 
most notably impacted by gene mutation were of direct relevance to the cardinal 
clinical features of the condition. Of immediate interest were the pathways 
involved in serotonin and dopamine release, which where the most highly 
enriched (highest combined score) within the upregulated gene list, and have well 
reported links associating their dysregulation with the onset of seizures, an 
invariable feature of SNIP1-related syndrome [245, 246]. 
 
Epilepsy affects ~65 million individuals globally [252] and whilst some epilepsies, 
or seizures, have well defined aetiologies, the underlying cause remains 
undefined in many cases. Correctly diagnosing an epilepsy syndrome has 
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significant implications with regard to treatment options [253]. A lack of 
knowledge regarding the underlying molecular basis of these syndromes is a 
contributing factor as to why epilepsy has been reported to be the leading 
neurological cause of reduced quality-adjusted life years (QALY), a measure of 
the quantity and quality of life as a result of healthcare interventions (Johnson 
2019). Determining the underlying molecular cause of the SNIP1-related 
syndrome here, may provide an opportunity for clinicians to find the most suitable 
treatment option in order to achieve the greatest improvement in the quality of life 
experienced by affected individuals within our cohort, and others elsewhere 
affected by this condition.    
 
Serotonin and dopamine and neurotransmitter release pathways 
Both serotonin and dopamine are monoaminergic neurotransmitters that have 
been associated with the regulation of seizures [245, 246], a cardinal 
characteristic feature of this condition (Table 4.1). Two genes in the serotonin 
and dopamine and neurotransmitter release pathways, SYT1 (synaptotagmin 1) 
and SYN3 (synapsin III), are members of pre-synaptic protein families (the 
synaptotagmins and synapsins) responsible for regulating synaptic vesicle traffic 
and neurotransmitter release [254] by playing important roles in the process of 






Figure 4.13: Showing the location of synaptic proteins in the synapses. 
Highlighted () are the two families of proteins identified due to genes of their 
family members being upregulated in our disease group (compared to controls) 
via enrichment analysis. Image taken (and modified) from Osimo et al. [257]. 
 
Normal brain function is critically reliant on the stringent regulation and timing of 
neurotransmitter release [256]. An action potential of +30mV within the 
presynaptic neurone will open voltage-gated Ca2+ channels, located in the 
presynaptic active zone (Figure 4.14A), initiating the release of a neurotransmitter 
filled synaptic vesicle. The influx of Ca2+ diffuses towards the synaptic vesicle and 
is detected by Ca2+ sensing proteins, from the synaptotagmin family 
(synaptotagmin 1 or synaptotagmin 2), located on the surface of the vesicle 
causing it to fuse with the presynaptic plasma membrane [258].  
Synaptotagmin 1, encoded by the SYT1 gene and responsible for the fast 
(millisecond) synchronous release of neurotransmitter [259], contains six different 
domains which are capable of acting mostly independently by sensing different 
molecules involved in different cell physiology pathways  [260]. The C2A and C2B 
domains are the regions of the protein responsible for detecting Ca2+ ions; the 
C2A domain is capable of binding three Ca2+ ions with the C2B domain binding 
two Ca2+ ions (Figure 4.14B) [260]. The binding of Ca2+ to synaptotagmin 1 
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causes a conformation change within the protein that permits its interaction with 
the membrane fusion machinery [258]. Along with syntaxin binding protein 1 
(MUNC18), Ca2+-dependent activator proteins for secretion (CAPs) and the 
complexins (Figure 4.13), synaptotagmin 1 regulates the assembly of the SNARE 
(soluble N-ethylmaleimide-sensitive factor attachment) complex which is 
responsible for mediating exocytosis [261], the fusion of the synaptic vesicle with 
the presynaptic membrane and subsequent release of neurotransmitter into the 
synaptic cleft [262].  
 
 
Figure 4.14: A) Schematic drawing of a synapse indicating the location of the 
active zone (image adapted from Südhof [263]). B) A schematic view of 
synaptotagmin1, with each functional domain is coloured differently, showing the 
location of Ca2+ binding to the C2A and C2B domains (image replicated and 
modified from Brachya et al. [260]). 
 
In 2018, Baker et al. described 11 individuals with de novo heterozygous 
missense mutations in SYT1 with neurodevelopmental delay (NDD) displaying a 
range phenotypic features (Appendix H), many overlapping those seen in 
SNIP1-related syndrome patients (Table 4.4).  
Important differences between the presentations of these two disorders, is the 
absence of seizures and skull dysplasia in individuals affected by SYT1-
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associated NDD. These cardinal features of SNIP1-related syndrome may relate 
to a more global developmental role of SNIP1.  
Whilst other non-neurological features, such as congenital heart defects and 
respiratory issues are common to both SYT1-associated and SNIP1-related 
disorders endocrinological features, such as hypothyroidism and hypoglycaemia 
appear to be completely absent from the SYT1-associated disorder (Table 4.4). 
 
Table 4.4: Comparison of the clinical presentation in the 33 affected individuals 




Interestingly, SYT1 over expression, a possible outcome from the upregulation of 
SYT1 in our disease group, has been reported to repress tumor necrosis factor-
alpha (TNF-α)-dependent nuclear factor-kappa beta (NF-κβ) transcriptional 
activation [264].  Notably, the NF-κβ signalling pathway is the same pathway the 
SNIP1 protein has been shown strongly to inhibit [238]. 
Synapsins are a family of evolutionary conserved, neuron-specific 
phosphoproteins [265]. Being present in all synapses in the brain, with the 
exception of ribbon synapses, they comprise ~1% of all proteins found in the brain 
making them one of most abundant families of synaptic proteins [266]. As a result 
of alternative splicing three synapsin genes, SYN1, SYN2 and SYN3, encode a 
number of synapsin proteins generating distinct isoforms displaying isoform-
specific distribution [255] [265]. Amino acid analysis of synapsin I and II, the first 
of the synapsins to be identified, showed that the N-terminus of each protein is 
highly preserved between the different isoforms whereas the C-terminus is more 
variable (Figure 4.15) reflecting their different functional properties and 





Figure 4.15: The synapsin family protein domains. Domain A, a short N-terminal 
region, is shared by all synapsin isoforms and contains a phosphorylation site 
that controls the reversible association with synaptic vesicles. Domain B is rich in 
small amino acids, varies between isoforms and is considered as a linker region 
connecting domain A to domain C. Domain C is a large region (~300 amino acids) 
believed to stabilise the interaction with the synaptic vesicle by penetrating its 
lipid bilayer. After domain C, the amino acid sequence diverges in the different 
synapsin gene products. However, all isoforms bear a proline-rich domain within 
the C-terminal region (within domains D, G, H or J). The amino acid scale is 
shown along the top. Image taken and modified from Cresca et al. [268]. 
 
The synapsin proteins have five major functions (Figure 4.16) with synapsins I 
and II playing similar roles in cellular processes. The later characterised synapsin 
III isoforms are predominantly expressed in early neuronal development but do 
maintain a role in synaptogenesis, neurogenesis and neuronal plasticity [266]. 
The synapsin proteins act over longer period of time, compared to the 
synaptotagmins, ranging from minutes to days when undertaking a role involved 





Figure 4.16: The major functions of synapsins taken from Mirza and Zahid, 2018 
[266]. 
 
Mutation of synapsin genes have been associated with a number of neurological 
disorders including; Alzheimer’s disease, schizophrenia, bipolar disorder, 
multiple sclerosis, Huntington’s disease and of most relevance to this study, 
epilepsy [266]. Molecular analysis has implicated both synapsin I and II with the 
development of epilepsy. Nonsense and missense mutation of SYN1 has been 
reported in individuals with autism spectrum disorders (ASDs) and epilepsy [269] 
and a polymorphism (rs37733634) in SYN2 was shown to be significantly 
associated with idiopathic generalized epilepsy (IGE) [270].  
Mutation of SYN3 has not yet been reported to cause epilepsy. However, a study 
conducted in 2006 proposed synapsin III as a candidate for familial partial 
epilepsy with variable foci based on protein-protein interactions, described in the 
human protein reference database (HPRD), with synapsin I, a protein previously 
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linked with epilepsy [271]. Furthermore, in 2015 Zaltieri et al. presented evidence 
that synapsin III is involved in the regulation of dopamine neuron synaptic function 
[272]. The link between altered dopaminergic systems and epilepsy is well known 
[246] with a direct link between increased hippocampal extracellular 
concentrations and seizure activity previously demonstrated [273]. Taken 
together this information places SYN3 upregulation, as a result of mutation in 
SNIP1, as a strong possible cause of the observed epilepsy and/or NDD aspect 
of the phenotype in the affected individuals within our cohort. 
 
Interrogation of the disorders associated with these genes identifies putative 
treatments and therapies that may be of benefit to individuals with SNIP1-
associated syndrome [256, 271]. In 2018, Baker and Gordan et al. described the 
use of pramipexole, a non-ergot dopamine agonist (NEDA) widely used in the 
treatment of Parkinson’s disease (PD), in a single patient open-label treatment 
experiment to treat SYT1-associated disorder. It was reportedly associated with; 
rapid and sustained reduction of the movement disorder, reduction in the 
frequency and severity of agitated and self-injurious behaviours, and increased 
responsiveness to social and environmental stimuli. In addition a reduction in 
EEG abnormalities was observed. Although this treatment has not yet been 
trialled on a second patient and further validation is required to assess the true 
effectiveness of this treatment, it is a promising finding that has the potential to 
reduce some of the clinical features of SNIP1-associated syndrome patients 
[256]. Additionally, the identification of serotonin and dopamine release pathways 
as the possible cause of epilepsy in our patients suggests the use of anti-epileptic 
drugs targeting these pathways may alleviate symptoms in SNIP1-associated 
syndrome individuals. For example phenytoin, carbamazepine, valproic acid, 
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lamotrigine and zonisamide have all been shown to cause an increase in 
extracellular serotonin levels inhibiting the onset of many types of seizures [274]. 
 
Developmental biology pathways   
Due to the broad spectrum of phenotypic features another enriched pathway of 
interest is the developmental biology pathway which achieved the third highest 
combined score, for upregulated pathways. Interestingly, a few genes identified 
have been linked to disorders displaying overlapping characteristics of SNIP1-
associated syndrome. The gene with the most notable overlap of phenotypic 
features is CHL1 (Cell Adhesion Molecule L1 Like). In 2012, Chen et al. described 
an infant with partial monosomy 3p (3p26.2 --> pter) and partial trisomy 5q (5q34 
--> qter) presenting with psychomotor retardation, developmental delay, 
clinodactyly of the thumb, coarctation of the aorta, patent ductus arteriosus, 
peripheral pulmonary stenosis, atrial septal defect, microcephaly, brachycephaly, 
a small oval face, almond-shaped eyes, a down-turned mouth, a widened nasal 
bridge, hypertelorism, epicanthic folds, long philtrum and low-set large ears [275].  
Important differences between the presentation of this individual and SNIP1-
associated syndrome is the absence of craniosynostosis, which to date has been 
observed in all our patients. Additionally, a number of CNVs impacting the CHL1 
gene have been linked to learning and language difficulties, another common 
feature of SNIP1-associated disease [276-278]. The prominent overlap of 
phenotypes may be suggestive of a link between a mutation in SNIP1 affecting 
the CHL1 protein and its associated functions. 
 
The CHL1 (close homolog of L1) gene, located at 3p26.3, encodes a protein 
belonging to the L1 family of neural cell adhesion molecules (NCAM), forming 
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part of the larger immunoglobulin superfamily (IgSF) [276, 277]. Members of the 
L1 family, often referred to as immunoglobulin cell adhesion molecules (IgCAMs), 
are essential for normal brain development. IgCAMs facilitate a range of 
developmental processes including cell proliferation and migration, 
neuritogenesis, axonal fasciculation, synaptogenesis, and stabilization of 
synapses. Disruption of IgCAM genes and subsequent disturbance of these 
processes has been linked to a number of neuropsychiatric disorders such as 
schizophrenia and mood disorders [279]. 
Members of the L1 family may either be a transmembrane glycoprotein, such as 
CHL1, or linked to the cell surface by a glycosylphosphatidyl inositol (GPI) 
anchor. They are characterised by the presence of six Ig-like domains located at 




Figure 4.17: The schematic structure of CHL1 demonstrating the characteristic 
structure of a transmembrane immunoglobulin cell adhesion molecules (IgCAMs) 
containing six Ig-like domains and five FN3 repeats. Image modified from 
Irintchev and Schachner, 2012 [279]. 
 
CHL1, is expressed in most neurones within the central nervous system (CNS) 
and display higher levels of expression in embryonic brains compared to adult 
brains [279]. CHL1 regulates neurite overgrowth, axonal guidance, migration, 
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differentiation of neurones and in the mature brain accumulates at the axonal 
membrane to regulate synapse function [276]. Murine models of CHL1 function 
have shown Chl1 deficiency causes aberrant neurotransmission, motor co-
ordination and behaviour providing further evidence of its importance in normal 
brain functioning [276].  
 
A further gene of interest enriched in the developmental biology pathway is 
ROBO1 (roundabout guidance receptor 1) a transmembrane receptor involved in 
signal transduction, located at 3p12. Like CHL1, ROBO1 is a member of the 
NCAM family however, its role in axon guidance defines a separate, novel IgSF 
subfamily [281]. 
SLIT-Roundabout (SLIT/ROBO) signalling is now known to be involved a number 
of processes including, kidney induction and heart tube formation [282]. There 
are four members of the ROBO family (ROBO1, ROBO2, ROBO3 and ROBO4) 
three of which are expressed in human brain cells each containing five Ig 
domains, three FN3 domains and four conserved cytoplasmic domains. ROBO2 
and ROBO3 are only seen in the nervous system but not in the vascular system 
where ROBO1 is known to be expressed in both systems making it an interest 
candidate for both the neurological and cardiac phenotypes observed in SNIP1-





Figure 4.18: The schematic structure of ROBO family members. ROBO1-3 
showing the typical structure wiht five Ig domains, three fibronectin type III (FN3) 
repeats and four conserved cytoplasmic domains and ROBO4 comprising of only 
three Ig domains, two FN3 domains and two cytoplasmic domains. Image 
modified from Ypsilanti et al., 2010 [283] and Yadva and Narayan, 2014 [282]. 
 
Disruption of ROBO1 expression has been linked to learning difficulties 
particularly dyslexia susceptibility [284]. Although SNIP1-associated syndrome 
affected individuals experience learning difficulties the clinical feature of most 
relevance is that the disruption of ROBO1 has been reported to give rise to a 
relevant cardiac phenotype [285].  
Loss of function (LOF) ROBO1 variants were identified in three unrelated 
probands displaying different cardiac phenotypes including; ventricular septal 
defect (VSD), tetralogy of Fallot (a combination of four heart defects; VSD, 
pulmonary valve stenosis, a misplaced aorta and right ventricular hypertrophy) 
and congenital heart disease (CHD).  Additionally, two mouse models with Robo1 
variants have been found to exhibit an atypical slit-Robo signalling pathway 
leading to the development of septation and outflow tract defects and, 





Although requiring further validation, the identification of molecules known to be 
involved with brain development (CHL1 and ROBO1) and neurotransmitter 
release (SYT1 and SYN3), previously linked to neurodevelopment and 
neurological condition and displaying considerable overlap with SNIP1-
associated syndrome phenotypes provides insight into the function of SNIP1 as 
a transcriptional regulator. 
 
4.3.4 Future work 
The genetic and transcriptomic studies defined here have laid important 
foundations for a greater understanding of the pathomolecular basis of a novel 
form of neurodevelopmental delay. Currently the p.Glu366Gly amino acid 
alteration identified in the Amish is the only known cause of this condition. As no 
other families are reported elsewhere with this or other SNIP1 alterations, it is 
important to work with genome sequencing teams worldwide to identify additional 
families with this and other candidate SNIP1 mutations to learn more about 
genotype-phenotype outcomes associated with this condition.  
An additional important next step is the validation and further investigation of the 
genes and developmental pathways identified as altered through whole 
transcriptome sequencing. This could be achieved through the use of a Taqman 
low density array (TLDA) which will perform real-time PCR detection and relative 
quantitation of expression for the genes of interest (targets). The TLDA platform 
is a closed system utilising a validated singleplex PCR methodology. The TLDA 
card, capable of running 24 duplicates, is designed with targets pre-allocated to 
reaction wells enabling fast and simultaneous detection of multiple gene targets 
[286]. Patient and control samples for these studies have been obtained, and this 




In parallel with this functional studies, using (for example) murine models and 
transgenic cell lines, could be conducted to assess the expression of SNIP1 in 
the brain and to more precisely describe the binding partners and subcellular 
localisation of the SNIP1 protein, and define its molecular role including potential 
downstream impacts. Due to its likely involvement in developmental pathways, 
studies in embryonic mice, <E8.0, may determine its potential role in formation of 
the nervous plate and heart tube, given the presentation of related neurological 
and cardiac phenotypes. Additionally, as craniosynostosis is a cardinal clinical 
sign of this condition these studies may identify molecules of relevance to skull 
development and suture formation/closure, and provide important insights into 
these poorly understood biological processes.  
There are numerous potential benefits to this work involving the broadening of 
the clinical spectrum of this disorder and elucidating the functional outcomes of 
mutations in SNIP1. The SNIP1 mutation has now been incorporated into regional 
molecular diagnostic sequencing panels utilised by the Amish communities. This 
will enable early diagnosis, aiding early intervention and patient management as 
well as preventing the future misdiagnosis of this condition. Together this will 
ensure affected individuals and their families are provided with adequate genetic 
counselling and access to potential therapies and treatments that may help 
reduce the observed phenotypes of SNIP1-related syndrome and improve the 
quality of life for those affected by the disorder. The enrichment of SNIP1-related 
syndrome within the Amish communities of Indiana has provided a unique 
opportunity to not only confirm the genetic cause but to investigate the functional 
consequences of the identified mutation which can be used to inform possible 









INTERROGATION OF AMISH AGGREGATED 
EXOME DATA TO IDENTIFY POTENTIALLY 
DELETERIOUS COINCIDENTAL HETEROZYGOUS 
SEQUENCE VARIANTS AND DETERMINE THE 
ALLELE FREQUENCIES OF PATHOGENIC 






 Interrogation of Amish aggregated exome data to 
identify potentially deleterious coincidental 
heterozygous sequence variants and determine the 
allele frequencies of pathogenic variants seen within 
the various Amish communities 
 
5.1 Aims 
Over recent years the WoH Project has accumulated extensive single nucleotide 
polymorphisms (SNP) and exome datasets from patients and individuals from the 
Amish community. The aim of this project was to begin to explore these datasets 
more widely, to describe and characterise the architecture of the Anabaptist 
genome. The overarching objectives of the study were; 
 To interrogate exome datasets to identify potentially deleterious autosomal 
recessive variants in genes already known to cause disease, 
coincidentally carried by individuals enrolled on the study, to learn more 
about the spectrum of inherited diseases present in the community.  
 To more precisely determine the allele frequencies (AF) of the pathogenic 
variants identified across the various Amish communities. 
 To share information gained from the analysis of the Anabaptist genome 
within the healthcare system locally and with the scientific and clinical 





Sequence variations (variants) occur throughout the genome. Some arising at 
positions that alter the DNA sequence in a way that changes the amino acid 
sequence of the encoded protein (non-synonymous) where other variants will 
have no effect on a resultant protein (synonymous). Non-synonymous variants 
effect the function of protein and therefore the phenotypic characteristic of an 
individual, often effecting susceptibility towards a genetic disorder [287].  
There are several types of non-synonymous variants including; nonsense, 
frameshift and missense. Nonsense variants are single nucleotide changes that 
result in the introduction of a premature stop codon (pre termination codon, PTC). 
Frameshift variants are caused by the insertion or deletion (indels) of a number 
of nucleotides within a DNA sequence altering the reading frame (triplet codon 
pattern). Missense variants are point mutations that do not introduce a PTC but 
still alter the amino acid sequence of resultant protein and have the potential to 
affect its functionality. Nonsense and frameshift variants are considered the most 
likely to be disease causing (pathogenic) due to their ability to dramatically alter 
the function of a protein. In some cases, due to a cellular quality control 
mechanism known as nonsense-mediated decay (NMD),  an aberrant protein is 




5.2.1 Variant annotation  
Online genomic databases are one way the scientific and clinical communities 
have gone about collating information on variants identified in many laboratories 
across the globe to facilitate data sharing and enable standardisation of variant 
classification. However, determining the clinical significance of (particularly novel) 
sequence variants which is vitally important for rare disease diagnostics, is still 
extremely challenging [289].  
In 2015, the American College of Medical Genetics and Genomics (ACMG) and 
the Association for Molecular Pathology (AMP) published standards and 
guidelines as an educational resource to aid clinical laboratory geneticists in the 
interpretation of sequence variants [289]. Although compliance to these 
standards is voluntary its use has been widely endorsed globally proving 
instrumental in the promotion of consistency and agreement of sequence variant 
classification across the clinical genetics community [290]. The ACMG/AMP 
guidelines incorporate several types of evidence that are used to classify variants. 









The first step in annotating a VCF file involves determining if a variant has been 
previously reported, at what frequency and in which populations (Figure 5.1). 
There are a number of publically available databases containing this information 
which can be used depending on which is best suited to the research or clinical 
needs of a particular study [291]. The two commonly used databases are the 
Single Nucleotide Polymorphism Database (dbSNP) [292] and the Genome 
Aggregation Database (gnomAD) [89].  
 
The Single Nucleotide Polymorphism Database (dbSNP) 
The Single Nucleotide Polymorphism database (dbSNP) was established in 1999 
by the National Centre for Biotechnology Information (NCBI) as a freely available 
catalogue of simple genetic polymorphisms [293]. Collated as a tool to aid the 
understanding of human variation and molecular genetics  for use in a broad 
range biological applications including large scale association studies, gene 
mapping, functional analysis, pharmacogenomics and evolutionary biology [287].  
 
The name of this database, dbSNP, is slightly contradictory given the variety of 
variants included in the database including; single-base nucleotide substitutions 
(SNPs), small-scale multi-base deletions or insertions (indels), retroposable 
element insertions and microsatellite repeat variations (short tandem repeats or 
STRs).  The name probably reflects the fact that single nucleotide variants are 
the largest class of variants with in dbSNP, comprising ~99.7%, of the database 
[287, 292, 293]. However, this too is confusing as single nucleotide variants are 
not always polymorphisms. A polymorphism, by definition, is a variant that occurs 
in >1% of the population [294]. The spectrum of variants included in dbSNP 
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ranges from neutral polymorphisms to disease-causing clinical mutations and 
provides information on clinical actionability.   
 
In terms of variant annotation the dbSNP database is a useful source of 
information reporting; the context of a variant (showing the surrounding 
sequence), the frequency of the variant in different populations and the 
experimental method used to assess the possible functional implications the 
variant [287].  
 
The Genome Aggregation Database (gnomAD)  
The Genome Aggregation Database (gnomAD) is a large-scale reference data 
set cataloguing genetic diversity observed across 125,748 human exomes and 
15,708 human genomes [89]. This data set builds on the work of its predecessor 
the Exome Aggregation Consortium (ExAC) which collated variant data from 
60,706 exomes [295].  
 
GnomAD has now become a vital tool for both the clinical interpretation of 
variants. As the largest database of high-quality variant calls it permits the filtering 
of candidate variants by frequency at the highest resolution, which is particularly 
important for analysis low-frequency variants [295].  
An important point to consider when using frequency data from gnomAD is the 
origin of the exome and genome data included in the database. Although 
individuals, and first-degree relatives, known to be affected by severe paediatric 
disease have been removed, included individuals were sequenced as part of a 
number of different disease-specific and population studies. This means the 
database may contain individuals with severe disease which should be taken into 
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consideration when investigating the number of reported homozygotes for a given 
variant to assess its likely pathogenicity.  
 
Two other databases; ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) [296] at the 
National Centre for Biotechnology (NCBI), an open access database, and Human 
Gene Mutation Database (HGMDPro), a commercially available database 
(http://www.hgmd.cf.ac.uk/ac/index.php), [297] are also now routinely utilised by 
researchers, clinical laboratory staff and clinicians to ascertain and aid 
interpretation of genetic variation [298]. 
  
ClinVar 
Initially released in 2013, populated predominantly by variants described in 
OMIM® and GeneReviewsTM, this freely accessible archive of germline and 
somatic variants now holds over 600,000 submitted records from ~1000 
submitters, from 60 countries on five continents [299], providing information on 
>430,000 unique variants [300]. Although not the first centralised database of 
human genetic variation, ClinVar was the first to aggregate data from many 
different sources, including clinical testing laboratories [300], and to include both 
germline and somatic variants of any size, type or genomic location [301] unlike 
other databases such as HGMD or the Catalogue of Somatic Mutations in Cancer 
(COSMIC) [302].  
Another benefit of ClinVar, particularly for those in a clinical setting, is its use of 
the specific standardised terminology recommended by the American College of 
Medical Genetics and Genomics (ACMG) to classify the clinical significance of 
variants causing Mendelian disorders as; “pathogenic,” “likely pathogenic”,  
“uncertain significance”,  “likely benign”,  or “benign” [95]. Although the accuracy 
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of individually submitted variant interpretations is not evaluated, ClinVar 
calculates an aggregated interpretation based on those provided by each 
submitter and reviews the level of supporting evidence used to ascertain the 
clinical significance by allocating a review status to each variant, taking into 
account the type of submitter [301].  The review status is summarised on each 
variation report in the form of gold stars. Table 5.1 provides definitions of each 
review status and the corresponding number of gold stars.  
Whilst this process ensures the quality and reliability of submitted variants 
included within the database the requirement of expert panels and steering 
committees to assess evidence and award any status higher than two stars may 
hinder variants obtaining relevant review statuses within appropriate timeframes. 
An example of this would be the GJB2 gene variant, NM_004004.5 
(GJB2):c.35delG; p.Gly12Valfs, which although first identified as a genetic cause 
of hearing loss in 1997 [155] and subsequently being found to be responsible for 
~50% of all hearing loss in European populations (Smith, Bale et al. 2005), was 







Table 5.1: ClinVar review status, assignment of stars and description of each 
when each status is awarded. 
Gold 
stars 




Evidence for a variant has been included in 
practice guidelines for a particular genetic 
disorder. Evidence is reviewed by the ClinGen 
Steering Committee who award practice guideline 




The evidence for a particular variant has been 
reviewed by expert panel and a consensus of 






Obtained when two (or more) submitters with 
assertion criteria* and evidence independently 





Assigned to a variant when multiple submitters 
provide assertion criteria* and evidence but there 
are conflicting interpretations.  





Allocated to variants where one submitter has 
provided an interpretation with assertion criteria* 
and evidence  
None 
No assertion for 
the individual 
variant 
The allele has not interpreted directly in any 
submission for example, it has been submitted to 





The variant submission included an interpretation 





The allele was included in a submission that did 
not provide an interpretation. 
 *Assertion criteria refers to a publication that describes the criteria used by the 
submitter to assign the variant to an ACMG category 
 
 
ClinVar has been instrumental in facilitating the sharing of variant interpretations, 
particularly within the clinical genetics community. Its use is encouraging 
communication and debate regarding differences in variant interpretations in 
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different laboratories as well as helping promote the standardisation of reporting 
the clinical significance of variants [300]. 
 
HGMD  
First made publicly available in April 1996 [303], HGMD was the first 
comprehensive and publicly available database of germline mutations underlying 
human inherited disease [304]. It was recently reported to contain >203,000 
different genetic lesions, in over 8000 genes that have all been manually curated 
from more than 2600 journals. [305].  
HGMD is available in two versions. The public version of HGMD is freely available 
to registered users, but is updated with newly reported mutations twice a year. 
The professional version is only available via paid subscription (via QIAGEN) but 
is updated more regularly being curated and populated with newly reported 
mutations every quarter. It also includes a number of additional functions making 
it possible to interrogate particular variants, providing links relevant publications, 
and is available as a flat file permitting its use in exome and genome VCF 
annotation [305].  
 
Unlike ClinVar, HGMD does not use standardised ACMG terminology to classify 
variants. Instead variants in HGMD are assigned to one of six classes (Table 5.2) 
depending on the strength of the clinical and functional evidence provided in the 
peer-reviewed scientific literature in which the variant was described. A further 
difference between HGMD and ClinVar is that HGMD do not regularly review or 
remove variants, or genes, no longer considered to be disease-causing meaning 
it contains a lot of historical data providing out of date interpretations. One 
example is a missense variant of CASR, linked to familial hypoparathyroidism 
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and hypocalciuric hypercalcemia, which is still reported as DM in HGMD but was 
awarded a two star reviewed clinical significance of benign/likely benign in 
ClinVar in February 2018. In addition a number of genes, CDKN1A, CDKN2B and 
CDKN2C, are also still regarded as containing disease-causing mutations, even 
though the genes themselves are no longer considered disease causing. 
 
Table 5.2: Summary of the six variant classes used by HGMD [305]. 




Variants that are very likely to be causing the 





Variants where there is some degree of 
uncertainty regarding the interpretation of 





Variants with evidence to support a significant 
association with a disease/clinical phenotype in 
addition to evidence that the variant is likely to 
be of some functional relevance although there 





A direct functional effect has been 









Variants should not only have been reported to 
be significantly associated with disease, but 
should also display direct evidence of being of 
functional relevance  
Retired records R 
Variants that have been removed from HGMD. 
 Found to have been erroneously 
included 
 If the variant has been subject to 
retraction/correction in the literature 
resulting in the record becoming 





Despite this HGMD data is considered an extremely useful resource and is used 
extensively to aid classify variants according to their pathogenicity and to perform 
meta-analyses on different types of gene mutation causing human inherited 
disease improving our understanding of the mutation spectrum and molecular 
mechanisms underlying hereditary disease. With more than 100,000 registered 
users of its public version, and in excess of 7.8 million queries successfully served 
since 2007, it is an essential tool for many researchers and diagnostic 
laboratories when annotating sequencing data so much so that NHS England 
currently holds a licence accessible to all NHS clinical scientists and clinicians 
[305]. 
 
5.2.2 International effort to share genomic variant data  
The development and maintenance of online genomic databases is not only 
important for obtaining evidence to determine the clinical significance of genetic 
variants or reviewing the mutational spectrum of specific genes, it is a vital 
repository of information for use in bioinformatic projects that will underpin 
personalised genomic medicine. Despite the considerable progress in disease 
gene identification since the advent of NGS technologies, the majority of 
annotated genes have yet to be assigned a function, in the context of human 
disease traits [306]. In recent years there has been an enormous international 
effort within the genomics community to identify the best ways of sharing genomic 
data, including benign variants, to maximise the utility of the available data and 
increase our knowledge of annotated genes by more precisely defining their role 
in disease. Several programmes, at both a national and international level, have 
been established in an effort to achieve a comprehensive understanding of the 




In the US, two National Institutes of Health (NIH) projects, ClinVar and ClinGen, 
have formed a partnership to improve knowledge of clinically relevant genomic 
variation through the sharing, archiving, curation and dissemination of genomic 
data. ClinVar, as detailed in section 2175.2.1 is an online database that collates 
information on genetic variants and its relationship to human health. Whereas 
ClinGen is a central clinical genome resource that works to define the clinical 
relevance of genes and variants for use in precision medicine and research. The 
overall aim of this partnership is to “improve patient are through genomic 
medicine” (Figure 5.2). 
 
 
Figure 5.2: Schematic illustrating the overall aims of the NIH ClinGen project 
describing it hopes to improve patient care through genomic medicine 
reproduced from https://www.clinicalgenome.org/about.  
 
Other NIH-supported programmes include the establishment of Centres for 
Mendelian Genomics (CMGs) which have been responsible for the development 
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of a number of gene-matching tools including; GeneMatcher, MyGene2 and 
Matchbox. Gene-matcher tools were designed to connect clinicians with 
researchers in human and model organism genetics [306]. These gene-matcher 
tools are now able to communicate through the use of a common application 
programming interface (API) [307] hosted by the Matchmaker Exchange (MME). 
This initiative, launched in October 2013, aimed to internationally unify efforts in 
gene-phenotype matching by facilitating the interaction between multiple 
disconnected projects (Figure 5.3) to by providing a robust and systematic 
approach to rare disease gene discovery.  
 





One example of the power of the MME initiative is demonstrated through the work 
of Bruel et al. who over a period of 2.5 years used the application to successfully 
matched 84% of the genes they submitted (60/71) and enabling confirmation of 
the pathogenicity of 39% of these matched genes (23/60) [308].  
 
5.2.3 Contribution of Amish knowledge to the international genetic 
community 
As well as greatly expediting disease diagnosis, the increased availability and 
widespread use of NGS technology for clinical genetic testing generates large 
amounts of genomic data on the individuals investigated. When undertaken in a 
community setting, this provides an opportunity to greatly advance knowledge of 
the architecture of genetic disease of direct relevance to that population. 
Research undertaken by the WoH and other research groups, including research 
undertaken by the Clinic for Special Children (CSC), has led to the accumulation 
of a large body of genomic information regarding known and candidate new 
pathogenic variants present within the Anabaptist communities. Together with 
other groups working with Anabaptist communities, WoH is leading the creation 
of an “Anabaptist specific mutation database” to support clinical services 
managing patients. To increase the clinical utility of Anabaptist variant data it is 
being shared with existing public variant databases, including ClinVar, to aid 
variant interpretation globally.  
 
Genomic data from the Anabaptist community, which display a higher incidence 
of some rare genetic variants due to the presence of founder mutations, is 
beneficial in a number of ways. For example, it may enable the matching of cases 
with families with similar phenotypic and genotypic profiles located elsewhere. An 
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early example is that of Ellis-van Creveld (EVC) syndrome, which was first 
described in 1940 by Richard Ellis and Simon Van Creveld [2]. Ellis-van Creveld 
syndrome is a rare form of dwarfism involving skeletal and chondroectodermal 
dysplasia with an incidence in non-Amish populations of 7/1000000. However, 
the condition is present at greatly increased frequency in some Amish Demes 
reaching ~1/5000 [309] where it has been possible to trace the lineage of the 
variant back to a single founder couple, Samuel King and his wife, who 
immigrated to Eastern Pennsylvania in 1744 [310]. After the initial discovery and 
description of this condition in the Amish, other cases of EVC syndrome occurring 
globally were more easily recognised; a number of other more recent examples 
of this stem from the work of the WoH Project including GM2 and GM3 synthase 
deficiencies, HERC2 (Blue eye delay) syndrome, KPTN (MASD) syndrome, 
Troyer (SPG20) syndrome and Mast (SPG21) syndrome. Thus, the willingness 
of the Amish communities to partake in genetic studies, such as those conducted 
by WoH, has been paramount to the increased understanding within the medical 





5.3 Results  
 
5.3.1 Identifying potentially deleterious coincidental heterozygous 
sequence variants 
Exome data from 26 individuals with moderate-severe intellectual disability 
with/without additional syndromic features was de-identified, aggregated and 
analysed to identify potentially deleterious heterozygous variants, not thought to 
be responsible for the difficulties experienced by the individuals but being 
coincidentally carried. This work was undertaken as a proof-of-principle study to 
ascertain the utility of such an approach for facilitating the identification of 
candidate disease associated variants within a community setting (summarised 
in Figure 5.4). Variants were initially filtered to prioritise only heterozygous 
variants predicted to be of high functional impact (nonsense and frameshift) that 
passed stringent quality control constraints (PASS, Filter [VCF]). Only variants 
with high Phread scores (Q scores) were included in the analysis in order to 
reduce the likelihood of false positive variant calls. 
As an additional quality metric only variants with good quality calls were included 
in our analysis. This involved reviewing the allele depths for each heterozygous 
call in each individual to ensure the proportion of the alternative allele was ~50%, 
compared to the reference allele. Concerns over the quality of a heterozygous 
call, due to uneven allele ratios, were investigated using the Integrative Genomics 
Viewer (IGV) software. IGV, a desktop visualisation tool for large integrated 
genomic datasets [311], permits the interrogation of variant calls by displaying 
the coverage and quality of read alignments.  
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Figure 5.4: Summary of the Amish exome data analysis including filtering criteria, number of variants and 
location of results. 
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Variants previously described as associated with human genetic disorders 
Initial findings identified seven nonsense variants, responsible for autosomal 
recessive disease, reported as pathogenic, or likely pathogenic, in ClinVar or 
described as a disease-causing mutation (DM) in HGMDPro (Table 5.3). A further 
five frameshift variants reported as pathogenic, or likely pathogenic, in ClinVar or 
described as a disease-causing mutation (DM) in HGMD were also identified 
(Table 5.4). Eight, of a total of 12 (nonsense and frameshift) variants identified in 
our cohort had previously been seen in the Amish community (shown in blue in  
Table 5.3 and  
Table 5.4), six of which (KPTN, WDR73, SPG21, TMCO1, SLITRK6 and 
ST3GAL5) where identified through the work of the WoH.  
Of the four variants not yet reported in the Amish, three have strong evidence in 
support of their pathogenicity due to the fact they are reported in ClinVar as 
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review statuses indicating multiple submitters have independently provided 
evidence in supporting the same interpretation. However, the pathogenicity of the 
fourth variant in FRY is uncertain as there is insufficient evidence to support it 
being a disease gene as it is not reported in ClinVar and has only been observed 
in one family, in the literature, where it was described in one large family with 

















































































Table 5.3: Nonsense variants classified as pathogenic or likely pathogenic in ClinVar or with a disease-causing mutation (DM) in HGMD® 
reported to cause an AR disorder/phenotype. Variants previously reported in the Amish are highlighted in blue. The variant in FRY is 
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Table 5.4: Frameshift variants classified as pathogenic or likely pathogenic in ClinVar or with a disease-causing mutation (DM) in 


















































































Variants not previously described as associated with human genetic disorders  
There were 94 genes containing 95 nonsense variants and 170 genes containing 
202 frameshift variants within the aggregated exome data that had not previously 
been reported in either ClinVar or HGMD. To assess the potential pathogenicity 
of these variants, the genes in which these variants were located were 
investigated via a PubMed literature review. This literature review involved 
looking for any association with a human disease including model organisms or 
cell line studies which proposed an associated link with a human disease 
phenotype.  
This analysis indicated 61 genes, housing nonsense variants, and 122 genes, 
housing frameshift variants, within our cohort, where a putative link to a human 
disease phenotype had been proposed in the literature (Appendix I). Out of these 
61 genes only nine genes, containing a nonsense variant in our cohort, were 
putatively linked to an autosomal recessive disorder reported in humans. 
However, some of these genes have been linked to more than one 
phenotype/disorder in the literature, such as TIMP4, which has been associated 
with both focal epilepsy and Kawasaki disease (Table 5.5). Similarly, ten genes 
out of the 122 identified in our cohort as containing a frameshift variant were 
linked to 11 autosomal recessive disorders (Table 5.6).  
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Table 5.5: Candidate novel heterozygous nonsense variants identified in genes previously associated with an autosomal recessive 

























































































































































































For variants reported in more than one transcript in our data, only the canonical (Refseq) transcript has been used. For transcripts that did 
not have a Refseq transcript available the NCBI database was used to find the longest isoform was used as the predicted effect of the 
variant was the same in all transcripts. Variants found in the literature that are reported in ClinVar as pathogenic or likely pathogenic are 





























Table 5.6: Candidate novel heterozygous frameshift variants identified in genes previously associated with an autosomal recessive 
disorder in humans identified in our Amish aggregated exome dataset. 
 
 
Chromosomal variant (hg38) cNomen Chromosomal variant (hg38) cNomen
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For variants reported in more than one transcript in our data, only the canonical (Refseq) transcript has been used. For transcripts that did 
not have a Refseq transcript available the NCBI database was used to find the longest isoform was used as the predicted effect of the 







































































Next, heterozygous missense variants identified within the aggregated Amish 
exome dataset were analysed. Given the large number of variants (10,767) only 
those previously reported as pathogenic or likely pathogenic in ClinVar were 
initially prioritised for further evaluation. A total of 32 missense variants were 
identified as pathogenic. However, upon further investigation 16 had been 
reclassified in ClinVar (to “conflicting interpretations of pathogenicity”, “benign”, 
“uncertain significance” or “other”) with one variant in a gene now reported to  
show an X-linked mode of inheritance, so these were subsequently removed from 
this dataset. Table 5.7 summarises the remaining 15 missense variants, found in 
14 different human disease genes, grouped by primary system affected by the 
disorder. Additional information in the summary table includes; associated 
disorders, ClinVar significance, and the frequency (in European, non-Finnish; 
which was used due to the Finnish population being a population isolate with a 
different enrichment of variants compared to the rest of Europe) and number of 
homozygotes (Total) reported in gnomAD.  
Eight of the variants identified have previously been reported in the Amish 
community, indicating that there are seven additional rare (AF ~1% or less) 
heterozygous missense variants previously associated with an autosomal 
recessive disease in humans present within the Amish community that have yet 
to be reported to cause disease within the community. Further work is required 
to establish the pathogenicity of these variants.
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Table 5.7: Rare (AF ~1% or less) heterozygous missense variants identified in the aggregated Amish exome data that have previously 
been associated with autosomal recessive disease in humans and are reported as pathogenic or likely pathogenic in ClinVar. Grouped 












Deafness, autosomal recessive 1A AR GJB2 NM_004004.5:c.229T>C;p.(Trp77Arg) Pathogenic 2 Oct 4, 2017 0.00002638 0
Congenital glucose-galactose malabsorption AR SLC5A1 NM_000343.3:c.1673G>A;p.(Arg558His) Pathogenic 1 Dec 9, 2016 0.00003099 0
Myeloperoxidase deficiency AR MPO NM_000250.1:c.995C>T;p.(Ala332Val) Pathogenic 0 May 1, 2004 0.01791 45
Myeloperoxidase deficiency AR MPO NM_000250.1:c.752T>C;p.(Met251Thr) Pathogenic 0 Nov 15, 1997 0.01365 26
von Willebrand disease, recessive form AR VWF NM_000552.3:c.2561G>A;p.(Arg854Gln) Pathogenic 2 Nov 21, 2018 0.005343 5
Pyruvate kinase deficiency, amish type AR PKLR NM_000298.5:c.1436G>A;p.(Arg479His) Pathogenic 1 Apr 14, 2017 0.00009292 0
Progressive intrahepatic cholestasis AR ATP8B1 NM_005603.4:c.923G>T;p.(Gly308Val) Pathogenic 1 Dec 19, 2017 0.000008795 0
Iminoglycinuria, digenic, hyperglycinuria AR SLC36A2 NM_181776.2:c.260G>T;p.(Gly87Val) Pathogenic 0 Dec 1, 2008 0.01259 24
Glutaryl-CoA oxidase deficiency AR SUGCT NM_001193311.1:c.1006C>T;p.(Arg336Trp) Pathogenic 2 Oct 31, 2018 0.008083 9
Ataxia, spastic, 4 AR MTPAP NM_018109.3:c.1432A>G;p.(Asn478Asp) Pathogenic 0 Dec 1, 2014 - -
Psychomotor retardation, epilepsy, and craniofacial 
dysmorphism
AR SNIP1 NM_024700.3:c.1097A>G;p.(Glu366Gly) Pathogenic
0
Jan 1, 2012 - -
Cohen syndrome AR VPS13B NM_017890.4:c.8459T>C;p.(Ile2820Thr) Pathogenic 0 Jul 21, 2016 - -
Trichothiodystrophy, nonphotosensitive 1 AR MPLKIP NM_138701.3:c.430A>G;p.(Met144Val) Pathogenic 0 Mar 1, 2005 0.00005277 0
Familial renal glucosuria AR SLC5A2 NM_003041.3:c.1961A>G;p.(Asn654Ser) Pathogenic 0 Feb 1, 2004 0.007871 10
BCHE, dibucaine-resistant I, postanesthetic apnea n/a BCHE NM_000055.2:c.293A>G;p.(Asp98Gly)
Pathogenic/
Likely pathogenic













5.3.2 Determining the AF of pathogenic variants seen within the various 
Amish communities  
In order to learn more about the prevalence of 165 pathogenic variants known to 
be associated with the disease and present in the Amish communities (Appendix 
A), and as part of  wider strategy to develop new more streamlined genotyping 
approaches for disease diagnosis in the community, 171 distantly related 
anonymised Amish individuals from Ohio (Holmes County), Ohio (Geauga 
County), Indiana, and Wisconsin communities were genotyped using a 
multiplexed amplicon, PLEXseq [102] sequencing approach. As expected, initial 
findings showed remarkably divergent allele frequencies for these variants 
reflecting the distinct ancestral histories of each Amish community. 
 
Each of the 171 samples were run in triplicate on the PLEXseq panel to enable 
validation. For a sample to be included in the allele frequency calculation for a 
given variant, at least two out of the three repeats needed to be concordant. 
Samples that did not meet this criteria, due to failed or conflicting genotypes, were 
not counted. 
 
The two most commonly occurring variants in our dataset are responsible for 
hereditary hemochromatosis NM_000410.3 (HFE):c.187C>G and NM_000410.3 
(HFE):c.845G>A (Table 5.8), and were observed at an AF of 0.1579 and 0.1140 
respectively. This is corroborated by the high AF observed within our cohort and 





Table 5.8: Allele frequency analysis of the most commonly observed variants 
within different Amish communities.  
Disorder Gene MOI Variant Region AF  
gnomAD 
Freq.  










Ohio Holmes 0.1176 












Ohio Holmes 0.1397 
Ohio Geauga 0.0909 
Wisconsin 0.1400 
TOTAL 0.1140 
gnomAD frequencies refers to the European (non-Finnish) frequency. MOI; 
Mode of inheritance. 
 
Unlike the HFE variants that are observed in all regions investigated, a number 
of variants were only observed in one region within our cohort. Variants seen in 
only one Amish community, but reported in more than one person are 
summarised in Table 5.9. 
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Table 5.9: Allele frequency analysis of heterozygous variants only observed within one Amish community within our cohort. 
Disorder Gene MOI Variant Region AF  
gnomAD Freq.  
(March 2019) 






Ohio Holmes - 
Ohio Geauga - 
Wisconsin 0.0600 
TOTAL  0.0088 






Ohio Holmes 0.0221 
Ohio Geauga - 
Wisconsin - 
TOTAL  0.0088 






Ohio Holmes - 
Ohio Geauga 0.0185 
Wisconsin - 
TOTAL  0.0059 






Ohio Holmes 0.0294 
Ohio Geauga - 
Wisconsin - 
TOTAL  0.0113 
Non-syndromic intellectual disability, 







Ohio Holmes 0.0368 
Ohio Geauga - 
Wisconsin - 
TOTAL  0.0146 






Ohio Holmes - 
Ohio Geauga 0.0182 
Wisconsin - 
TOTAL  0.0058 






Ohio Holmes - 
Ohio Geauga 0.0182 
Wisconsin - 

















TOTAL  0.0058 











TOTAL  0.0056 










TOTAL  0.0058 











TOTAL  0.0058 











TOTAL  0.0058 











TOTAL  0.0058 
gnomAD frequencies refers to the European (non-Finnish) frequency. MOI; Mode of inheritance. AR; Autosomal recessive. 
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5.3.3 Community allele frequency data confirming rare disease 
Interrogation of our aggregated Amish exome dataset, which has now been 
expanded from an initial 26 exomes to the current 117, has allowed the AFs of 
variants within the community to be determined. Knowledge of the AFs within the 
community of variants in genes not yet associated with human disease or where 
the evidence for disease association is not yet conclusive, is hugely 
advantageous as it has the capacity to confirm, or refute the disease gene 
association. This study has been able to conclusively confirm the pathogenicity 
of three candidate pathogenic variants within the Amish community and 
















Indiana - 0 0
Ohio Holmes 0.0221 3 0
Ohio Geauga 0.0273 3 0
Wisconsin 0.0200 1 0
Total 0.0205 7 0
Indiana n/a n/a n/a
Ohio Holmes n/a n/a n/a
Ohio Geauga n/a n/a n/a
Wisconsin n/a n/a n/a
Total n/a n/a n/a
Indiana 0.0870 4 0
Ohio Holmes 0.0441 6 0
Ohio Geauga 0.0182 2 0
Wisconsin - 0 0
Total 0.0351 12 0
0
0





















Situs inversus (SI) 























The genetic data presented here forms part of a proof-of-principle study which 
aims to characterise the spectrum and frequencies of inherited diseases in the 
Amish community to aid the identification of novel disease genes, disease 
diagnosis, clinical management and genetic counselling. This involved examining 
aggregated exome sequencing data from 26 Amish individuals to identify 
potentially deleterious heterozygous variants coincidentally carried by individuals 
from the Amish community and utilising a multiplexed amplicon sequencing 
approach to study the prevalence of 165 pathogenic variants by calculating the 
allele frequencies in a cohort of 171 Amish individuals.  
 
5.4.1 Analysis of Amish aggregated exome data 
Analysis of exome sequencing data revealed the presence of 12 variants, 
reported to be pathogenic in ClinVar or disease-causing in HGMD, coincidentally 
carried and not thought to be responsible for the difficulties experienced by the 
individuals within the cohort. Seven of these variants are already well established 
as pathogenic within the Amish community confirming that this method is capable 
of accurately identifying causative variants. Interestingly this analysis also 
identified seven variants reported to be pathogenic in ClinVar/HGMDPro that 
have not yet been observed within the community, but are clearly present.  This 
provides an opportunity for health care providers in the community to more readily 
link observed phenotypes with genetic disorders and the responsible genotypes. 
For example, although not yet described as pathogenic in ClinVar or HGMD a 
frameshift variant in GJC3 (NM_181538.2:c.329dup; p.Glu111Glyfs*67) was 
identified in our exome sequencing data (Appendix I). A literature review of this 
gene discovered heterozygous missense mutation (c.807A>T; p.Glu269Asp) of 
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GJC3, which encodes the gap junction protein connexin 29, is reported to cause 
NSHL [158, 312, 313] . It would therefore be pertinent for current and new 
patients recruited to the Amish Hearing Loss Programme to be screened for the 
frameshift GJC3 variant identified in our cohort.  
 
One of the most promising applications of this type of study is its potential to 
identify variants that will enable early intervention and deliver improved outcomes 
for affected individuals. For example, individuals homozygous for the identified 
CYP1B1 variant (NM_000104.3:c.1064_1076del; p.Arg355Hisfs*69) are likely to 
experience autosomal recessive buphthalmos as a result of congenital (infantile) 
glaucoma. This rare variant has an AF of 0.0003648 in gnomAD (European, non-
Finnish), with no reported homozygotes, supporting pathogenicity. Buphthalmos 
is congenital enlargement of the eye, which requires early surgical treatment to 
ensure the preservation of existing vision [314].   
Another variant of interest is a nonsense variant (NM_016138.4:c.422T>A; 
p.Val141Glu) identified in COQ7 which is reported in ClinVar as pathogenic and 
responsible for a primary coenzyme Q10 (CoQ10) deficiency disorder. This 
autosomal recessive multisystem disorder presents with neurologic 
manifestations, including fatal neonatal encephalopathy with hypotonia, a late-
onset slowly progressive multiple-system atrophy-like phenotype and may 
include dystonia, spasticity, seizures, and intellectual disability. A diagnosis of 
this deficiency disorder can be established through a genetic test confirming the 
presence of biallelic pathogenic variants. Early diagnosis provides the opportunity 
to implement early treatment, in the form of high, dose oral CoQ10. Dietary 
supplementation is reported to limit disease progression including the 
progression of renal disease and onset of a neurological phenotype [315]. This 
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disorder has not yet been reported within the Amish community, but the presence 
of heterozygotes for this variant within our exome dataset indicates that it is 
present and should be considered as a potential diagnosis in individuals 
presenting with a potentially consistent phenotype.   
This approach for identifying coincidentally carried variants has the potential to 
identify other variants underlying treatable disorders that which could then be 
included in an Amish targeted genetic newborn screening (NBS) programme.  
 
The importance and successful application of NBS is best demonstrated through 
its use to screen for phenylketonuria, an error of amino acid metabolism, 
characterised by mutations of the phenylalanine hydroxylase (PAH) gene, which 
if not treated it can result in in profound and irreversible mental disability. 
However, early detection, through NBS, and implementation of a phenylalanine-
restricted diet soon after birth can stop levels of phenylalanine becoming raised 
in the blood preventing the neuropsychological deficits [5].  
Since its introduction in the US in 1963 [316], to screen for phenylketonuria, NBS 
has helped diagnose millions (1 in every 320 new-borns) of potentially severe or 
lethal conditions before clinical symptoms are observed. Each year in the US, 
99.9% of the ~4 million infants born are screened [317]. However, within Amish, 
and Mennonite, families the proportional of all children in a family receiving NBS 
has been reported to be as low as 40% despite the majority of families 
recognising its importance [318]. The successful generation and implementation 
of an Amish (or Anabaptist) specific NBS would require support from the Amish 
communities and collaboration between the local health care providers, to ensure 
its accessibility, and clinical research partnerships, such as WoH and CSC, to 




This pilot, proof-of-principle study demonstrates the clinical value of examining 
exome sequencing data from a community such as the Amish to identify 
coincidentally carried variants and its capacity to detect known and novel 
pathogenic variants that have yet to be reported but are clearly present within the 
community. Information gained from this study can be used to inform clinicians 
about the nature and spectrum of disorders present within the different Anabaptist 
communities, accelerating genetic diagnosis and permitting the development of 
health policies and the implementation of early targeted treatments for affected 
individuals within these communities. 
 
5.4.2 Determining allele frequencies  
Allele frequencies of 165 variants were investigated in 171 unaffected individuals 
from different Amish demes. The findings of this study revealed different carrier 
frequencies for most variants in the different communities. This is likely to reflect 
the specific migration events that occurred within the population since the genetic 
bottleneck event in the 18th and 19th century, when individuals fled Europe 
heading for the US, to the subsequent relocations of affiliations as the Amish 
population expanded. Knowledge of carrier frequencies within different regions 
can be used to estimate disease prevalence and improve the clinical 
management of disorders by increasing awareness of the disorder amongst 
clinicians and the local Amish community, tailoring diagnostic services, facilitating 
the planning and dissemination of healthcare resources and implementing 




This study as has also been beneficial in highlighting the co-occurrence of more 
than one homozygous pathogenic variant within the same individual/family and 
how it can impede a clinical diagnosis. A retrospective analysis of 2076 un-related 
patients with a molecular diagnosis conducted in 2017 found that 4.9% of 
individuals had received a dual diagnosis, where two or more disease loci are 
responsible for their clinical characteristics [319]. 
A notable example of this issue, from the literature, is Fitzsimmons syndrome 
which was described in 1987 by Fitzsimmons and Guilbert on diagnosing twins 
presenting with progressive spastic paraplegia, brachydactyly with cone shaped 
epiphyses, short stature, dysarthria, and “low-normal” intelligence. Exome 
sequencing conducted in 2009, comparing one of the twins with the only other 
reported case of this syndrome in the literature found no single genetic cause 
shared by the affected individuals. Instead multiple genetic causes were 
identified. The twins were found to have heterozygous mutation of the SACS 
gene, a known cause of AR spastic ataxia of Charlevoix Saguenay in addition to 
heterozygous mutation in TRPS1, a gene known to cause Trichorhinophalangeal 
syndrome type 1 (TRPS1 type 1) which is responsible for the brachydactyly 
feature. The singleton was found to have a mutation in the TBL1XR1 gene, 
believed to be the cause of their cognitive impairment and autistic features but no 
underlying genetic cause was found to be the cause of their spasticity or 
brachydactyly [320].  
 
Due to the unique genetic architecture of the Amish community, resulting from 
the limited number of founder individuals, it can be assumed that the proportion 
of individuals possessing multiple disease loci within this endogamous population 
257 
 
will be higher than reported in unrelated patients due to the enrichment of certain 
variants within the population.  
This phenomena was detected in a family with two siblings each with features 
suggestive of a syndromic disorder, initially believed to be unrelated. The male 
sibling, presented with intellectual disability and dysmorphic facial features and 
was found to have a pathogenic variant in MTPAP (NM_018109.3:c.1432A>G; 
p.Asn478Asp) known to cause spastic ataxia [321]. He has subsequently 
developed spasticity and ataxia consistent with this disorder. The female sibling 
who had entirely normal development, presented with pectus excavatum, single 
palmar creases and aortic stenosis, was found to be homozygous for a variant in 
HYAL2 (NM_003773.4:c.443A>G) previously linked to cor triatriatum sinister 
(and orofacial clefting) [184] confirming the presence of two distinct genetic 
disorders within the family. After discovering this second pathogenic variant 
within the family the male sibling, was tested for the HYAL2 variant and also found 
to be homozygous, explaining his dysmorphic facial features. The father of these 
children complained of palpitations and dizzy spells and was subsequently 
diagnosed with hypertrophic cardiomyopathy (HCM), and was found to be 
heterozygous for the Amish founder variant in MYBPC3 
(NM_000256.3:c.3330+2T>G) associated with HCM. This finding confirmed the 
presence of three distinct genetic disease loci/disorders present within this single 
family. 
 
5.4.3 Community allele frequency data confirming rare disease genes 
The work outlined in this chapter, and subsequent expansion of this dataset, has 
permitted the rapid interrogation of aggregated Amish exomes allowing the AFs 
of variants within the community to be determined. The impact of these findings 
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is increased by aligning the exome data with metadata, providing information on 
which community and church group an individual originates, enabling the AFs to 
be evaluated in the context of the different regions.  
From a clinical perspective, this information is extremely beneficial as it is 
assisting local clinicians in confirming disorders which are already recognised in 
the different communities, but even more importantly, identifying disorders which 
have not previously been reported within the Amish community and may be being 
missed by the clinics. From an academic perspective, it has the proven capacity 
to confirm, or refute, the pathogenicity of novel, putative pathogenic variants 
within a community.  
This study has conclusively confirmed the pathogenicity of three novel 
pathogenic variants within the Amish community and consolidated three putative 
human disease genes, for which the evidence of association with the reported 
disease phenotype was previously limited.  
Firstly, the pathogenicity of a homozygous founder frameshift variant in CEP55 
(NM_018131.4: c.514dup; p.Ile172Asnfs*17) as the cause of hydranencephaly 
and renal dysplasia, present in two siblings with a lethal foetal disorder [322] was 
confirmed (Appendix J).  
Two recent studies of single families, one [323] the other of Canadian Mennonite 
ancestry [324] reported loss of function mutations in CEP55 and corresponding 
phenotypes, with foetuses presenting with Meckel-like syndrome and MARCH 
(multinucleated neurones, anhydramnios, renal dysplasia, cerebellar hypoplasia 
and hydranencephaly) syndrome. This, alongside the increased frequency of this 
variant in the Amish community, has enabled us to learn more about the clinical 
features of this disorder, and has corroborated mutation of CEP55 as a cause of 
hydanencephaly and renal dysplasia.      
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A further example is the confirmation of the missense SNIP1 variant 
(NM_024700.3:c.1097A>G), discussed in chapter 4, as the underlying molecular 
cause of psychomotor retardation, epilepsy, and craniofacial dysmorphism 
(PMRED). This variant has a high allele frequency, ~6%, in our aggregated 
exome data, being particularly enriched in the communities of Indiana, but is yet 
to be reported in gnomAD. The high prevalence of this variant has been 
instrumental in being able to precisely define the clinical phenotype and confirm 
pathogenicity of the variant and disease gene association.  
Finally, the pathogenicity of the MNS1 variant, NM_018365.2: 
c.407_410del;p.Glu136Glyfs*16, in the Amish, and mutation of MNS1 as a cause 
of laterality defects (situs inversus, SI) and male infertility in humans has been 
confirmed by our studies (Appendix K).  Due to the nature of this condition the 
presence or absence of SI in homozygous individuals is a randomised event, 
attributed to the inability of dysfunctional embryonic nodal cilia to perform normal 
rotation [325]. This means that a large number of individuals need to be 
genotyped and phenotyped to clearly demonstrate a causative link between 
homozygosity for a particular variant and SI. This is made possible within the 
Amish due to the large family sizes that are typically seen within this founder 
community. The AF of the MNS1 founder variant within the Amish, determined 
through interrogation of aggregated Amish exomes, was also instrumental in 
collating sufficient genetic evidence to support the pathogenicity of the MNS1 
variant. This data, taken together with the previous report of an SI and male 
infertility phenotype observed in Msn1 knock-out mice [326] confirmed the 




One example of the utility of this type of aggregated exome data for refuting the 
potential pathogenicity of a variant and enabling the exclusion of a potential 
candidate genetic cause of disease is illustrated by the nonsense SLC15A5 
variant (NM_001170798.1:c.865G>T; p.Glu289Ter) investigated as a potential 
novel cause of NS-SNHL in chapter 3. SLC15A5 was excluded as a candidate 
cause of hearing loss due to additional genotyping data, generated via a similar 
high-volume sequencing approach by our collaborators working within the 
Pennsylvanian Amish communities. The high frequency of the SLC15A5 variant 
within the Pennsylvanian communities, and subsequent detection of 
homozygotes, lead to its rejection as a candidate cause of hearing loss.  
This data also demonstrated the importance of considering the Amish as distinct 
communities and church groups with differing genetic backgrounds, as opposed 
to one large population. Whilst variants common among all Amish communities 
exist, likely originating from a shared European ancestor, the distinct migration 
patterns and geographical isolation of different communities since the original 
migration to the US, has given rise to large differences between AFs within each 
community. Another benefit of the Pennsylvanian dataset is the large number of 
individuals sequenced within a single community. The AF of the SLC15A5 variant 
may not be enriched within in the Pennsylvanian community, when compared to 
other Amish communities, but the increased number of individuals for whom 
aggregated data is available increases the likelihood of a homozygotes being 
detected is increased.  
 
In addition to the aggregate exome data, the PLEXseq approach allows us to 
rapidly genotype variants of interest within the Amish and obtain community 
specific AFs. The flexible nature of this platform allows for the rapid inclusion of 
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new candidate variants, seen within the community, which can then be 
scrutinised. Moving forward this approach will be used as a platform to provide 
newborn screening and diagnostic testing for affected individuals with the data 
generated also being anonymously aggregated in order for the AFs of known and 
putative disease associated variants to be determined. This data can then be 
used to determine the spectrum of disease across the different communities 
which can be used to help inform local health policies.  
One example of where this data has already proved to be valuable for this 
purpose is in determining the likely presence of individuals with undiagnosed 
cartilage hair hypoplasia in the Wisconsin communities, due to the extremely high 
allele frequency of the RMRP founder mutation (NR_003051.3:g.70A>G) within 
this community [327]. 
Cartilage hair hypoplasia (CHH) is a rare, autosomal recessive, metaphyseal 
chondrodysplasia characterized by sparse hair, short stature and short limbs in 
combination with mild to moderately severe cellular immunodeficiency and 
erythropoiesis [328-330].  Individuals present with a highly variable phenotype 
and can been misdiagnosed clinically with achondroplasia, due to a similar 
physical appearance of short stature and short limbs. However, CHH affected 
individuals are at risk of severe immunodeficiency, which depending on its 
severity needs to be carefully monitored and treated. Individuals displaying 
severe immunodeficiency disorder (SCID) will typically require a bone marrow 
transplant. Whereas some individuals, displaying milder immunodeficiency, may 
be more susceptible to contracting infections. For these individuals contracting 
varicella (chickenpox) comes with a very high risk mortality, especially in 
undiagnosed individuals that are unlikely to receive the immediate, high-dose 
acyclovir treatment [331].  CHH can be detected through a new born T-cell 
262 
 
Receptor Excision Circles (TREC) test which measures the number of circular 
DNA molecules (TRECs) formed within developing T-cells. A healthy infant blood 
sample will have one TREC per 10 T-cells, reflecting a high rate of T-cell 
generation whereas a sample from an infant presenting with SCID will lack TREC 
completely [332].  
Knowledge about the high allele frequency of the Amish RMRP founder mutation 
within the Wisconsin Amish has been helpful for healthcare providers serving this 
community who have worked with the community to provide community sensitive 
education and information about the condition and promote uptake of newborn 
screening. 
 
The work outlined in this chapter highlights the value of knowledge about known 
and newly defined pathogenic variants within a community. This information can 
now be used to develop a comprehensive genetic testing platform tailored to the 
specific genome of the Amish community that has the potential to be expanded 
as new information about inherited disorders arises. This will provide an 
immensely powerful tool for clinicians and local health care providers to utilise to 
support the delivery of improved healthcare outcomes for members of the Amish 
community. 
 
5.4.4 Future work and considerations  
Due to the success of the proof-of-principle study identifying potentially 
deleterious coincidental heterozygous sequence variants the immediate next 
step is to broaden the parameters of the study by expanding the dataset to 
include exome sequencing data from more individuals. Currently at least 150 
exomes will be included in the next round of analysis which will help us learn even 
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more about known pathogenic variants present in the community which are yet 
to be reported.  
The information from this study will also inform variant selection for the next 
stages of the PLEXseq genetic testing panel development.  Allele frequencies of 
the known pathogenic variants not yet reported ( 
Table 5.3,  
Table 5.4 and Table 5.7) will be determined within the different Amish demes. 
The information about possible underlying genetic causes of disease within the 
community can then be used by clinicians and local health care providers. 
 
With regard to determining the allele frequencies of the most commonly occurring 
pathogenic variants seen within various Amish communities the next step for this 
study is to increase the number of control samples included PLEXseq genetic 
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demes. In addition, the number of variants assessed can be increased with 
primers being modified for variants that failed to produce genotypes 
(NM_020435.3 (GJC2):c.203A>G and NM_152743.3 (BRAT1): c.638dup) in the 
pilot study. Increasing the cohort will enable a more accurate representation of 
the frequencies of variants present in the different communities.  
 
Although beyond the scope of the current study, this approach of exome 
sequencing data analysis has the potential to validate the clinical significance of 
variants in online databases, such as ClinVar and HGMD, and variants reported 
in the literature as disease causing, for example by identifying healthy 
homozygotes for previously reported pathogenic variants in genes associated 
with fully penetrant congenital onset disorders.  
Aggregation databases such as gnomAD are a fantastic resource for the 
interpretation of novel variants by providing extensive frequency data including 

















































































more data from population isolates If this data were included it will be important 
that the population of origin is clearly delineated (as with the Finnish and 
Ashkenazi Jewish) to avoiding skewing the frequency data of the more exogamic 
populations.    
 
Analysis of genotyping data from the Amish community also affords the 
opportunity to gain insight into pathogenic polymorphisms by expanding current 
knowledge of globally common single nucleotide variants (SNVs) that whilst in 
isolation are benign, have the potential to cause recessive disease when 
occurring in association with a loss of function (LoF) variant in a complex 
compound heterozygous fashion (Figure 5.5).  
 
 
Figure 5.5: Schematic representation of a common SNVs causing recessive 
disease when occurring in combination with a LoF variant in a complex compound 
heterozygous fashion. 
 
Finally, the work of the WoH project over the last 15years has generated a vast, 
and continually increasing, SNP mapping and exome sequencing dataset that 
could be utilised to further understand the link between autozygosity and disease 
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by looking at the regions in which founder mutations are located and determining 
a relationship to aid the identification of future novel variants.  
 
These studies demonstrate the numerous and wide-ranging benefits of 
community based studies to the global scientific community and wider society. 
The analysis of exome sequencing data from the Amish population has potentially 
huge benefits in aiding variant interpretation which in turn will assist in the delivery 
of genetic diagnoses, genetic counselling and therapeutic treatments for 
individuals and families affected by rare genetic disease both within and outside 
















 Final discussion and future work 
 
The work of this thesis highlights the importance of genetic studies conducted 
within population isolates such as the Amish, and the huge benefits that this 
research offers to the patients and families involved and to clinical genetics 
services and scientific knowledge globally. These benefits are particularly evident 
when determining the molecular causes and defining the clinical phenotypes of 
otherwise rare genetic disorders that have, due to the present of founder 
mutations, become enriched within these communities.  
 
The WoH project, to which the studies outlined here contribute, is a long-running, 
non-profit community genetic research program. The study aims to discover the 
spectrum, nature and molecular basis of inherited diseases in the Amish, and 
ensure information gained from these studies directly benefits its members by 
improving healthcare outcomes. The implementation of community-appropriate 
educational programmes, for both local healthcare providers and members of the 
community, is transforming molecular diagnostic and counselling services 
regionally by enabling substantial cost savings through supporting the provision 
of early and accurate diagnosis, and the introduction of targeted disease-specific 
clinical management strategies.  
A longer term initiative, now being implemented in clinical-diagnostic labs locally 
who serve the community, is the introduction of a community specific genetic 
newborn (NBS) programme. The current USA NBS service entails a primarily 
metabolic screen for a variable number of disorders (State dependent) from a 
heel prick sample taken from a newborn collected on filter paper. Conversely, the 
targeted Amish NBS in development which can be performed utilising the same 
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filter paper heel prick sample permits the screening of hundreds of pathogenic 
founder mutations and offers a flexible cost-effective genetic testing platform 
which may be readily expanded to incorporate new disease-associated variants 
as they are discovered. This programme is made possible by the founder 
mutation basis of inherited diseases in the community, and knowledge of the 
frequency and nature of the specific mutations responsible.  
 
One notable example of the benefits of a genetic-based approach to NBS is in 
the diagnosis of propionic acidemia, an AR neonatal onset metabolic disorder 
caused by mutation of the PCCB (propionyl-CoA carboxylase subunit beta) gene 
[333]. The resulting dysfunction of the mitochondrial enzyme propionyl CoA 
carboxylase leads to the accumulation of propionyl-CoA which inhibits 
mitochondrial metabolism, a vital process in the critic acid cycle (an essential 
pathway used in aerobic respiration) [334]. Affected individuals are usually 
asymptomatic at birth but present with poor feeding, vomiting and fatigue during 
the first few days of life. If left untreated, at its most severe, an otherwise healthy 
newborn can start to display lethargy and seizures followed by coma and 
eventually death [334, 335]. However, nutritional intervention in the form of a 
propiogenic amino acid restricted diet, which prevents propionyl-CoA 
accumulation and allows affected individuals to maintain as close to normal 
plasma concentrations of propionyl-CoA, can prevent the onset of the otherwise 
observed difficulties [335]. It is widely accepted that pre-symptomatic diagnosis 
of propionic acidemia and propiogenic amino acid restriction significantly reduces 
morbidity and mortality rates delivering more positive clinical and neurological 
outcomes [333]. Although newborn screening in the form of a metabolic assay is 
currently available, it has been reported that >60% of individuals are already 
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symptomatic at the time of diagnosis, or may not be detected by the metabolic 
test [333]. The introduction of an accurate and sensitive genetically-based test, 
stemming from knowledge of founder mutation underlying the condition, will 
provide a greatly facilitate timely and accurate diagnosis, enabling earlier 
treatment and surveillance aimed at reducing potential preventable morbidity and 
mortality. Additionally, the genetic-based NBS approach allows the inclusion of 
inherited disorders which do not necessarily involve metabolic outcomes (e.g. 
SNIP1-associated syndrome), so that patients and families may benefit from early 
intervention and treatment approaches as they are developed.  
 
The growing knowledge of the full spectrum of inherited diseases present across 
all Amish communities will be instrumental in informing decisions regarding a 
variants’ inclusion within genetic NBS. As this approach becomes established, it 
may be considered prudent to develop regional specific genetic NBS platforms to 
detect the inherited conditions particular to individual Amish communities, such 
as the inclusion of variants responsible for cartilage hair hypoplasia and Troyer 
syndrome (Ohio Amish).  
One example of how regional-specific candidates can be identified is by 
establishing the allele frequencies (AF) of pathogenic variants known to be 
present in the Amish. In this study, the allele frequencies of GJB2 variants, and 
other founder gene mutations linked to hearing loss were determined to learn 
more about their prevalence in different Amish communities. As expected, 
remarkably divergent AF for each gene were observed reflecting the distinct 
ancestral histories of each Amish community. Notably the KCNQ1 founder 
mutation, responsible for Jervell and Lange-Nielsen syndrome (JLNS) an 
autosomal recessive syndromic form of congenital profound SN hearing loss 
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associated with a prolonged QT interval on ECG and potentially fatal 
tachyarrthymias if undiagnosed and untreated, is present in both the Holmes 
County and Geauga Ohio Amish communities making it a clear candidate for 
inclusion on a genetic NBS for these communities 
A further example of a potential candidate for consideration of inclusion on a 
genetic NBS platform is the SNIP1 variant, conclusively demonstrated through 
this study to be causative of a SNIP1-associated syndrome, given its high 
prevalence within the Ohio, Indiana and Wisconsin Amish communities. The high 
prevalence of this variant enabled the investigation of 33 individuals, presenting 
with this novel complex neurological disorder enabling the clinical phenotype, to 
be defined which has laid important foundations for a greater understanding of 
the underlying biological mechanisms responsible for the condition.  
Demonstrating the power of interrogating aggregated sequencing data to expand 
current knowledge of the spectrum of disease within the Amish community. The 
identification of the precise molecular cause of this disorder is fundamental to 
accurately diagnose this syndrome in future affected individuals, and in the 
development of prospective targeted treatments for the complications associated 
with this disorder such as the severe intractable seizures that afflict the majority 
of affected children.    
 
Additional studies, conducted as part of the Amish hearing loss programme, 
aiming to investigate the nature, aetiology and frequency of genetic causes of 
hearing loss within the Amish community, has successfully provided genetic 
diagnoses to families, and allowed local healthcare providers to implement 
targeted diagnostic and clinical management strategies, including overseeing the 
monitoring and screening of additional features that may develop in syndromic 
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forms of the condition. The link between diagnostic delay in hearing loss, and 
substantially increased negative outcomes for affected individuals, has been 
widely reported [136-138] highlighting the importance of timely and accurate 
precise diagnoses particularly with regard to the monitoring of syndromic forms 
and implementation of protective management strategies. As knowledge of the 
spectrum of gene mutations within the Amish communities is expanded new 
variants can be readily included into the NBS platform facilitating early diagnosis 
and treatment. Additional benefits of such an approach include: providing the 
families of affected individuals with accurate information about the prognosis and 
progression of the condition and enabling the provision of appropriate 
reproductive counselling advising on recurrence rates in future offspring. In 
summary, the implementation of a genetic NBS within the Amish community has 
enormous potential to transform the diagnosis of inherited conditions and 
subsequent implementation of strategic care plans, including targeted 
treatments, for affected individuals. This will reduce the economic burden of 
diseases within communities by delivering substantial cost savings and improve 
healthcare outcomes.  
 
A further possible utility of a genetic testing approach to screening within the 
Amish relates to carrier testing in adults, and the potential for detection of adult 
onset diseases such as a form of hypertrophic cardiomyopathy (HCM), due to an 
MYBPC3 gene mutation responsible for which is at extremely high frequency 
across many Amish communities. HCM is a relatively common autosomal 
dominant disorder, displaying variable expressivity and incomplete penetrance 
[336]. Clinical presentations of HCM range from asymptomatic hypertrophic 
(enlarged), non-dilated left ventricle to progressive heart failure or sudden cardiac 
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death (SCD) [337, 338]. Although considered the most common cause of SCD in 
young people globally, the majority of affected individuals do not experience 
substantial symptoms and often remain undiagnosed [336, 339]. Unlike propionic 
acidemia, HCM is a common global disease and is reported to affect 1 in 500 
people in more than 50 countries [338, 339]. In 2015, it was suggested that 
potentially pathogenic MYPBC3 variants may be carried by more than 60 million 
people, in part due to the high occurrence of founder mutations present in 
different populations [336].  
The expansion of a targeted population genetic testing approach to provide 
carrier testing for consenting adults would enable the identification of individuals 
at risk of developing HCM symptoms (or indeed diagnose already symptomatic 
individuals), so that the appropriate management and treatment options can be 
put in place. The WoH and the Amish communities are working alongside the 
Cleveland Clinic and other Cardiology departments serving the Amish to develop 
a clinical care programme for adults affected with HCM, due to the Amish 
MYBPC3 mutation, at a significantly reduced cost. Additionally, due to the high 
frequency of HCM in the Amish arising from the same MYBPC3 founder mutation, 
ongoing studies are expanding the knowledge of the molecular basis of the 
condition by defining genetic variants and modifiers which may be of global 
benefit to families with this condition. 
Whilst, determining the carrier status of individuals can be clinically actionable, 
as described with MYBPC3, and should be shared immediately, the identification 
of carrier status for other conditions require no clinical intervention but will inform 
an individual’s reproductive risk [340]. It is the recommendation of many 
international guidelines that carrier testing for this purpose should be postponed 
until an individual can be actively involved in the decision making process [340]. 
274 
 
In these cases, although the genetic data identifying individuals as carriers would 
be available from a NBS there is no immediate need to share this information. 
The Amish community may wish to introduce a programme that permits the 
sharing of an individual’s carrier status only when later requested, as with the Dor 
Yeshorim service used within the Jewish community.  
Dor Yeshorim (also called Committee for Prevention of Genetic Diseases) was 
screening service to minimise, and eventually eradicate, fatal and debilitating 
recessive genetic disorders from their communities. The system involves 
individuals being tested, often through high school programmes [340], for a 
number of genetic disorders observed at significantly higher frequencies than 
other populations including; TaySachs disease, cystic fibrosis, Gaucher disease 
type I, Canavan disease, familial dysautonomia, Bloom syndrome, Fanconi 
anemia, glycogen storage disease type 1a, mucolipidosis type IV, and Niemann–
Pick disease type A  [341]. The resulting genotyping data is confidential held until 
requested. When two individuals wish to start a relationship they submit unique 
ID numbers to the service which informs the couple if any offspring are likely to 
have one the genetic conditions. The exact genotypes any one individual are 
never disclosed in an effort to remove the possibility of discrimination or 
stigmatisation. Although one option, the Amish communities do not necessarily 
need to implement a community-wide policy on the sharing of carrier status 
information gained from targeted community testing programmes. It may be 
decided that the sharing of this information is a decision for individual families or 
church groups to agree upon.  
 
The value of studying genetic disorders, particularly those of a rare or recessive 
nature, within population isolates is now widely recognised. The work outlined 
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here demonstrates the capacity of community genetic studies, undertaken in the 
Amish communities, to elucidate the molecular cause of genetic disorders and 
identify novel disease genes. Findings from these studies are of major clinical 
relevance to both individuals within the community, families affected by rare 
genetic disorders worldwide and to the global clinical genetics community. The 
WoH is extremely privileged to work within the Amish communities with the most 
important outcomes of these studies remaining the translational benefits they 







7.1 Appendix A - Amish Genome Project – Plexseq variant list 
Transcript Variant Chromosomal Variant [hg38] 
NM_005957.4(MTHFR):c.1129C>T NC_000001.11:g.11794766G>A 
NM_001166120.1(HSD3B2):c.35G>A NC_000001.11:g.119415454G>A 
















































































































































































7.3 Appendix C – details of expression vector maps 








7.4  Appendix D - Flow diagram summarising the BAAP guidelines for aetiological investigation into bilateral severe to 


















7.6 APPENDIX F - Hearing loss in the Amish 
 
7.6.1 Causes of SNHL in the Amish Community 
PCNA 
The proliferating cell nuclear antigen (PCNA) gene is located on chromosome 
20p12.3 and contains 6 exons [342]. PCNA is essential for DNA replication and 
repair [343], playing a central role at the DNA replication fork by recruiting 
necessary enzymes [344], and in accordance with such a fundamental cellular 
role is notably highly conserved through evolution. Our group identified a 
hypomorphic missense amino acid variant in the PCNA gene as a cause of 
sensorineural syndromic hearing loss (SHL) in the Ohio Amish population [177]. 
Hearing loss occurs as part of a more clinically complex DNA damage repair 
disorder with some overlap with xeroderma pigmentosum (XP) and Cockayne 
syndrome (CS). Other syndromic clinical features associated with the PCNA 
variant include ocular and cutaneous telangiectasia, premature aging, 
photophobia, photosensitivity with predisposition to sun-induced malignancy, 
short stature, learning difficulties and neurodegeneration with cerebellar atrophy 
[177]. This rare cause of SHL was originally identified in a single extended Amish 
family comprising four affected individuals (three siblings and a more distant 
cousin), and remains the only PCNA mutation described in a human inherited 
disorder. The causative mutation was identified using a combined strategy of 
homozygosity mapping and whole exome sequencing (WES), which identified a 
single candidate gene variant in PCNA (c.683G>T; p.Ser228Ile) in a particularly 
small (0.77Mb) autozygous region containing just six genes, which comprised the 
only autozygous region shared by all affected individuals. More recently a further 
affected Amish individual, from Wisconsin, has since been identified and 
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confirmed to be homozygous for the same p.Ser2281Ile founder mutation, 
validating this gene as causative of this condition [345]. To date this variant has 
only been identified, by our group, in the Holmes County communities of Ohio at 
an allele frequency (AF) of 0.015% which is significantly higher than the 
0.000007955% reported in gnomAD [295] indicating this variant is enriched within 
this community.  
PCNA functions as an essential sliding clamp protein during DNA replication and 
repair processes. A significant impairment of PCNA protein function is likely to be 
incompatible with life, and our functional studies determined that the causative 
variant likely affects only specific functional aspects of molecular function [177]. 
SNHL in this condition was universal, of prelingual onset and of moderate to 
profound severity and worse at higher frequencies. Early onset of SNHL is a 
distinguishing factor from other DNA repair disorders in which SNHL typically 
displays an older age of onset, and is not a universal feature. It should be noted 
however, that due to its complex tertiary structure, and the large number of 
molecular interacting partners involved in the diverse functional roles of PCNA, 
other sequence alterations identified in other functional domains of PCNA may 
well exhibit clinical outcomes distinct to those associated with the p.Ser228Ile 
variant present in the Amish.   
 
SLITRK6 
Gene SLIT and NTRK-like family member 6 (SLITRK6), located on chromosome 
13q31.1, comprises a single coding exon [346]. The gene encodes an integral 
membrane protein with leucine rich repeat domains and is expressed in specific 
brain regions and the neural retina, in which it is thought to play a role in 
synaptogenesis [178]. Our group identified the genetic basis of an autosomal 
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recessive deafness and myopia syndrome characterised by severe congenital 
myopia and SNHL, associated with sequence variants in SLITRK6  identified in 
three separate families (of Amish, Greek and Turkish origins) [178]. In a single 
Amish family comprising three affected siblings, whole genome SNP genotyping 
identified a single notable homozygous region of 12.2Mb common to all affected 
siblings. Despite the relatively large size of the homozygous genomic region 
identified, it fortuitously contained only five protein coding genes, in which dideoxy 
sequencing identified a single nonsense variant (c.1240C>T; p.Q414X) in one; 
exon 2 of SLITRK6, that appropriately co-segregated in the family. Our studies of 
SLITRK6 -/- mice showed delayed synaptogenesis of the retina in postnatal 
development [178] and HEK293 cell transfection studies showed impaired cell 
surface localisation of the mutant protein. The SNHL in these individuals was 
bilateral, moderate to severe and of prelingual onset, requiring hearing aids. 
Congenital myopia was severe from –6 to –11 diopters refractive error. The 
heterozygous parents of the affected siblings both had a low degree of myopia, 
perhaps indicative of an intermediate or milder phenotype in heterozygotes, 
although neither had HL and it is impossible to conclusively determine whether 
the myopia may relate to the SLITRK6 variant. Subsequently other Amish families 
from Pennsylvania were identified with the condition [159] in whom the same 
homozygous c.1240C>T mutation was identified. This group undertook control 
studies to estimate a 4.7% carrier frequency in an Old Order Amish population 
(n=571). All affected individuals display a similar phenotype of high myopia and 
SNHL, which is progressive and severe to profound by early adulthood. 
Audiological testing in all affected individuals showed absent distortion product 
otoacoustic emissions (DPOAEs) and auditory brainstem responses (ABRs) 
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were dys-synchronised bilaterally. Four affected individuals had absent ipsilateral 
middle ear muscle reflexes (MEMRs).  
 
HARS 
The HARS (histidyl-tRNA synthetase) gene is located on chromosome 5q31 and 
comprises 13 exons [347]. HARS encodes a molecule with a role in protein 
biosynthesis, which catalyses ligation of histidine to tRNA. Puffenburger et al. 
identified three patients from Amish families in Pennsylvania who displayed 
features suggestive of Usher syndrome type 3 [179]. Usher syndrome is classified 
into three major types, distinguished by severity of HL, age of onset, and the 
presence of vestibular abnormalities. Usher syndrome shows genetic 
heterogeneity and is further subdivided by genetic basis, with 15 genes currently 
associated with the condition. HARS mutation as a novel cause of Usher 
syndrome is classified as type 3B [348]. Clinical features of individuals in whom 
the HARS variant was identified include progressive visual impairment in 
childhood with horizontal nystagmus, optic pallor, photosensitivity, bull’s eye 
macula and pigmentary changes consistent with retinitis pigmentosa (RP), 
progressive SNHL, delay in gross motor development, lower limb brisk reflexes 
and ataxia with normal intellect. Other features described include visual 
hallucination in response to fever (Charles-Bonnet syndrome), acute psychosis 
with catatonia, and sudden unexplained death in one child. No newborn auditory 
screening data was available, although for affected individuals all evoked auditory 
waveforms were absent by 5 years. 
Homozygosity mapping performed using samples from the three affected 
individuals determined that the gene most likely resides within an 8.4Mb region 
of homozygosity of chromosome 5q31, containing 187 genes. WES of two 
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individuals with filtering for homozygous variants within the mapped region 
identified a single novel variant (c.1361A>C;p.Tyr454Ser) in HARS. Screening of 
406 Old Order Amish control chromosomes identified 7 heterozygous carriers of 
the variant, with an allele frequency of 1.72%. The group identified a further 
individual of Amish descent in Canada with an identical phenotype who was also 
homozygous for the c.1361A>C variant.  
 
YARS 
The YARS gene is located on chromosome 1p35.1 and encodes tyrosyl-tRNA 
synthetase, an enzyme that catalyses the aminoacylation of tRNA. Dominant 
variants in YARS have been associated with Charcot-Marie-Tooth (CMT) disease 
type C dominant intermediate [349]. More recently, a recessive multisystem 
disorder characterised by developmental delay, small stature, spasticity, 
areflexia, hypertriglyceridaemia, liver dysfunction, lung cysts and abnormal 
subcortical white matter was identified in two siblings of Polish origin [350]. 
Expanding on this phenotype Williams and Demczko [180] have presented 
unpublished work describing an Amish family with distantly related common 
ancestors and four individuals (three siblings and one cousin) affected with 
bilateral SNHL, nystagmus, visual impairment, developmental delay, pancreatic 
insufficiency, cholestatic liver disease, hypoglycaemia and white matter 
abnormalities on MRI brain, who were identified through whole exome 
sequencing to be homozygous for a variant in YARS (c.499C>A; p.Pro167Thr). 
Further work is ongoing to confirm this association, including functional studies. 
Variants in other aminoacyl-tRNA synthetases including HARS (see above) and 




The ST3 beta-galactoside alpha-2,3-sialyltransferase 5 (ST3GAL5) gene 
encodes GM3 synthase; a sialyltransferase enzyme that synthesises GM3 
ganglioside from lactosylceramide, the first step in synthesis of complex 
gangliosides [351]. The ST3GAL5 gene is resident on chromosome 2p11.2 and 
contains seven exons [352]. Our group first identified an infantile onset epilepsy 
syndrome caused by mutation in ST3GAL5 resulting in GM3 synthase deficiency 
[30]. In a large Amish family, eight affected individuals from two interlinking 
branches were identified to have infantile onset epilepsy, with developmental 
delay and blindness. Seizures arise in the first year, with associated 
developmental regression, with several seizure types, which are refractory to 
treatment. Other features include generalised irritability, poor feeding requiring 
gastrostomy in two children, dystonic arm movements, hypotonia and visual 
deterioration of likely cortical origin. Homozygosity mapping identified a single 
candidate genomic region in which a homozygous nonsense mutation 
(c.862C>T; p.R288X) was identified in ST3GAL5, with appropriate segregation 
within the family. GM3 synthase deficiency has also been termed Salt and Pepper 
Developmental Regression Syndrome and has been associated with further 
features within the Amish population, including SNHL (Wang, Wang et al. 2016), 
pigmentary changes of the skin [353] and optic nerve defects [354]. Auditory 
brainstem responses (ABRs) showed absent cochlear microphonics and 
abnormal thresholds were recorded in all eight Amish children homozygous for 
the c.862C>T variant, with waveform phase reversal in most. Cortical auditory-
evoked potentials showed abnormal morphology in seven of these individuals 
[355]. GM3 synthase deficiency has subsequently been described by several 




The lon peptidase 1 (LONP1) gene encodes a homohexameric enzyme of the 
AAA+ superfamily of ATPases. Lon peptidase 1 is multifunctional; it regulates 
quality control processes for protein synthesis, assembles protein complexes 
within the respiratory chain and regulates mitochondrial gene expression [359-
361]. LONP1 consists of 19 exons at cytogenetic location 19p13.3 [362]. Mutation 
in LONP1 has been associated with cerebral, ocular, dental, auricular, and 
skeletal anomalies (CODAS) syndrome. CODAS syndrome was first described in 
an endogamous Mennonite community [183] characterised by clinical features of 
developmental delay, dysmorphic facial features including ptosis, median nasal 
groove and malformed ears, bilateral cataracts, dental anomalies including 
delayed tooth eruption and anomalous cusp morphology, SNHL and skeletal 
features of short stature, delayed epiphyseal ossification, metaphyseal hip 
dysplasia and coronal clefts of the vertebrae. A further case of CODAS in a child 
of Mennonite ancestry was subsequently described and further characterised the 
phenotype [363], suggesting autosomal recessive inheritance of the condition. 
Strauss et al. identified ten further individuals with CODAS syndrome from Amish, 
Mennonite and mixed European backgrounds [364]. WES or dideoxy sequencing 
identified four LONP1 mutations; among the Pennsylvania Amish, eight 
individuals were identified to be homozygous for a founder mutation (c.2161C>G; 
p.Arg721Gly) in LONP1. In an Amish control group a high population allele 
frequency of 5.9% was identified (compared with 0.00073% in GnomAD). The 
group sequenced LONP1 in the Mennonite individual originally described by 
Shebib et al. [183] who was found to be homozygous for a different variant 
(c.2026C>T; p.Pro676Ser) and a further individual of mixed European ancestry 
was found to be compound heterozygous for two further mutations c.1892C>A 
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(p.Ser631Tyr) and c.2171C>T (p.Ala724Val). The affected Amish individuals 
showed a mixed picture of hearing loss; two had low frequency conductive 
hearing loss (CHL) with impaired tympanic membrane mobility. The two further 
individuals had both CHL with mild to moderate SNHL at medium to high 
frequency. Further details of the CODAS phenotype from these individuals 
highlight the severity of the condition with several children dying from laryngeal 
obstruction in the first few days of life and usually have swallowing difficulties 
requiring gastrostomy feeding. Other features include hypotonia, scoliosis, 
imperforate anus, omphalocele, rectovaginal fistula, cryptorchidism and tongue 
hemiatrophy. Due to the high allele frequency of c.2161C>G it would be expected 
that more cases of CODAS syndrome would be present in the Amish population, 
although this discrepancy may be explained in part by allele frequency 
differences in different Amish communities, as well as the high rate of neonatal 
mortality associated with gene mutation and many cases remaining undiagnosed. 
  
7.6.2 Conductive hearing loss in the Amish community 
HYAL2 
The HYAL2 gene encodes hyaluronidase 2, an enzyme with weak activity to 
degrade hyaluronan, an extracellular matrix glycosaminoglycan that is expressed 
during development [365]. HYAL2 is located on chromosome 3p21.31 and 
consists of four exons [366]. We identified HYAL2 as a novel gene associated 
with SHL in an extended Amish family of three distantly related nuclear families 
with five affected individuals, as well as a further two affected siblings with a 
similar phenotype in a Saudi Arabian family [184]. Mutation in HYAL2 causes 
principle clinical features of cleft lip or palate (CLP), which can be unilateral or 
bilateral, and facial dysmorphism with characteristic features of frontal bossing, 
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hypertelorism, flattened and wide nasal bridge and tip, cupped ears with 
thickened helices and micrognathia. Other more variable features include 
congenital cardiac abnormalities, including cor triatriatum, predominantly CHL 
(although one individual had SNHL), pectus excavatum, single palmar creases, 
2-3 toe syndactyly, myopia, staphyloma and cataract. A combination of 
homozygosity mapping of the five affected individuals with WES of a single 
affected individual identified a 10.18Mb region of homozygosity shared between 
affected individuals within the extended Amish family. Only a single candidate 
deleterious variant was identified, located in the HYAL2 gene (c.443A>G; 
p.K148R). In the Saudi Arabian family similar methods identified a missense 
variant (c.749C>T; p.P250L) in HYAL2. Mice HYAL2-/- studies demonstrated 
comparable phenotype with cleft palate, facial dysmorphism and variable 
features of cor triatriatum sinister in 50%, and hearing loss in 100% of HYAL2-/- 
mice. Functional studies demonstrated that both reported mutations significantly 
reduced the level of hyaluronidase-2 expression. In these families, CHL was 
described in four individuals and was variable, from mild to moderate impairment, 
unilateral or bilateral and pre or postlingual. A further individual had severe to 
profound SNHL that was prelingual.  
  
7.6.3 Mixed hearing loss in the Amish community 
COL1A2  
Collagen type I alpha 2 chain (COL1A2) is a large gene consisting of 52 exons 
located at 7q21.3.The COL1A2 gene encodes the pro-alpha 2 chain of type 1 
collagen, which is comprised of two alpha-1 chains and one alpha-2 chain that 
form a triple helix. Mutations in COL1A2 and COL1A1 have been identified as a 
cause of osteogenesis imperfecta (OI) types I II, III and IV. The four different types 
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of OI are inherited in an AD manner and have overlapping phenotypes and 
genotypes, varying in severity from a perinatal lethal form to a mild form with blue 
sclera and occasional fractures. Variability is often seen between individuals 
within the same family. Clinical features include fractures with minimal or no 
trauma, bone deformity, short stature, progressive mixed hearing loss, 
dentinogenesis imperfecta and connective tissue abnormality. Hearing loss in OI 
occurs in the majority of individuals by adulthood [367]. Often this starts with CHL 
caused by fracture of middle ear bones, with later SNHL developing with age. 
Usually onset is progressive and postpubertal, although hearing loss starting in 
childhood can occur. 
Mcbride et al. [186] reported a COL1A2 mutation (c.2098G>T; p.Gly610Cys) 
identified by dideoxy sequencing in several interrelated Amish families with 64 
individuals subsequently identified with the COL1A2 gene variant, displaying a 
variable phenotype [185]. A subsequent study used linkage analysis in these 
individuals to identify further candidate linkage loci that may contain further 
modifier genes that influence the severity of OI. This identified a candidate 
modifier locus on chromosome 1q, which the investigators suggested may 
involve the PTGS2 gene which is involved in regulating bone formation [368].  
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7.7 APPENDIX G - Expression studies of Slc15a5 inner ear mouse tissue  
 
Figure 7.1: Antibody staining of the inner mouse ear (E16.5) a) with the antibody 
raised against slc15a5 and b) with antibody raised against odf2. Brown staining 













7.9 APPENDIX I - Amish Genome Project additional tables 
 




APOL5 Schizophrenia  18571626 
B4GALNT3 Neuroblastoma 21741930 
C10orf53 Meningiomas 25981829 
CCDC17 Keratoacanthoma 27788211 
CCDC66 Human retinal dystrophy  28369829 
CCDC83 Colon cancer 22923163 
CES1 Carboxylesterase 1 deficiency 18485328 
CFAP61 Obesity  28224759 
CLDN17 Gastric cancer  24325792 
CLEC4G Inflammatory Response  26943817 
COQ7 Coenzyme Q10 deficiency, primary, 8 26084283 
DNAH6 Heterotaxy and ciliary dysfunction 26918822 
DNALI1 Immotile cilia syndrome 19944400 
EFS Prostate cancer 25296736 
EPHA10 Breast cancer 27566654 
FAM109B Meningiomas  25981829 
FAT2 Spinal meningioma 27900010 
FLT1 Eclampsia 14764923 
FOLR3 Meningomyelocele  20683905 
GPT Glutamate pyruvate transaminase polymorphism 9119391 
HAGH Glyoxalase II deficiency 7424909 
HLA-DRB4 Encephalitis 28026046 
HLTF Colorectal cancer, associated 21479407 
HOXC5 Cervical cancer 10208853 
HSD17B8 Colorectal cancer 20049862 
IGSF10 Hypogonadotropic hypogonadism 27137492 
KCNC4 Spinocerebellar Ataxia 13 20712895 
KMT2C Intellectual disability 22726846 
KRT23 




KRT37 Celiac disease 21627641 
MAPK13 Gynecological cancer 26969274 
MED12 






MUC19 Sjogren's Syndrome 18184611  
MUC3A 








Pancreatic Ductal Carcinoma 







squamous cell carcinoma 
20002008 
28331341 
PIFO Laterality defects 120643351 
PRSS2 Pancreatitis, chronic, protection against 16699518  
PYHIN1 Diffuse Scleroderma and Limited Scleroderma, Asthma (risk) 21804549 
RERGL Familial colorectal cancer  24127187  





RXFP2 Cryptorchidism 20636340  
SECISBP2 Thyroid hormone metabolism, abnormal 16228000 
SLC22A11 
Gout 




SRR Streptococcal Meningitis, Serine Deficiency 22990841 
TCF20 
Vertebrobasilar Insufficiency and Breast Sarcoma 
Autism spectrum disorder 
25228304 
THBS3 






Open angle glaucoma patients 





TMEM78 Nasopharyngeal carcinoma 22260379  
TMPRSS5 Autosomal recessive hearing loss  17918732 
TNNI3K 
Cardiac conduction disease with or without dilated 
cardiomyopathy 
24925317  
TOP1MT Non-small-cell lung cancer 28355294  
TRAP1 
















Neurogeneis and Brain function 
27670918  
28596978  
USP54 Cancer 28129647  
VPS13C Parkinson disease 23, autosomal recessive, early onset 26942284 
XIRP1 Brachial Plexus Lesion and Myopathy, Myofibrillar, 5 24725425  
ZNF599 Hypospadias 22378287  








ABHD14B neuroendocrine tumors 21681495 
ACSM3 Hypertension, essential 7907320 








ACTA1 Myopathy, congenital, with fiber-type disproportion 1 15468086 
ACTA1 Myopathy, actin, congenital, with cores 15520409 








AK2 Reticular dysgenesis 
19043417 
19043416 
ANO9 Colorectal carcinoma (stage II & III) 26317553 
AP1G2 
Cardiac Arrest 
Long Qt Syndrome 1 
21658281  
APOBR Obesity  25955518 
ARMC2 Lung function 21946350 
ATP5J Colorectal cancer 24124598 
ATP5J Alzheimer's disease and severe cerebral amyloid angiopathy 22008262 
ATXN3 Machado-Joseph disease (Spinocerebellar ataxia type 3) 7874163 
ATXN3 Machado-Joseph disease (Spinocerebellar ataxia type 3) 7874163 













AVPR2 Nephrogenic syndrome of inappropriate antidiuresis 15872203 
BCL7C Lymphoma 9931421 
BRMS1 









Colon and Prostate Cancer 
25426562 
24946957 
CACNA1G Childhood Absence Epilepsy 17397049 
CACNA1G Spinocerebellar Ataxia Type 42 26456284 
CCDC40 
Ciliary Dyskinesia, Primary, 15 
Primary Ciliary Dyskinesia15: Ccdc40-Related Primary Ciliary 
Dyskinesia 
21131974 
CCDC7 Colorectal cancer 22024937 
CCDC88B Sarcoidosis  22837380 
CEP164 Nephronophthisis 15 22863007 












CLTCL1 Chromosome 22Q11.2 Microduplication Syndrome 26549885 
CLTCL1 
Congenital Insensitivity To Pain With Severe Intellectual 
Disability 
26549885 
CPNE8 Prion disease  19795140 
CRIPAK Non-small cell lung cancer 25444907 
CSPG4 Chordoma 26689475 
CSPG4 Chondrosarcoma 27292772 
CWH43 Colorectal cancer 24959000 
DAGLB Hallucinogen Dependence 26595473 
DLEC1 Lung cancer 27287342 
DNAH14 Embryonic lethal genes 26036949 
DNAH14 Endometrial cancer 28339086 
ECHDC1 Breast and ovarian cancer  19517271 
EGFR Inflammatory skin and bowel disease, neonatal, 2 24691054 
EGFR 





EPPK1 Vater/Vacterl Association 23549274 
ERV3-1 Choriocarcinoma (and other cancers) 
25016529 
24043713 
FAM46A Retinitis Pigmentosa 25 17803723 
FAM46A Skeletal dysplasia 26803617 
FAM81B Breast cancer 27491861 
FBXW8 Intellectual disability 25626716 
FCGBP Endometriosis  27817035 







Developmental delay and congenital anomalies (craniofacial 
dysmorphism, including a cleft lip) 
12836054 
GPR27 
Speech delay, contractures, hypertonia and 
blepharophimosis 
19332160 
HELQ Natural menopause 28118297 
HELQ Breast cancer 
27792995 
26351136 




Ankylosing spondylitis, susceptibility to 
(synovitis, chronic, suscpetibility to) 
8053961 
HLA-B 
Severe cutaneous adverse reaction, susceptibility to 
Stevens-johnson syndrome, susceptibility to, included 
Toxic epidermal necrolysis, susceptibility to, included 
15057820 
HLA-B 
Severe cutaneous adverse reaction, susceptibility to 
Stevens-johnson syndrome, susceptibility to, included 
Toxic epidermal necrolysis, susceptibility to, included 
15743917 
HLA-B 
Abacavir hypersensitivity, susceptibility to 
Drug-induced liver injury due to flucloxacillin, included 
15247624 
12462283 
HLA-DPA1 Inflammatory Bowel Disease 3 12073072 
HLA-DPA1 Kikuchi Disease 28613580 
HLA-DPA1 Posner-Schlossman Syndrome 25863099 
HLA-DRB1 Sarcoidosis, susceptibility to, 1 14508706 
HLA-DRB1 Pemphigoid, susceptibility to 23502333 
HLA-DRB1 Rheumatoid arthritis, susceptibility to 28711139 
HLA-DRB1 Multiple sclerosis, susceptibility to, 1 
21833088 
28676141 
IL36B Psoriasis 21881584 




KCNJ12 Hirschsprung's disease 28399120 




LMO7 Emery-dreifuss muscular dystrophy 24825363 




Encephalopathy due to defective mitochondrial and 
peroxisomal fission 2 
22499341 
26783368 





MS4A12 colon cancer 27881006 
MTMR11 breast cancer 20413845 
MTX1 Gaucher's Disease 15024629 
MUC21 Colorectal Cancer 1 28575854 
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MUC3A Ulcerative colitis and Crohn's disease. 11289722 
NDOR1 bladder carcinoma 26722457 
NDUFA8 Mitochondrial Complex I Deficiency 
15576045 
9860297 
NETO1 autism 20499253 




PDE11A Pigmented nodular adrenocortical disease, primary, 2 16767104 
PDGFRL Colorectal cancer, somatic 7898930 
PDGFRL Hepatocellular cancer, somatic 7898930 
PDGFRL Behçet disease 22926996 
PGK2 Ovary and ovarian cancers 19333399 
PLAC4 Early onset preeclampsia 23312075 
PNPLA7 Susceptibility to menstrual disorder 25867316 
POLQ Breast cancer, ovarian cancer and other cancer types 
27264557 
25409685  
PRMT6 HIV-1 26611710 





RGL4 Associated with chemosensitivity 20224928 







SCAPER Parkinson's disease 25294124 
SCAPER Atopic dermatitis (recalcitrant) 25935106 
SCGB3A2 Asthma, susceptibility to 11813133 
SCGB3A2 Graves' disease 
23934357 
21170691 
SH2B3 Myelofibrosis, somatic  20404132 
SH2B3 Thrombocythemia, somatic  20404132 
SH2B3 Erythrocytosis, somatic 20843259 




SLC22A3 Coronary Artery disease 
27417586 
27621937  
SLC22A3 Oesophageal cancer 
28533408 
28743982  
SLC25A5 Non-Syndromic Intellectual Disability 23783460 
SLC6A18 Myocardial infarction 21420947 
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SLC6A18 Iminoglycinuria, Digenic 
20377526 
19033659  
SP7 Osteogenesis Imperfecta, Type XII 20579626 
SPZ1 Non-small cell lung cancer 23463593 





TEX9 Nevoid basal cell carcinoma syndrome  9388465 
TMEM242 Developmental delay  26391891 
TRPM1 














VN1R2 Gliomas 23451178 
ZNF443 Wilms tumor cells 23267699 
ZNF510 Oral squamous cell carcinoma 21497587 










AN AMISH FOUNDER VARIANT CONSOLIDATES 
DISRUPTION OF CEPP5 AS A CAUSE OF 
HYDRANENCEPHALY AND RENAL DYSPLASIA  
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MNS1 MUATATION ASSOCIATED WITH SITUS 
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